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Dementia with Lewy bodies (DLB) is a significant cause of dementia in the older population 
with a core set of clinical symptoms that help to distinguish DLB from other forms of dementia 
such as Alzheimer’s disease (AD). The core symptoms of DLB include fluctuating cognition, 
recurrent complex visual hallucinations and parkinsonism. Additionally, depression is 
experienced in around half of DLB patients and is associated with faster rate of cognitive 
decline, higher mortality rates and a poor response to treatment. The subgenual anterior 
cingulate cortex (sgACC) is integral in mood regulation, displaying structural, functional and 
metabolic abnormalities in depression, and shows early and extensive pathological changes in 
DLB. However, little is known about how any pathological or neurochemical changes in 
sgACC contribute to the aetiology of depression in DLB. 
Post-mortem tissue from cingulate cortex subregions was used to quantify neuropathological 
lesions in DLB cases with and without depression, and cognitively normal controls. 
Neurochemical analysis was performed to assess disease and depression specific changes in the 
sgACC in GABAergic, glutamatergic and monoaminergic transmission. Synaptic changes were 
assessed using confocal and stimulated emission depletion (STED) microscopy. 
Neuropathological burden in cingulate subregions showed disease, but not depression specific 
changes in DLB. Abnormalities in GABAergic and glutamatergic neurotransmission were 
observed in DLB cases with depression, showing greater dysregulation compared to DLB cases 
without depression. Dopaminergic deficits were observed in sgACC in DLB cases, with a 
greater reduction in DLB cases with depression, whereas no major changes in serotonergic or 
noradrenergic neurotransmission were observed in DLB.  
The results demonstrate that neurodegenerative neuropathological changes within the cingulate 
cortex do not appear to influence the development of depression in DLB. An imbalance in 
GABAergic/glutamatergic transmission within the sgACC was greater in DLB cases with 
depression, which may suggest greater dysregulation in excitation and inhibition, possibly 
contributing to the development of depression in DLB. This work also demonstrates the major 
role of dopaminergic neurotransmission in the aetiology of depression in DLB. Overall, this 
work indicates that treatment of depressive symptoms in DLB could benefit from modulation 
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Dementia is a syndrome characterised by progressive decline in memory, thinking, behaviour 
and the ability to perform everyday activities. It is one of the major causes of disability 
worldwide, and has a physical, psychological, social and economic impact not only on patients, 
but also on their families, carers and society. Around 50 million people live with dementia 
worldwide, with nearly 10 million new cases diagnosed every year. The number of people 
living with dementia in 2030 is estimated to reach 82 million (WHO, 2019, Collaborators, 
2019). In England and Wales, deaths due to dementia continue to increase and it is now 
acknowledged as the leading cause of death, accounting for 12.8% of all deaths registered 
(Office for National Statistics). 
The major causes of dementia are the primary neurodegenerative dementias, which are 
progressive and irreversible due to neuronal dysfunction and neuronal death. The most 
common forms include Alzheimer’s disease (AD), vascular dementia (VaD), dementia with 
Lewy bodies (DLB) and frontotemporal dementia (FTD) (WHO, 2019). Both clinically and 
pathologically AD is the most common form of neurodegenerative dementia, accounting for 
60-70% of all dementia cases (World Alzheimer Report, 2019). AD is characterised by 
progressive cognitive decline and impaired ability to form recent memories (McKhann et al., 
2011). The pathological characteristics of AD are intracellular neurofibrillary tangles, initially 
observed in the transentorhinal cortex, then temporal and insular cortex and eventually all 
cortical areas, as well as diffuse and neuritic extracellular amyloid plaques, that are initially 
observed in the neocortex, before spreading to the limbic, then subcortical brain areas and 
eventually the brainstem (Braak et al., 2006, Thal et al., 2002). Tau pathology is also associated 
with several other neurodegenerative disorders known as tauopathies, which include 
progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic grain 
disease (AGD) and Pick's disease (PiD) (Irwin, 2016). 
Parkinson's disease (PD) is the most common neurodegenerative movement disorder (Dorsey 
et al., 2007), and is characterised by the classical motor features of Parkinson’s, such as resting 
tremor, bradykinesia, rigidity, gait and postural instability, associated with the loss of 
dopaminergic neurones in the substantia nigra (SN) (Lang and Lozano, 1998). Dementia is 
often a late complication in PD (PDD), occurring in 75–90% of patients with a disease duration 
of 10 years or more (Buter et al., 2008). PD belongs to a group of neurodegenerative disorders 
called synucleinopathies, which have a common pathological substrate, α‐synuclein protein, 
3 
which accumulates in Lewy bodies (LB) and dystrophic Lewy neurites (Trojanowski and Lee, 
2001). Other synucleinopathies include dementia with Lewy bodies (DLB) and multiple system 
atrophy (MSA) (Jellinger, 2003b). 
In dementia, cerebral multi-morbidity is common and increases with age (Jellinger and Attems, 
2011), with over 50% of cases exhibiting pathological lesions associated with more than one 
neurodegenerative disease (Kovacs et al., 2013). AD often presents with cerebrovascular 
disease, LB pathology, transactivation response DNA binding protein 43 kDa (TDP-43) 
pathology, argyrophilic grain disease (AGD) and hippocampal sclerosis (Nagy et al., 1997, 
Attems et al., 2014). Co-morbid AD pathology is also commonly observed in DLB (Walker et 
al., 2015). 
1.1.1 Dementia with Lewy bodies  
DLB is a common form of neurodegenerative dementia, second only to AD in terms of 
prevalence, accounting for approximately 15-20% of all neuropathologically defined cases 
(McKeith et al., 2005). The prevalence of DLB in the whole population over 65 is 0.36%, 1 in 
270 people, or 4.2% of all dementia cases, with 7.5% observed clinically (Vann Jones and 
O'Brien, 2014). The incidence of DLB reaches 0.1% for the general population and 3.2% 
annually for all new dementia cases (Zaccai et al., 2005). Cognitive fluctuations, parkinsonian 
extra-pyramidal symptoms, recurrent complex visual hallucinations and rapid eye movement 
(REM) sleep behaviour disorder are the core clinical features of DLB (McKeith et al., 2017). 
Three indicative biomarkers are used clinically in the diagnosis of DLB: reduced dopamine 
transporter uptake in basal ganglia using single photon emission computed tomography 
(SPECT) or positron emission tomography (PET); abnormal 123iodine meta-
iodobenzylguanidine (MIBG) myocardial scintigraphy; as well as polysomnographic 
confirmation of REM sleep without atonia. A ‘probable DLB’ diagnosis can be made if two or 
more core symptoms, or one core symptom and one or more indicative biomarkers are present, 
whereas ‘possible DLB’ may be diagnosed if one core or one indicative biomarker is present 
in isolation (McKeith et al., 2017). 
1.1.1.1 Core clinical symptoms of DLB 
1.1.1.1.1 Cognitive fluctuations 
Fluctuating cognition refers to spontaneous alterations in arousal, attention and cognition, 
which can be marked by periods of reduced awareness to external stimuli and changes in 
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responsiveness to one’s surroundings, followed by normal, or near normal functioning  (Ballard 
et al., 2001, McKeith et al., 2017). Cognitive fluctuations are a core symptom of DLB affecting 
90% of cases, compared to 29% of PDD and 20% of AD cases (Ballard et al., 2002b, Walker 
et al., 2000, McKeith et al., 2005). DLB patients experience cognitive fluctuations more 
frequently than AD, where fluctuations are different in nature. These episodes of fluctuating 
cognition are typically associated with decreased executive and perceptual performance, 
confusion and difficulties in communication, whereas in AD they are primarily linked to 
memory impairment (Walker et al., 2000, Bradshaw et al., 2004). 
Cognitive fluctuations are likely to arise from functional instability of specific neural networks, 
rather than structural abnormalities (Taylor et al., 2013). In DLB, cognitive fluctuations are 
closely related to attentional dysfunction (Ballard et al., 2001), with dysfunction of attention–
executive networks being implicated in the aetiology of cognitive fluctuations in DLB (Peraza 
et al., 2014). 
Cholinergic dysfunction in DLB may also contribute to manifestation of fluctuating cognition, 
and cholinergic abnormalities are more profound in DLB compared to AD (Perry et al., 1994). 
Cholinergic deficits often occur early in DLB, with the temporal cortex more susceptible to 
reductions in choline acetyltransferase activity, whereas AD patients experience cholinergic 
loss in the later stages of the illness, with the frontal and parietal cortices affected the most 
(Tiraboschi et al., 2002). In DLB patients, improvements in attention are observed following 
treatment with the cholinesterase inhibitor rivastigmine (McKeith et al., 2000), further 
supporting cholinergic deficiency in fluctuating cognition in DLB.  
1.1.1.1.2 Parkinsonism 
Parkinsonism is the predominant clinical feature of PD, which can manifest as resting tremor, 
bradykinesia, rigidity, mask-like face, stooped posture and shuffling gait (Gibb and Lees, 
1988). Parkinsonian extra-pyramidal symptoms also affect about 70% of DLB patients 
(Aarsland et al., 2001a). Subtle differences in motor symptoms exist between DLB and PD 
patients. DLB patients mainly present with a motor phenotype primarily involving gait and 
postural difficulties, with very few DLB patients experiencing resting tremor compared to PD 
(Aarsland et al., 2001b, Burn et al., 2003). PDD patients often experience more severe motor 
features compared to DLB, with differentiation of DLB from PDD based on the timing of 
dementia and parkinsonian symptoms, whilst in PDD the presentation of extrapyramidal 
symptoms precedes the cognitive symptoms by at least a year (McKeith et al., 2005). AD 
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patients can also experience extrapyramidal symptoms, which often increase with disease 
progression (Tosto et al., 2015a). Parkinsonian features such as bradykinesia and rigidity are 
thought to be mediated by dopamine deficiency in PD and DLB (Zetusky et al., 1985). Gait 
and postural instability are more commonly observed in DLB patients than in PD, which are 
thought to be associated with cholinergic loss (Burn et al., 2003, Burn et al., 2006). 
1.1.1.1.3 Visual hallucinations 
Recurrent complex visual hallucinations (VH) occur in up to 80% of DLB cases (McKeith et 
al., 2017). The presence of VH in the early stages of the disease distinguishes DLB from other 
dementias (Fenelon et al., 2000). Recurrent complex VH in DLB manifest as well formed, 
complex vivid images of objects, animals and people (Burghaus et al., 2012). Gender 
differences in the context of VH have been observed, which might be related to personal 
experiences, with women more likely to hallucinate children, family members and pets, 
whereas men are more likely to hallucinate ‘machines’ (Urwyler et al., 2016). In AD, VH occur 
in 25% of patients (Ballard et al., 1999), which are often brief and simple, such as seeing 
shadows and patterns, and are often associated with greater cognitive impairment and in more 
advanced stages of the dementia (Hope et al., 1999). Around 20% of PD patients also 
experience VH, which are simple and non-threatening, involving the perception of movement 
or a presence in the peripheral visual field. PD patients can also experience auditory 
hallucinations, which are neutral in nature, unlike the threatening auditory hallucinations 
characteristic of schizophrenia (Fenelon et al., 2000). VH have also been observed in 
cognitively normal blind patients, known as Charles Bonnet syndrome (CBS). The content of 
VH in CBS often involves people, animals, plants and inanimate objects, which can occur in 
colour or black and white, more frequently occurring in the evening or at night, suggesting that 
sensory deprivation or low arousal (sitting or otherwise resting) are facilitating factors 
(Teunisse et al., 1996, Ffytche, 2005). 
Although abnormalities in saccadic eye movements, visual perception and pupil reactivity are 
frequently observed in DLB patients (Armstrong, 2012), and may result from pathology in the 
visual system (Diederich et al., 2014), the absence of major pathological changes in the primary 
visual cortex (Khundakar et al., 2016), as well as preservation of the lateral geniculate nucleus 
(Erskine et al., 2016), suggests that VH in DLB might be due to an impairment in ‘top down’ 
visual processing. DLB patients with VH show higher burden of Lewy body pathology in the 
inferior temporal, parahippocampal gyrus and amygdala compared to PDD, involved in visual 
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perception (Harding et al., 2002). Impairment in perception and attention in DLB patients may 
stem from cholinergic dysfunction (Collerton et al., 2005), with cholinergic deficits in DLB 
strongly correlating with VH severity and frequency, and improvement of VH with 
cholinesterase inhibitor treatment (Marra et al., 2012). 
1.1.1.1.4 REM sleep behaviour disorder 
REM sleep behaviour disorder (RBD) is a sleep disturbance characterised by a loss of normal 
skeletal muscle atonia with prominent motor activity and dreaming (Ferman et al., 2002, 
McKeith et al., 2017). Patients with RBD act out their dreams, often with violent or injurious 
behaviour during sleep. It can result in loud vocalisations, screaming and talking, as well as 
thrashing, punching, kicking and even falling out of bed, which can cause self-injury or injury 
to their bed partners (Schenck et al., 2013).  
RBD is often associated with α-synuclein accumulation and is considered a prodromal 
symptom of many synucleinopathies, such as DLB, affecting 76% of DLB cases, as well as 
PD, MSA and pure autonomic failure (Schenck et al., 2013, Boeve et al., 1998, Ferman et al., 
2002). RBD is not as common in tauopathies, such as AD and PSP, and tends to occur 
concurrently with or after the onset of dementia or parkinsonism (Boeve, 2010).  
Sleep-related brainstem nuclei, the peri–locus ceruleus, pedunculopontine nucleus (PPN) and 
laterodorsal tegmental nucleus, are key structures in modulating REM sleep (Chan et al., 2018). 
Cholinergic neurotransmission is known to be severely impaired in DLB due to dysregulation 
of cholinergic neurones in the PPN and nucleus basalis of Meynert (NBM), possibly 
contributing to the development of RBD (Kasanuki et al., 2018, Chan et al., 2018). LB related 
pathological changes and neuronal loss in the brainstem occurs early in DLB and PD (Braak et 
al., 2002), with post-mortem RBD cases showing predominant LB pathology in brainstem and 
limbic areas (Boeve et al., 2004). Early brainstem nuclei degeneration in synucleinopathies 
therefore might explain earlier occurrence of RBD in DLB and PD (Boeve et al., 2004). 
1.1.1.2 Supportive symptoms of DLB 
In addition to the core clinical features of DLB, there are several supportive features that may 
assist with a clinical diagnosis of DLB. Supportive symptoms of DLB, such as severe 
sensitivity to neuroleptics, repeated falls, syncope, postural instability, autonomic dysfunction, 
hypersomnia, hyposmia, delusions, apathy, anxiety and depression are very common, although 
they lack diagnostic specificity (McKeith et al., 2017).  
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DLB patients are particularly vulnerable to developing neuroleptic sensitivity, which occurs in 
30-50% of patients, even when exposed to low doses (Ballard et al., 1998). This can result in 
sudden sedation, rigidity, immobility, confusion, as well as death (Aarsland et al., 2005). 
Severe neuroleptic sensitivity has also been observed in 27% of PD and 39% of PDD patients, 
although it is rare in AD (Aarsland et al., 2005). Neuroleptic drugs, also known as 
antipsychotics, are used to manage psychosis, principally in schizophrenia, as well as mania 
and delusions (Aarsland et al., 2005, Ballard et al., 1998), and typically act by inhibiting 
dopaminergic D2 receptors (Madras, 2013). DLB patients show a reduction in striatal D2 
receptors, therefore neuroleptic medication may exacerbate striatal dopaminergic deficits 
further (Piggott et al., 1999).  
Autonomic dysfunction is a common feature in DLB and PD, with abnormalities in autonomic 
function often observed in prodromal stages of the disease (Postuma et al., 2013). Autonomic 
dysfunction can present as urinary incontinence, observed in 80% of patients with LB 
disorders, sexual dysfunction, affecting 75% of patients with PD, and 30% with DLB, 
constipation, affecting 90% of PD and 83% of DLB patients, and orthostatic hypotension, 
affecting 30-50% of patients with PD, with a higher prevalence in DLB, reaching 50-60% 
(Allan et al., 2007, Palma and Kaufmann, 2018, Thaisetthawatkul et al., 2004, Horimoto et al., 
2003). Repeated falls and syncope are also partly attributable to the presence of autonomic 
dysfunction (Stubendorff et al., 2012). The prevalence of falls in dementia is 8 times higher 
than in older people without dementia, with a prevalence of 90% in PDD, 77% in DLB, 47% 
in AD and 47% in VaD (Allan et al., 2009), and can cause significant injuries, 
institutionalisation, increased morbidity and mortality (Shaw, 2002). In DLB, syncopal attacks 
with complete loss of consciousness and muscle tone are thought to be associated with LB 
pathology in the brainstem (McKeith, 2004). 
Depression, anxiety, apathy and delusions are the most common neuropsychiatric symptoms 
in DLB, which may assist in diagnosis. Depression affects 50-80% of DLB and 40% of PD 
patients (Stefanova et al., 2000, Yamane et al., 2011). The incidence of depression is much 
greater in DLB patients compared to AD (Chiu et al., 2017), with depression often present at 
prodromal stages of DLB (Fujishiro et al., 2015). Depression in dementia is associated with 
poor quality of life, increased morbidity and a more rapid progression of dementia (Barca et 
al., 2010, Lenze et al., 2005, Starkstein et al., 1992). Depression often goes undetected and 
undiagnosed (Baller et al., 2010) due to the overlapping symptoms of dementia and depression 
as well as other comorbid disorders (Kallenbach and Rigler, 2006). Anxiety and apathy are 
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frequent symptoms in DLB and PD patients, and often co-exist with depression (Brown et al., 
2011, Shiba et al., 2000, Wen et al., 2016, Breitve et al., 2016). Delusions are also common 
neuropsychiatric symptoms in DLB, presenting in 65% of patients at some point during the 
illness, often occurring as recollections of hallucinations and perceptual disturbances that can 
have complex and bizarre content. In contrast, delusions in AD patients often present as 
mundane ideas based on forgetfulness and distorted or misinterpreted memories (McKeith et 
al., 2004, Tzeng et al., 2018). 
1.1.1.3 DLB biomarkers 
The revised DLB clinical diagnostic criteria refer to several indicative and supportive 
biomarkers for differential clinical diagnosis of DLB (McKeith et al., 2017). Dopamine 
transporter (DAT) imaging is used to detect nigro-striatal dopaminergic neurodegeneration 
associated with PD and DLB (Seifert and Wiener, 2013). DAT imaging shows 78% sensitivity 
and 90% specificity in differential diagnosis of DLB (McKeith et al., 2007), with DLB patients 
showing reduced dopamine transporter (DAT) uptake in the putamen compared to AD using 
SPECT imaging that correlates with autoradiographic evidence of reduced DAT in post-
mortem tissue (Colloby et al., 2012b, Piggott et al., 1999). While DLB and PD show similar 
levels of striatal DAT loss, the differences arise in the subregional pattern of striatal dopamine 
depletion, where selective degeneration of ventrolateral SN neurones is seen in PD. This may 
explain the differences in clinical phenotypes between DLB and PD (Walker et al., 2004). 
Cardiac postganglionic, presynaptic sympathetic denervation is common in Lewy body 
disorders (LBD), and can be detected using 123Iodine-MIBG myocardial scintigraphy. DLB 
patients show extensive reduction in cardiac 123Iodine-MIBG uptake, which is indicative of 
cardiac sympathetic neuronal loss (McKeith et al., 2017, Oide et al., 2003, Yoshita et al., 2015). 
It shows 69% sensitivity and 87% specificity for discriminating probable DLB from probable 
AD (Yoshita et al., 2015), as well as PD from MSA, which is associated with preganglionic 
sympathetic dysfunction (Druschky et al., 2000). 
Polysomnography (PSG) is a sleep study methodology, used to diagnose sleep disorders, by 
recording the electroencephalogram (EEG), oxygen level in the blood, heart rate, breathing, 
eye and leg movements during sleep. PSG confirmation of REM sleep without atonia is a 
highly specific predictor of DLB (McKeith et al., 2017). A positive confirmation of PSG in a 
patient with dementia and a history of RBD is sufficient for a probable DLB diagnosis (Boeve 
et al., 2013). 
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Other supportive biomarkers can also aid in diagnostic evaluation but lack specificity in 
diagnosis of DLB. Structural magnetic resonance imaging (MRI) can be useful in detecting the 
medial temporal lobe atrophy (MTA) typically observed in AD, with DLB patients showing 
relative preservation of the medial temporal lobe (Burton et al., 2009). MTA represents loss of 
volume in the hippocampus and entorhinal cortex associated with neurofibrillary tangle 
pathology (Braak and Braak, 1991). Structural imaging can also be useful for the exclusion of 
other possible causes of dementia such as gliomas, subdural hematomas, vascular 
malformations and normal pressure hydrocephalus (Harper et al., 2014). 
Functional imaging reflects cerebral metabolic activity and helps to identify characteristic 
patterns of hypometabolism associated with different neurodegenerative diseases using 
fluorodeoxyglucose (FDG)-PET and SPECT. Occipital metabolism/perfusion is a supportive 
biomarker in DLB diagnosis, showing reduced metabolism in DLB patients compared to AD 
(Ishii et al., 1998). Relative preservation of the posterior cingulate cortex (PCC) metabolism 
compared to precuneus and cuneus, called the cingulate island sign (CIS), is commonly 
observed in DLB compared to AD patients, and is another supportive biomarker in diagnosis 
of DLB (Graff-Radford et al., 2014). Lower pathological neurofibrillary tangle (NFT) burden 
in DLB compared to AD has been suggested to be a correlate of the CIS in DLB (Graff-Radford 
et al., 2014). 
EEG changes have been reported in DLB, showing predictive value of 90% for the diagnosis 
of DLB compared with AD (Bonanni et al., 2008, McKeith et al., 2017). EEG provides a 
functional measure of neuronal and synaptic integrity. DLB patients show pronounced slow-
wave activity, with increased delta and theta power in posterior occipital and parietal regions 
(van der Zande et al., 2018). These abnormalities positively correlate with severity of cognitive 
fluctuations, and may be useful in the differential diagnosis of DLB and AD even in the earliest 
stages of dementia (Bonanni et al., 2008, Ferman et al., 2011). 
In vivo imaging of amyloid and tau has been useful in identifying early pathological changes, 
and can help predict disease progression and treatment response based on the presence of 
multiple pathologies (McKeith et al., 2017). The C11 Pittsburgh compound B (PiB), which 
demonstrates high affinity and selective amyloid-beta (Aβ) binding, has been suggested to 
predict the progression of mild cognitive impairment (MCI) to AD (Villemagne et al., 2011b). 
PiB retention is suggested to be lower in DLB than in AD patients and shows high specificity 
(Kantarci et al., 2019). Other novel fluorine 18–labelled (18F) PET tracers, 18F-florbetapir, 18F-
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florbetaben and 18F-flutemetamol, which bind to fibrillar amyloid-β aggregates, have also 
shown high sensitivity and specificity for diagnosis of AD (Fleisher et al., 2011, Vandenberghe 
et al., 2010, Duara et al., 2013, Villemagne et al., 2011a, Schipke et al., 2012). PET ligands 
showing high affinity for NFT aggregates, such as 18F-MK-6240 PET and 18F-T807 show 
minimal off-target binding in the human brain, and may be useful in differential diagnosis of 
different tauopathies (Betthauser et al., 2019, Wooten et al., 2017), and can be useful in 
identifying DLB due to reduced retention compared to AD patients (Kantarci et al., 2017). 
While cerebrospinal fluid (CSF) or blood α-synuclein biomarkers for DLB are not currently 
available, some studies have shown an increase in plasma oligomeric α-synuclein in DLB and 
PD (El-Agnaf et al., 2006), as well as total α-synuclein in PD and MSA compared to controls 
(Lee et al., 2006). Total α-synuclein levels in CSF were shown to be significantly lower in 
patients with PD (Tokuda et al., 2006) and DLB compared to controls (Wennstrom et al., 2012). 
CSF biomarkers of AD, including Aβ 1–42 (reflecting amyloid burden), total-tau (reflecting 
neuronal degeneration) and phospho-tau (reflecting neurofibrillary tangle density), can be 
useful in determining concomitant AD pathology or predicting cognitive decline in DLB 
(Hansson et al., 2006). Decreased levels of CSF Aβ 1-42 have been observed in PD patients 
(Alves et al., 2010), associated with faster cognitive deterioration and possible transition to 
PDD (Alves et al., 2014). Total tau CSF levels were shown to be higher in DLB patients 
compared to PD, PDD and controls, but lower than in AD (Parnetti et al., 2008, Parnetti et al., 
2011). 
1.1.1.4 Treatment of DLB 
Due to the many facets of DLB, treatment is often complex and challenging, and while there 
are no treatments that slow the progression of disease, symptomatic treatments for motor, 
cognitive, neuropsychiatric, autonomic and sleep dysfunction can be effective in improving the 
patient’s quality of life (Taylor et al., 2019). Non-pharmacological approaches can be used to 
improve the quality of life in patients with DLB, and exercise-based interventions have also 
been suggested to be beneficial in improving cognition and motor symptoms (Uc et al., 2014).  
The efficacy of deep brain stimulation (DBS) in treating cognitive impairment in PDD has been 
shown using bilateral stimulation of the subthalamic nucleus (STN) and the nucleus basalis of 
Meynert (NBM), although has not been applied to DLB (Freund et al., 2009). Pharmacological 
treatment of cognitive symptoms with the cholinesterase inhibitors, rivastigmine and donepezil 
has been shown to improve cognition in DLB patients (McKeith et al., 2000, Rowan et al., 
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2007), whereas memantine, an N-methyl D-aspartate (NMDA) receptor antagonist, has also 
shown efficacy in treating cognitive symptoms in DLB and PDD patients (Aarsland et al., 
2009). 
As in PD, levodopa (L-DOPA)/carbidopa treatment for motor symptoms in DLB has proven 
the most effective (Seppi et al., 2011).  While L-DOPA compensates for the decrease in 
endogenous dopamine in the striatum, an increase in the levels of dopamine in the nucleus 
accumbens (NAcc), limbic regions and prefrontal cortex (PFC) can result in the exacerbation 
of neuropsychiatric and cognitive symptoms in DLB patients (Lucetti et al., 2010). 
Levodopa/carbidopa treatment may be most useful to patients with prominent parkinsonism, 
but few or no neuropsychiatric symptoms (Goldman et al., 2008). Dopamine agonists are less 
likely to be used in DLB, as they can induce compulsive behaviours (Hassan et al., 2011). 
Cholinesterase inhibitors have also been shown to improve neuropsychiatric symptoms in 
LBD, such as VH and delusions (McKeith et al., 2000), whereas clozapine has proven to be 
effective in treatment of PD associated psychosis (Connolly and Fox, 2014, Seppi et al., 2011). 
The evidence for antidepressant efficacy in treatment of depression in DLB is sparse. The 
selective serotonin reuptake inhibitors (SSRI) and serotonin and norepinephrine reuptake 
inhibitors (SNRI) for treatment of depression in PD are well tolerated, although they lack 
efficacy (Starkstein and Brockman, 2017), whereas tricyclic antidepressants (TCAs), 
nortriptyline and desipramine, have been shown to be efficacious for the treatment of 
depression or depressive symptoms in PD (Liu et al., 2013). Reduction of depressive symptoms 
in LBD patients has been observed following treatment with electroconvulsive therapy (ECT), 
as well as repetitive transcranial magnetic stimulation (rTMS) (Takahashi et al., 2009). 
Symptoms associated with autonomic dysfunction, such as constipation and postural 
hypotension respond well to standard medications (Seppi et al., 2011).  
1.1.2 Neuropathological features of DLB 
1.1.2.1 α-synuclein 
1.1.2.1.1  α-synuclein structure 
α-synuclein is a 140 amino acid (AA) protein encoded by the SNCA gene. Alpha-synuclein has 
an N-terminal lipid-binding α-helix, a non amyloid-beta component (NAC) domain and a C-
terminal acidic tail (Figure 1.1) (Chiba-Falek, 2017). The N-terminus of α-synuclein is a 
12 
positively charged region, with 11-AA repeats that contain a highly conserved KTKEGV motif, 
which is also present in the α-helical domain of apolipoproteins. These repeat sequences enable 
α-synuclein to form a helical structure, which is important in α-synuclein lipid interactions 
(Sode et al., 2006), with point mutations associated with synucleinopathies located in this 
region. The C-terminal domain of α-synuclein is an acidic tail of 43-AA residues, which is 
largely unstructured (Davidson et al., 1998, Ulmer et al., 2005) and a target of various post-
translational modifications (Oueslati et al., 2010). The NAC domain (AA61-95) of α-synuclein 
was first observed in amyloid plaques associated with AD (Ueda et al., 1993), and is believed 
to be responsible for α-synuclein aggregation (Alexopoulos et al., 2013). The C-terminal 
interaction with the NAC region, especially the phosphorylation of serine 129 residue, is 
thought to be responsible for inhibition of α-synuclein aggregation (Esposito et al., 2007).  
 
Figure 1.1 α-synuclein structure.  
(Top) Schematic representation of α-synuclein protein. The N-terminal domain (amino acids 
1–60) is responsible for α-synuclein-membrane interactions, with point mutations located in 
this region (A30P, E46K, G51D, H50Q and A53T), associated with PD. The central non-β 
amyloid component (NAC) hydrophobic region (amino acids 61-95) is required for the 
aggregation and formation of amyloid fibrils. The acidic C-terminal (amino acids 96–140) is 
largely unstructured and has a number of phosphorylation sites (tyrosine 125, 133, 136 and 
serine 129). (Bottom) α-synuclein aggregation. Under physiological conditions free cytosolic 
α-synuclein can exist as a monomer or conformation specific membrane bound. Under 
pathological conditions soluble α-synuclein monomers associate to form oligomers, which 
further generates protofibrils (immature fibrillar aggregates), then fibrils, which leads to the 
formation of large and insoluble aggregates, known as Lewy bodies and Lewy neurites. 
Adapted from (Jones et al., 2014). 
 
The natively unfolded monomeric α-synuclein, approximately 14 kDa, is present in the cytosol, 
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synucleins functions are based on different cellular locations (Ahn et al., 2002). α-synuclein 
has also been shown to exist as a helically folded tetramer when isolated from red blood cells 
(Bartels et al., 2011). 
1.1.2.1.2 α-synuclein function 
α-synuclein is predominantly expressed in the central nervous system (CNS) and synthesised 
in neuronal cell bodies. The physiological function of α-synuclein is poorly understood, with 
deletion of SNCA gene in mice showing no major abnormalities (Abeliovich et al., 2000a). 
While initially described as a nuclear protein (Mori et al., 2002, Yu et al., 2007), presynaptic 
localization of α-synuclein has become well established (Jakes et al., 1994), with studies also 
showing the presence of extracellular α-synuclein (El-Agnaf et al., 2003). α-synuclein 
facilitates exocytosis by pooling and trafficking synaptic vesicles and regulating SNARE 
(soluble N-ethylmaleimide-sensitive factor attachment protein receptor) protein assembly 
(Garcia-Reitbock et al., 2010). The SNARE proteins assemble into a four-helix bundle to 
facilitate the exocytotic release of neurotransmitters into the synaptic cleft, through interaction 
with other proteins, including α-synuclein, which supports exocytosis by maintaining the 
SNARE complex assembly (Burre et al., 2010, Sharma et al., 2011). α-synuclein involvement 
in neurotransmitter release is dependent on the function of the SNARE protein complex 
(Bennett, 1994), via direct interaction with synaptobrevin II (Figure 1.2), a major component 
of the SNARE complex (Burre et al., 2010). α-synuclein knockout mice show a significant 
decrease in SNARE complex proteins (Burre et al., 2010), as well as exaggerated levels of 
dopamine release following stimulation, which suggests that α-synuclein is involved in 
modulation of dopamine neurotransmission (Abeliovich et al., 2000b). Overexpression of α-
synuclein has been linked to changes in vesicular monoamine transporter-2 (VMAT-2) activity 
(Guo et al., 2008), an increase in oxidative stress (Chen et al., 2008) and degeneration of 
dopaminergic neurones (Gonzalez-Hernandez et al., 2004, Yamamoto et al., 2006). This is 
supported by a decrease in vesicular dopamine storage followed by degeneration of nigral 
dopamine neurones with α-synuclein overexpression (Ulusoy et al., 2012). α-synuclein has also 
been shown to be implicated in glutamatergic neurotransmission, where pathological α-
synuclein oligomer application to hippocampal slices results in a decrease in long-term 




Figure 1.2 The SNARE complex. 
The core SNARE complex is a four α-helical structure necessary in vesical fusion, which is 
facilitated by synaptobrevin, syntaxin, SNAP-25 and synaptotagmin, that come together to 
form a coiled-coil motif. Neurotransmitter release involves a series of events, that requires 
translocation of proteins in the membrane, disruption of the lipid bilayer, fusion pore formation, 
followed by neurotransmitter release into the synaptic cleft.  
 
 
1.1.2.1.3 α-synuclein aggregation 
Under pathological conditions, the unstructured soluble α-synuclein protein can assemble into 
amyloid aggregates, forming intracellular inclusions known as LB, which are characteristic of 
α-synucleinopathies (Spillantini et al., 1997). Several mechanisms have been suggested to be 
involved in α-synuclein aggregation and the pathogenesis of the α-synucleinopathies, and 
include changes in the ubiquitin-proteasome system (Emmanouilidou et al., 2010), 
mitochondrial dysfunction (Elkon et al., 2002) and production of reactive oxygen species (Junn 
and Mouradian, 2002), that can eventually lead to neuronal dysfunction and death (Cookson 
and van der Brug, 2008). The α-synuclein aggregation process follows a nucleation‐dependent 
pattern, where monomers assemble to form aggregation nuclei, followed by the formation of 
oligomers, intermediates of the aggregation process that are thought to be the most potent 
neurotoxic species of α-synuclein (Karpinar et al., 2009, Winner et al., 2011), causing a wide 
range of damaging effects (Figure 1.1). Other studies have demonstrated that α-synuclein fibrils 
can also induce toxicity (Braak et al., 2002, Volpicelli-Daley et al., 2011b). The formation of 
oligomeric and insoluble fibrillar α-synuclein species may be initiated, enhanced and 
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accelerated by SNCA gene mutations, with point mutations of A30P, A53T and E46K 
implicated in familial PD (Zarranz et al., 2004, Kruger et al., 1998, Polymeropoulos et al., 
1997). Post-translational α-synuclein modifications, i.e. phosphorylation of Ser-129 (Anderson 
et al., 2006), as well as overexpression (Yamada et al., 2004), can also promote α-synuclein 
aggregation. 
1.1.2.1.4 α-synuclein pathology in DLB 
The pathological hallmark of DLB is the loss of nigrostriatal dopaminergic neurones, induced 
by the aggregation of α-synuclein protein, which is a major component of LB and abnormal 
neuronal aggregates known as Lewy neurites (LN) (Spillantini et al., 1997). LB are typically 
intracytoplasmic eosinophilic inclusions with a dense core, consisting of dense granular 
material, which is surrounded by pale halo, composed of radiating filaments about 13 nm in 
diameter (Burkhardt et al., 1988, Galloway et al., 1992). Typically, LB are found in brainstem, 
limbic and neocortical brain regions, but also in the peripheral autonomic ganglia (Fumimura 
et al., 2007, McKeith et al., 2005). Compared to the brainstem LB, which are typically 
spherical, cortical LB are less defined and without a halo, with highest densities observed in 
the limbic regions, such as amygdala, cingulate, insula and entorhinal cortex (Burkhardt et al., 
1988). The major components of LB and LN are α-synuclein (Spillantini et al., 1997), ubiquitin 
(Kuzuhara et al., 1988) and neurofilaments (Schmidt et al., 1991). Recent proteomic studies 
have revealed complex molecular composition of cortical LB, identifying just under 300 
proteins, with 32% of identified proteins known to be involved in signal transduction and 
apoptosis, 19% in cytoskeletal function, 14% in metabolic activity, 10% in extracellular matrix 
formation, 8% in protein synthesis and degradation, 4% in neurotransmission and 
inflammation, with 11% of proteins of unknown function (Leverenz et al., 2007).   
The progression of α-synuclein pathology in DLB is thought to correspond to the stages of PD 
pathology spread. According to the staging system proposed by Braak, the ascending 
progression of α-synuclein pathology is initiated in the lower brainstem (dorsal motor vagal 
nucleus and intermediate reticular zone) , which then spreads into upper brainstem (raphe, locus 
ceruleus (LC) and substantia nigra (SN)) and the basal forebrain, eventually affecting 
amygdala, thalamus, hypothalamus and ultimately neocortex (Figure 1.3) (Braak et al., 2002). 
Pathological diagnosis of DLB requires the presence of limbic or neocortical LB pathology 
(McKeith et al., 2005). While the initial topographical spread of LB pathology in DLB and 
PDD patients may be different, with higher burden of LB pathology in the neocortical parietal 
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and temporal cortex observed in DLB cases, in the terminal stages of the disease they are 
indistinguishable (Ruffmann et al., 2016). DLB cases with higher neocortical compared to 
brainstem α-synuclein pathology often present with more severe dementia, whereas more 
severe presentation of parkinsonism has been associated with predominantly brainstem α-
synuclein pathology (Yamamoto et al., 2005). 
 
Figure 1.3 Propagation of α-synuclein, tau and Aβ in human brain 
 (Left) α-synuclein pathology ascends from the brainstem. LB and LN initially present in the 
olfactory bulb and the dorsal motor vagal nucleus and glossopharyngeal nerves of the medulla 
oblongata (stages 1 and 2), then spread to the pons, midbrain and basal forebrain (stages 3 and 
4), followed by the neocortex (stages 5 and 6). (Middle) Tau pathology initially develop in the 
locus coeruleus, transentorhinal and entorhinal regions (stages I and II), followed by 
hippocampal formation and some parts of the neocortex (stages III and IV), eventually 
affecting the neocortex by large (stages V and VI). (Right) Aβ plaques are firstly observed in 
the basal temporal and orbitofrontal neocortex (phase 1), then in hippocampus, amygdala, 
diencephalon, basal ganglia and neocortex (phases 2 and 3), with severe AD cases showing Aβ 





Neurodegeneration along specific pathways is assumed to be due to prion-like spread of 
misfolded proteins through anatomically interconnected brain regions (Ahmed et al., 2016, 
Danzer et al., 2012, Hansen et al., 2011, Luk et al., 2012). Grafted foetal nigral neurones in PD 
patients show LB inclusions years after transplantation, suggesting that physical contacts 
between susceptible regions, axonal transport and trans-synaptic transmission of misfolded and 
aggregated α-synuclein might have a role in the pathogenesis and propagation of PD 
(Kordower et al., 2008, Li et al., 2008). Therefore, specific clinical symptoms in LBD patients 
may be due to accumulation of misfolded proteins in different brain regions within specific 
anatomical pathways.  
1.1.2.2 Concomitant pathologies in DLB 
Multiple pathologies are not uncommon in the aged brain (Kovacs et al., 2013), with mixed 
dementia diagnosis typically given when pathological diagnostic criteria for more than one 
disorder has been met (Jellinger and Attems, 2007, Walker et al., 2015). In addition to α-
synuclein pathology, 50–80% of patients with DLB have concomitant AD pathology (Halliday 
et al., 2011) in the form of NFT, neuropil threads (NT), Aβ plaques and Aβ neuritic plaques 
(NP), (McKhann et al., 2011). NFT are intraneuronal aggregates in cell bodies, whereas NT 
present as axonal and dendritic segments containing aggregated and hyperphosphorylated tau 
(Braak and Braak, 1991). The primary site for NFT detection is the trans-entorhinal cortex, 
later showing abundancy in hippocampus and amygdala, with final stages of NFT spread 
reaching neocortex and ultimately involving primary motor and sensory areas (Hyman et al., 
2012) (Figure 1.3). In AD, Aβ deposition during the disease course follows five stages, firstly 
affecting only neocortical brain regions, followed  by allocortex, then basal ganglia, basal 
forebrain, and finally the cerebellum and brainstem nuclei (Figure 1.3) (Thal et al., 2002). 
While the presence of NFT or Aβ is not necessary for a neuropathological diagnosis of DLB 
(McKeith et al., 2005), concomitant AD type pathology is thought to contribute to faster 
cognitive decline in DLB (Howlett et al., 2015). α-synuclein, tau and Aβ have been shown to 
promote the accumulation of one another (Giasson et al., 2003, Kotzbauer et al., 2004), with 
induction of Aβ in vivo shown to enhance the aggregation of α-synuclein, suggesting that it 
may accelerate the progression of LBD (Masliah et al., 2001). 
The frequency of vascular pathologies increases with age, and vascular pathology is also 
commonly observed in DLB cases, which show more severe cerebrovascular lesions compared 
to PD (Jellinger and Attems, 2008). In DLB cases, cerebral amyloid angiopathy (CAA) is more 
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commonly observed when compared with PD (De Reuck et al., 2013, Jellinger, 2010), and 
shows a significant increase in total mini-bleeds compared to control cases (De Reuck et al., 
2013). DLB cases also present with more extensive white matter hyperintensities (WMH) 
compared to PDD, PD and controls (Joki et al., 2018). In PD, WMH were shown to be 
associated with more severe gait problems, bradykinesia and postural instability (Piccini et al., 
1995).  
The characteristic neuropathological substrate of FTD, TDP-43, has been observed in DLB, 
AD and control cases (McAleese et al., 2017). TDP-43 positive inclusions are observed in 45% 
of DLB cases, predominantly within the amygdala, hippocampus, dentate gyrus, entorhinal, 
occipito-temporal and inferior temporal cortices (Higashi et al., 2007). A similar distribution 
of TDP-43 has been observed in DLB and AD cases, with temporal cortex shown to be more 
severely affected in AD, whereas cingulate and insular cortices were unaffected in both groups 
(Higashi et al., 2007). 
1.1.3 Major depressive disorder (MDD) 
1.1.3.1 Diagnostic criteria 
Depression is a leading cause of disability that impacts all aspects of everyday life (Steger and 
Kashdan, 2009). The lifetime prevalence of major depressive disorder (MDD) is 9.6% for men 
and 20.4% for women (Steffens et al., 2000). The Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV) defines MDD by one or more major depressive episodes and the lifetime 
absence of mania and hypomania. To meet the criteria for MDD, one of the symptoms must be 
depressed mood or anhedonia with, additionally, five of the nine symptoms present during the 
same two-week period and experienced ‘nearly every day’ (Table 1.1) (American Psychiatric 
Association, 2013). MDD defined as above is the type of depression for clinical research 
studies and trials, whereas broader definitions of depression are also frequently used based on 







Table 1.1 DSM-5 criteria for major depressive disorder 
1Criteria A–C represent a major depressive episode (MDE). 2Clinical judgement is inevitably 
required to distinguish if MDE is present in addition to a normal response. 3Exclusion E does 
not apply to a significant loss if (hypo)manic episode was substance induced or attributable to 
medical condition. Adapted from (American Psychiatric Association, 2013). 
1.1.3.2 Treatment of depression 
The first antidepressant drugs were discovered by accident and belong to a family of 
monoamine oxidase inhibitors (MAOI). Originally used to treat tuberculosis, the MAOI drug 
iproniazid was trialled in depressed patients, who showed substantial improvement in mood 
and increased interest in their surroundings following the treatment (Cole et al., 1959). 
Monoaminergic pharmacological agents are commonly used as a first line treatment option in 
moderate to severe depression and are based on the hypothesis that decreased mood and 
development of depression is due to reduced monoaminergic drive. The efficacy of early 
MAOI antidepressants was largely based on their serotonergic actions, which has led to the 
development of new generation of antidepressants, the SSRI (e.g. escitalopram, sertraline and 
fluoxetine). SSRI drugs proved to be much safer to use and showed reduced side effects 
compared to TCAs (Cryan and Leonard, 2000, de Montigny and Blier, 1984), and are still the 
most widely prescribed antidepressants (Dupuy et al., 2011). While SSRI antidepressants are 
better tolerated than TCAs, studies have shown no difference in their efficacy (Arroll et al., 
2005, Geddes et al., 2000). Antidepressants with dual and triple action mechanisms, such as 
Five or more out of nine symptoms (including at least one of depressed mood and loss of interest or
pleasure) in the same 2-week period. Each of these symptoms represents a change from previous functioning.
1. Depressed mood (subjective or observed; Most of the day, nearly every day)
2. Loss of interest or pleasure (Most of the day, nearly every day)
3. Change in weight or appetite (Weight: 5% change over month; Appetite: Nearly every day)
4. Insomnia or hypersomnia (Nearly every day)
5. Psychomotor retardation or agitation (observed; Nearly every day)
6. Loss of energy or fatigue (Nearly every day)
7. Worthlessness or guilt (Nearly every day)
8. Impaired concentration or indecisiveness (Nearly every day)
9. Thoughts of death or suicidal ideation or attempt (Thoughts: recurrent; Attempt: any)
A
Symptoms cause significant distress or impairment.
Episode not attributable to a substance or medical condition 1, 2
Episode not better explained by a psychotic disorder. 






SNRI (venlafaxine, levomilnacipran), norepinephrine-dopamine reuptake inhibitors (NDRI; 
bupropion), and serotonin-norepinephrine-dopamine reuptake inhibitors (SNDRI; 
amitifadine), are also used for treatment of depression (Papakostas et al., 2007).  
Antipsychotic drugs have long been used in the treatment of MDD. The typical (first 
generation) antipsychotics were often used to treat severe depressive disorders accompanied 
with psychotic symptoms (Schatzberg and Rothschild, 1992a), but due to their side effects, 
such as extrapyramidal symptoms, tardive dyskinesia and neuroleptic malignant syndrome, are 
rarely used as a monotherapy. The atypical (second generation) antipsychotics show lower rates 
of side effects and less severe cognitive impairment, and in combination with other 
antidepressants have also been shown to improve the efficacy of treatment of psychotic 
depression, treatment resistant depression and as monotherapy for MDD (Chen et al., 2011, 
Schatzberg and Rothschild, 1992b, Kennedy et al., 2001). 
In addition to pharmacological interventions, other treatments are effective in alleviating 
depression. Psychotherapies, especially cognitive behavioural therapy (CBT), are a safe and 
effective treatment for MDD (McMain et al., 2015), which is based on the premise that 
maladaptive information processing (repetitive negative thinking) has a causal role in 
depression. A study on neural mechanisms of CBT treatment for depression showed increased 
connectivity in attentional control networks following treatment (Yang et al., 2018). 
ECT is a well-established treatment, proven to be effective in about 70% of patients with severe 
and treatment resistant depression (Kho et al., 2003). Restrictions to wide application of ECT 
in clinical settings are due to adverse effects on cognition and memory (Vasavada et al., 2017, 
Micallef-Trigona, 2014). rTMS is a non-invasive, safe neuromodulation therapy for MDD, 
supported by extensive clinical research (Janicak et al., 2008, Levinson et al., 2010, George et 
al., 2010). rTMS has been shown to have the same antidepressant efficacy as some 
antidepressants, with fewer adverse effects (Fregni et al., 2004). DBS was first used to treat 
movement disorders and recently has been extended to the treatment of psychiatric disorders. 
Neuroimaging has played an important role in identifying specific DBS targets. DBS has 
proved effective in producing antidepressant effects in treatment resistant depression patients 
(Lozano et al., 2008, Malone et al., 2009), with the subgenual anterior cingulate cortex 
(sgACC) (Holtzheimer et al., 2012, Choi et al., 2015, Berlim et al., 2014) and NAcc (Bewernick 
et al., 2010) being primary targets. 
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1.1.3.3 Late-life depression 
MDD is very common throughout the life course (Kessler et al., 2005), but development of 
depression in later life may be a risk factor of early presentation of dementia, therefore the 
pathophysiological mechanisms that underlie depression in later life and neurodegeneration 
may differ greatly from MDD in early-life. Depression in later life has a high prevalence, with 
1-5% of adults affected over 65 years of age (Fiske et al., 2009), and 17.1% of patients aged 
75 years and older having been given a diagnosis of MDD (Luppa et al., 2012). MDD in later 
life shows a higher incidence of functional decline, decreased quality of life, morbidity and 
mortality (Fiske et al., 2009), and is associated with an increase in health care costs (Luppa et 
al., 2008). The presentation of depression in older adults differs somewhat from younger 
populations, with a higher prevalence of sleep disturbances, fatigue, loss of interest in daily 
activities, and a feeling of hopelessness about the future (Butters et al., 2004). Apathy is a 
common feature of late-life depression and a predictor of poor response to treatment and poor 
remission rates (Levkovitz et al., 2011).  
Depression in neurodegenerative disorders is common, with variable prevalence depending on 
the screening method used (Barca et al., 2010, Vilalta-Franch et al., 2006). Studies using DSM-
IV criteria showed that the prevalence of MDD in PD patients was 17% (Reijnders et al., 2008), 
in AD 12-42% (Chi et al., 2015, Vermeiren et al., 2015), whereas in DLB it is approximately 
45-50%, and is more persistent than in AD (Fritze et al., 2011). Differences in depressive 
symptoms between DLB and AD have been observed, with pervasive anhedonia, sleep 
disruption and feelings of worthlessness being significantly higher in DLB patients (Chiu et 
al., 2017). 
It is not clear whether depression is a risk factor for developing dementia or an additional 
feature of dementia. While early life depression has been associated with an increased risk of 
dementia, later life depression is suggested as a prodrome of dementia (Bennett and Thomas, 
2014). MCI in later life may be associated with depression and shows underlying 
neuropathological changes (Tosto et al., 2015b). Cognitive deficits in later life depression are 
also prominent, which often persist despite remission of depressive symptoms (Kohler et al., 
2010a). It is not clear whether impairments in memory, executive function and/or processing 
speed are the basis of cognitive impairment in later life depression. A study showed that 
information processing speed is impaired in patients with late onset depression, with a greater 
effect on executive functioning than on memory deficits (Kohler et al., 2010b). 
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1.1.3.4 Depression in DLB 
Depression and anxiety are common prodromal psychiatric symptoms in DLB and also PD 
patients, and are associated with cognitive impairment (Fujishiro et al., 2015), faster cognitive 
decline (Boot et al., 2013), higher mortality rates and a poor response to treatment (Ritchie et 
al., 1998). These results are contradictory to a longitudinal study that found no clear association 
between anxiety and faster decline in cognition or dementia severity in DLB or AD patients 
(Breitve et al., 2016).  
There are many challenges in detecting depressive symptoms in dementia patients. Depression 
in dementia can often go undiagnosed due to overlap of symptoms between the two disorders. 
Furthermore, dementia leads to reduced awareness of depression, therefore in the more 
advanced stages of dementia the use of self-reporting depression assessment scales, such as the 
Geriatric Depression Scale (GDS) and Montgomery–Åsberg Depression Rating Scale 
(MADRS) could be difficult. GDS has been shown to be less suitable for patients with severe 
dementia, but is considered to be applicable for patients with mild dementia (Korner et al., 
2006). MADRS was developed for use in cognitively intact patients, where some symptoms 
can overlap with those found in dementia, and is also suitable for patients with mild dementia 
(Leontjevas et al., 2009). However, the Cornell Scale for Depression in Dementia (CSDD) is 
probably the most widely used tool to assess depression in dementia (Alexopoulos et al., 1988). 
It relies on an informant to confirm the responses of patients, and has been shown to be reliable 
and valid in various clinical settings (Barca et al., 2010, Towsley et al., 2012, Williams and 
Marsh, 2009, Jeon et al., 2016).  
1.1.4 Pathophysiology of depression 
1.1.4.1 Structural and functional abnormalities in depression 
The neural circuits that mediate mood are not completely understood, although several brain 
regions have been identified. The clinical phenomena of MDD potentially involves many brain 
systems involved in the regulation of mood, anxiety, reward processing, attention, motivation 
and stress responses (Price and Drevets, 2012). Initial studies in MDD examined structural 
changes in the brain (size or volume), and identified relevant regions and networks potentially 
involved in the pathophysiology of depression. Certain regions, such as the medial, dorsal and 
orbitofrontal prefrontal networks are intimately involved in regulating different aspects of 
mood (Price and Drevets, 2012). The medial prefrontal network modulates visceral function in 
relation to emotion, and has extensive projections to the amygdala, hypothalamus and 
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brainstem. This prefrontal network also extensively overlaps with the anterior cingulate cortex 
(ACC), especially sgACC (Ongur et al., 2003). The dorsal prefrontal circuit is associated with 
regulating executive functions, including problem solving, organization and working memory, 
cognitive domains that are typically affected in MDD (Price and Drevets, 2010). The orbital 
prefrontal network has extensive connections with several sensory related cortical areas. Apart 
from sensory integration, it also appears to be critical in integration of mood and emotional 
information into behavioural response (Price and Drevets, 2012).  
Patients with MDD show structural and functional abnormalities in several brain regions 
implicated in mood and emotional processing. Patients with late-life MDD show structural 
abnormalities in the dorsolateral prefrontal cortex (DLPFC), amygdala and cingulum (Knochel 
et al., 2015). Grey matter volume reductions are consistently observed in sgACC, orbital and 
ventrolateral PFC in MDD patients (Botteron et al., 2002, Drevets et al., 2008b, Price and 
Drevets, 2010). Reduction in glial density and neuronal size in layer VI, as well as GABAergic 
interneurone density in layer II was observed in the ACC in MDD (Cotter et al., 2002, Cotter 
et al., 2001). However, other studies found no changes in neuronal or glial cell density in 
orbitofrontal and ACC in later life depression (Khundakar et al., 2011a, Khundakar et al., 
2011b). Reduced GABAergic interneurone density and pyramidal cell volume in DLPFC was 
observed in patients with depression (Rajkowska et al., 2007, Khundakar et al., 2009), which 
may suggest that loss of cortical projections from DLPFC to ACC may contribute to ACC 
dysfunction, as observed in MDD.  
MDD patients show reduced cerebral blood flow and metabolism in PFC, ACC, PCC, 
amygdala, medial thalamus and parahippocampal cortex (Ongur et al., 2003). One functional 
imaging study has shown that apathy in late-life depression is associated with an impaired 
functional connectivity of the ACC with the DLPFC, as well as lower connectivity of the NAcc 
with amygdala and thalamus (Alexopoulos et al., 2013). This has been supported by another 
study showing altered functional and structural connectivity between prefrontal cortical and 
limbic regions in late-life depression (Yuen et al., 2014).  
1.1.4.2 Neurobiological changes in depression 
Several biological mechanisms have been implicated in the pathophysiology of MDD that 
potentially correlate with structural changes, including dysregulation of the hypothalamic–
pituitary (HPA) axis (Vreeburg et al., 2009), neurotrophic growth factor loss (Molendijk et al., 
2011) and inflammation in the periphery and the CNS (Vogelzangs et al., 2012). The HPA axis 
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regulates affective behaviours, with dysfunction of the HPA axis regarded as the 
neurobiological basis of affective disorders. Hyperactivity of the HPA axis results in an 
increase in corticosteroid levels that can be detected in patients with MDD (Holsboer and Ising, 
2010). HPA axis dysfunction and chronic elevation of glucocorticoids are thought to promote 
hippocampal atrophy and functional deficits in late-life depression (Kim et al., 2006, Lupien et 
al., 1998, Tata et al., 2006). The impaired negative feedback of the HPA axis can cause 
impaired neurogenesis in the hippocampus (Vreeburg et al., 2009, Manji et al., 2003). 
Glucocorticoid receptor (GR) downregulation due to an increase in cortisol release was 
observed in PD, followed by a chronic inflammatory response (Ros-Bernal et al., 2011). 
Dysregulation of the HPA axis occurs early in AD, resulting in increased cortisol levels. 
Animal models of stress have shown that elevated levels of cortisol increase Aβ formation by 
increasing the levels of the amyloid precursor protein (APP), as well as accelerating the 
development of NFT (Green et al., 2006). In AD, the presence of a lifetime history of MDD 
corresponds with higher levels of NP and NFT in the hippocampus, suggesting an interaction 
between MDD and AD neuropathology (Rapp et al., 2006).  
Brain-derived neurotrophic factor (BDNF) is thought to be involved in the pathophysiology of 
MDD, as well as the behavioural response to antidepressant medication (Molteni et al., 2009), 
and plays a role in neurogenesis, synaptic plasticity and neurotransmitter modulation. Reduced 
BDNF expression may result in deficits in neurogenesis (Jiang et al., 2017), as well as 
depressive behaviours (Jiang et al., 2017, Suri et al., 2013). Patients with MDD show altered 
expression of BDNF in the hippocampus and PFC in post-mortem studies (Pandey et al., 2003, 
Karege et al., 2005). BDNF has also been strongly correlated with dopaminergic 
neurotransmission (Hyman et al., 1991). Reduced levels of BDNF mRNA expression, as well 
as protein have been observed in the SN of PD patients (Mogi et al., 1999, Howells et al., 
2000). Polymorphism of the BDNF gene (rs6265) has also been shown to be associated with 
cognitive impairment in PD (Wang et al., 2019), with α-synuclein shown to facilitate 
impairment of BDNF signalling in a mouse model of PD (Fang et al., 2017). AD patients also 
show reduced BDNF mRNA and protein levels compared with controls (Laske et al., 2007, 
Holsinger et al., 2000). Increased expression of BDNF was shown to be associated with slower 
rate of cognitive decline during life (Beeri and Sonnen, 2016), as well as reduced behavioural 
deficits, reduced neuronal loss and synaptic degeneration, and increased neurogenesis in P301L 
mice (Jiao et al., 2016). 
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Inflammation and depression are closely associated. An upregulation of various pro-
inflammatory cytokines has been observed in MDD patients (Liu et al., 2012, Dowlati et al., 
2010), and this is suggested to alter glutamate and monoamine neurotransmission, GR 
resistance and hippocampal neurogenesis (Liu et al., 2003, Zalcman et al., 1994). Patients with 
MDD display cognitive deficits, which have been shown to correlate with the plasma levels of 
pro-inflammatory cytokines (Wilson et al., 2002, Bobinska et al., 2017). Neuroinflammation 
also plays a major role the pathogenesis of neurodegeneration (Amor et al., 2014). α-synuclein 
aggregation has been shown to be involved in microglial activation and induction of an 
inflammatory response (Surendranathan et al., 2015). Increased levels of proinflammatory 
cytokines and reduced levels of neurotrophins has been observed in the SN and striatum in PD 
patients (Nagatsu et al., 2000). In PD, PET imaging shows early inflammatory response in the 
brainstem, with widespread microglial activation correlating with dopaminergic terminal loss 
and disease progression (Ouchi et al., 2005, Gerhard et al., 2006). DLB cases with mild disease 
showed significantly higher microglial activation compared to moderate/severe disease 
(Surendranathan et al., 2018), which may suggest its importance in an initial acute immune 
response, rather than chronic inflammation. Early microglial activation is also consistent with 
MCI and early AD (Okello et al., 2009), with an increase in peripheral inflammatory markers 
consistently observed in AD (Lai et al., 2017). Systemic inflammatory changes are also 
observed in DLB and PDD using blood and CSF samples, which are more pronounced than in 
PD (King and Thomas, 2017). 
Neuroimaging correlates of cerebrovascular disease in patients with MDD in later life are high. 
The vascular depression hypothesis suggests that hyperintense white matter lesions (WMH) 
observed using MRI in the grey and white matter contribute to the pathogenesis of later life 
depression (Alexopoulos et al., 1997), especially in the form of ischaemic lesions (Thomas et 
al., 2002b). White matter structural differences in the ACC and corpus callosum have been 
observed in later life depression, which might suggest that altered neural connectivity may 
directly contribute to the pathogenesis of depression (Bae et al., 2006). White matter 
hyperintensities might also indicate disturbances to specific neural circuits or fibre tracts 
involved in mood regulation (Colloby et al., 2012a). Investigation of white matter 
microstructural changes in later life depression has also shown a loss of integrity in white 
matter fibres within limbic–orbitofrontal networks (Colloby et al., 2011). Microvascular 
changes in elderly depressed patients show decrease of capillary diameters in supragenual ACC 
(spACC) and sgACC in MDD (Sinka et al., 2012). An increase in intracellular adhesion 
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molecules on the cerebrovascular endothelium has been observed in post-mortem tissue of 
depressed elderly subjects, these being specific to the DLPFC (Thomas et al., 2002a). In 
contrast, other studies have found no significant increase in intercellular or vascular cell 
adhesion molecules in the serum of patients with late-life depression, and no correlation of 
serum levels and depression severity (Thomas et al., 2007).   
1.1.4.3 Monoamine hypothesis of depression 
The monoamine hypothesis of depression proposes that deficiency of monoamines, including 
serotonin (5-HT), noradrenaline (NA) and dopamine (DA) are the basis of depression. This 
was initially based on a number of observations, including investigation of the hallucinogen 
lysergic acid diethylamide (LSD) and its action on the serotonergic system, suggesting that 
serotonin may play a role in aetiology of mood disorders (Gaddum and Hameed, 1954, Woolley 
and Shaw, 1954). Furthermore, the use of the antihypertensive drug, reserpine, alleviated 
depression in a proportion of hypertensive patients (Muller et al., 1955). Reserpine is thought 
to interfere with vesicular storage of 5-HT and NA, which further reiterated the importance of 
monoaminergic transmission in depression. The MAOI drug iproniazid, originally used to treat 
tuberculosis, also has demonstrated efficacy in alleviating depressive symptoms (Cole et al., 
1959), which has led  to the development of the new generation of antidepressants, the SSRI, 
which are the most commonly prescribed antidepressants to this day. The monoamines are 
involved in the pathogenesis of several psychiatric disorders. DA neurotransmission changes 
are often associated with psychosis, 5-HT abnormalities associate with anxiety and panic 
disorders, whereas NA, 5-HT and/or DA are involved in depression (Moore and Bloom, 1979). 
While the biological approach to the treatment of depression has been dominated by the 
monoamine hypothesis for several decades, it does not provide an explanation as to why there 
is a delay in the therapeutic action of many antidepressants, which pharmacologically act via 
5-HT and NA systems, possibly suggesting that the clinical effect is due to the adaptive changes 
in the brain, rather than the primary drug effect (Hirschfeld, 2000). 
1.1.4.3.1 Serotonin 
Serotonin, also known as 5-HT is synthesised from the amino acid tryptophan and is found in 
the brain and periphery. It is important in physiological responses, such as arousal, circadian 
rhythms, neuroendocrine function, sexual behaviour and feeding, as well as mood and 
cognition. The 5-HT synthesizing neurones are localised in raphe nuclei of the brainstem and 
midbrain, which project diffusely throughout the brain and spinal cord. A reduction of 5-HT is 
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suggested as being a major underlying cause of MDD, and elevation of 5-HT, or of 5-HT 
neurotransmission, as reversing or alleviating symptoms in MDD. Reduced 5-HT levels 
following acute tryptophan depletion supports a role for decreased 5-HT in depression in 
recovered depressed patients (Delgado et al., 1990, Jans et al., 2007). However, the low 5-HT 
hypothesis of depression has been challenged by a number of studies. SSRI efficacy may not 
be due to elevated 5-HT concentration or increased 5-HT neurotransmission in the brain, since 
serotonin transmission is elevated in multiple depressive phenotypes (Lacasse and Leo, 2005, 
Andrews et al., 2015). Tryptophan depletion, which reduces serotonin levels in the synaptic 
cleft, fails to induce depression in healthy subjects (Ruhe et al., 2007). The polymorphism in 
the promoter region of the serotonin transporter (5-HTT) gene (5-HTTLPR) can result in 
decreased expression of the 5-HTT (Greenberg et al., 1999, Heinz et al., 2000), and has been 
shown to interact with stressful life events to predict depression (Gillespie et al., 2005). 
However, another study has shown a polymorphism of 5-HTTLPR to be related with reduced 
risk of depression (Karg et al., 2011). To address some problems with monoamine hypothesis 
in the pathogenesis of MDD, the monoamine receptor hypothesis has been proposed, which 
asserts that downregulation of 5HT autoreceptors (such as 5-HT1A) is a key mechanism of 
antidepressant efficacy. Since the 5-HT1A autoreceptor inhibits impulse flow of 5-HT neurones 
in the brainstem raphe nuclei, and the downregulation or desensitization of this receptor is 
induced by elevated 5-HT (resulting from antidepressant intake), this may increase impulse 
flow and 5-HT levels in axonal terminals (Liu et al., 2017). Downregulation of the 5-HT1A 
autoreceptor can take several days to weeks, which may explain the delayed onset of 
antidepressant efficacy.  
Decreased serotonin 5-HT1A binding in ACC has been observed in depressed patients using 
PET imaging (Wang et al., 2016), as well as decreased 5-HT2A binding in ACC and DLPFC 
in treatment resistant depression (Baeken et al., 2012). Post-mortem studies have shown an 
increase in the density of 5-HT2 receptor binding sites, and a decreased number of 5-HTT 
binding sites in MDD (Owens and Nemeroff, 1994). Additionally, an increase in serotonin 5-
HT1A autoreceptors in the dorsal raphe nucleus in MDD may suggest a compensatory response 
due to a decrease in extracellular 5-HT (Stockmeier et al., 1998). In patients with late-life 
MDD, PET imaging of 5-HT2A receptor showed no changes in the lateral orbitofrontal cortex, 
sgACC, pregenual ACC, striatum, amygdala, PFC, occipital and parietal cortices (Meltzer et 
al., 1999), suggesting that 5-HT2A receptors are differentially affected in late compared to early 
life depression. 
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Studies of the serotonergic system in neurodegenerative disorders in relation to depression has 
focused on both pathological and receptor changes. The largest serotonergic nucleus, the dorsal 
raphe, is often severely affected by LB pathology, which might explain the more severe loss of 
serotonergic innervation to the forebrain, resulting in a marked reduction of 5-HT levels in the 
striatum and PFC of DLB, PD and PDD patients (Ballard et al., 2013, Sharp et al., 2008). 
Serotonergic neurotransmission has been shown to be severely impaired in DLB compared to 
AD patients with depression, with reduced 5-HT and its metabolite concentrations observed in 
the PFC, temporal, limbic, occipital cortex and hippocampus (Vermeiren et al., 2015). A 
selective postsynaptic 5-HT1A receptor upregulation was observed in depressed DLB patients, 
which may be a compensatory mechanism for the decreased serotonergic neurotransmission to 
neocortical and limbic projection areas (Vermeiren et al., 2015). Reduced 5-HTT levels were 
also observed in the raphe nuclei in PD patients compared to controls using PET imaging 
(Guttman et al., 2007, Murai et al., 2001, Politis et al., 2010a), whereas an increase in 5-HTT 
binding in raphe and limbic regions was observed in PD patients with depression (Politis et al., 
2010b), possibly reflecting lower extracellular serotonin levels.  
1.1.4.3.2 Noradrenaline 
Noradrenergic neurones are found in the medulla oblongata and the dorsal vagal nucleus, with 
the highest density of noradrenergic cells bodies observed in the LC, which innervates the 
thalamus, dorsal hypothalamus, hippocampus, subcortical limbic regions, cerebellum, spinal 
cord and cortex. Peripherally, NA is part of the sympathetic nervous system and mediates 
responses of stress and acute anxiety, as well as the “fight or flight” response in animals and 
humans. Dysregulation of NA may also be involved in the pathogenesis of anxiety and 
depression (Goddard et al., 2010). An increase in firing rates of LC neurones was observed in 
animal models of stress compared to controls (Simson and Weiss, 1988), with reduction in 
firing rates observed following antidepressant treatment (West et al., 2009). LC lesions in 
animal models have shown to reduce depressive behaviours (Semba and Takahashi, 1988, 
Harro et al., 1999, Lin et al., 2011). This evidence suggest that increase in LC functional 
activity is associated with depressive behaviours.  
In vivo PET studies have found elevated NA transporter levels in LC and thalamus in patients 
with MDD (Moriguchi et al., 2017), which is in line with animal studies, that found an increase 
in mRNA and protein levels of the NA transporter in rat models of depression (Miner et al., 
2006, Chen et al., 2012). Post-mortem studies in MDD have shown reduced NA transporter 
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binding in the LC and other limbic areas, possibly due to a loss of NA axonal innervation 
(Ordway and Klimek, 2001, Klimek et al., 1997). Elevated α2-adrenoceptor levels in platelets 
have been observed in MDD patients (Kaneko et al., 1992, Garcia-Sevilla et al., 2004), with a 
decrease in α2-adrenoceptor density observed following antidepressant treatment with TCA 
(Gurguis et al., 1999). Chronic administration of TCA can also induce downregulation of α2-
adrenoceptor, which results in the facilitation of NA release (Cottingham et al., 2015). These 
findings suggest that downregulation of α2-adrenoceptor is involved in the therapeutic 
antidepressant mechanism, possibly through arrestin-mediated internalization and 
downregulation of α2-adrenoceptors (Cottingham and Wang, 2012), which gives us a better 
insight into antidepressant pharmacology. However, it should be noted, that other 
neurotransmitter systems, including GABA and acetylcholine, may be involved in the altered 
NA transporter regulation (Huang et al., 2015, Mandela and Ordway, 2006). 
Reduced NA concentrations are observed in the putamen, frontal, temporal and occipital 
cortices in DLB patients compared to AD and controls (Ohara et al., 1998). The loss of 
noradrenergic neurones in the LC is observed in DLB cases, as well as an increase in the mRNA 
for TH and sprouting of dendrites in the remaining neurones (Szot et al., 2006), which may be 
a result of the compensatory changes due to NA neuronal loss in the LC. The LC in DLB cases 
is severely affected by LB inclusions (Jellinger, 2003a), which may also play a major role in 
the NA neuronal loss in the LC. Degeneration of the LC is observed in PD (Paulus and 
Jellinger, 1991), which may play a role in depression in PD patients (Chan-Palay, 1993). This 
is supported by the lower catecholaminergic transporter binding (11[C]RTI-32 PET) in limbic 
regions and ventral striatum PD patients with apathy (Remy et al., 2005), and reduced 
noradrenergic innervation in ACC, amygdala and ventral striatum in PD patients with 
depression (Remy et al., 2005). Changes in the noradrenergic system, such as accumulation of 
tau pathology in LC, are also observed early in AD (Braak et al., 2006), with loss of 
noradrenergic innervation shown to be involved in AD pathogenesis and progression (Kalinin 
et al., 2007).  
1.1.4.3.3 Dopamine 
Dopamine (DA) is the most abundant catecholamine in the brain and is involved in regulating 
motor function, motivation, arousal, reward and pleasure (Salamone and Correa, 2012, Ben 
Zion et al., 2006, Berridge and Kringelbach, 2008). Dopaminergic projections give rise to four 
axonal pathways. The nigrostriatal projections of dopaminergic neurones extend from the SN 
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to the dorsal striatum, with the loss of these neurones most often associated with the motor 
symptoms of PD  (Vallone et al., 2000). The mesolimbic dopamine pathway arises from the 
dopaminergic cells in the ventral tegmental area (VTA), which project to the NAcc, amygdala, 
hippocampus and other limbic regions, important for motivational function, reward of mood 
regulation (Nestler et al., 2002). The mesocortical pathway also originates in VTA and 
primarily projects to the PFC, as well as cingulate and perirhinal cortex, and is involved in 
cognitive control, motivation and emotional response. The tuberoinfundibular pathway 
connects the hypothalamus to the pituitary gland, where it influences the secretion of hormones 
such as prolactin (Vallone et al., 2000), which has been shown to be involved in the regulation 
of the stress responses through the inhibition of the HPA axis (Torner, 2016). 
While in the past a considerable focus has been on serotonergic and noradrenergic systems in 
mood regulation, recently, the involvement of dopaminergic mechanisms in the 
pathophysiology of depression has gained increased interest (Nestler and Carlezon, 2006, 
Belujon and Grace, 2017). Dysregulation of the dopaminergic system has been linked to 
deficits in empathy (Kim et al., 2014), executive functioning (Lumme et al., 2007), as well as 
cognitive and emotional behaviour in MDD (Lacroix et al., 2003). Depressive symptoms, such 
as anhedonia and apathy have also been associated with dysfunction of the dopaminergic 
system (Wise, 2008), with PET imaging in anhedonic depressed patients showing significantly 
reduced DA transporter (DAT) binding compared with controls (Sarchiapone et al., 2006). In 
MDD patients increased striatal D2 receptor binding was observed using PET imaging 
(D'Haenen and Bossuyt, 1994), suggesting decreased DA turnover. Selective inhibition of DA 
neurones in the VTA was shown to induce a depression-like phenotype in mouse model, which 
was reversed by selective activation of the mesolimbic DA system (Tye et al., 2013). 
Some depressive symptoms, including apathy, loss of pleasure and interest, are driven by 
dopaminergic degeneration, therefore antidepressants with an effect on the dopaminergic 
reward system may prove useful in treatment outcome. While seldom used as a first choice 
antidepressant treatment, some dopaminergic compounds, including DA agonists, have proven 
to be effective in treating MDD (Leentjens, 2011, Hori and Kunugi, 2013).  
Selective dopaminergic neuronal loss occurs early in PD and DLB, which is associated with 
LB pathology and development of specific clinical symptoms (Schulz-Schaeffer, 2015). Higher 
α-synuclein burden in SN, VTA and NAcc was observed in LBD cases with depression 
(Patterson et al., 2018), which may suggest that α-synuclein pathology may be one of the main 
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factors driving these symptoms. α-synuclein interacts with DA metabolism and transmission 
(Galvin, 2006, Phan et al., 2017), and may play an important role in neuronal loss and 
development of depressive symptoms in LBD. The motor symptoms in PD and DLB stem from 
neurodegeneration of the nigrostriatal dopaminergic pathway, which can be demonstrated by 
DAT imaging, showing significant diagnostic value in differential diagnosis (Walker et al., 
2004). A correlation between higher apathy scores and lower striatal DAT binding has also 
been observed in PD (David et al., 2008). The development of depressive symptoms in PD was 
shown to be associated with mesolimbic dopaminergic pathway dysfunction, as demonstrated 
by reduced volume in VTA, cingulate and amygdala, as well as reduced [11C]RTI-32 binding 
in several limbic regions in PD patients with depression (Remy et al., 2005), which may relate 
to the loss of DA projections. AD patients also show dopaminergic system abnormalities, 
including reduced levels of DA and its receptors (Gibb et al., 1989, Storga et al., 1996). VTA 
dopaminergic neurones project directly to hippocampus, with DA shown to modulate 
hippocampal synaptic plasticity (Broussard et al., 2016, Rossato et al., 2009). In an AD mouse 
model, VTA dopaminergic degeneration resulted in lower DA levels in the hippocampus, 
which may impact memory deficits and dysfunction of reward processing in AD (Nobili et al., 
2017). An increase in subcortical and cortical LB pathology has been observed in MDD (Iritani 
et al., 2008, Tsopelas et al., 2011), as well as in amygdala in AD cases with a history of 
depression (Lopez et al., 2006), therefore LB pathology may be important in the aetiology of 
MDD, as well as depression in neurodegenerative disorders.   
1.1.4.4 Glutamatergic and GABAergic dysfunction in depression 
Glutamate is the primary excitatory neurotransmitter, whereas γ-aminobutyric acid (GABA) is 
the main inhibitory neurotransmitter in the brain. The synthesis of GABA and glutamate occurs 
through closely related metabolic pathways, with imbalance in excitatory/inhibitory 
neurotransmission suggested as greatly contributing to the development of mood disorders 
(Gabbay et al., 2012).  
A growing body of evidence has directed focus onto the glutamatergic system as being 
involved in the pathogenesis of depression. Studies have demonstrated that certain 
antidepressant drugs, such as TCAs, interact with glutamate receptors (Reynolds and Miller, 
1988), and modulate the release and/or reuptake of glutamate (McCaslin et al., 1992, Bouron 
and Chatton, 1999). Increased plasma and CSF glutamate levels have been observed in MDD 
patients, with reductions following antidepressant treatment (Kucukibrahimoglu et al., 2009, 
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Levine et al., 2000, Mitani et al., 2006). In vivo proton magnetic resonance spectroscopy (1H-
MRS) studies have demonstrated reduced glutamate metabolite levels in the frontal and 
cingulate cortex of patients with MDD (Auer et al., 2000, Hasler et al., 2007). These regions 
have been identified as key structures for MDD, and show reductions in neuronal and glial cell 
densities (Cotter et al., 2001, Ongur et al., 1998), reduced expression of glial enzymes allowing 
for glutamate reuptake from the synaptic cleft (Choudary et al., 2005). This suggests that this 
may result in elevated levels of extracellular glutamate, which is potentially neurotoxic and can 
affect the efficiency of glutamate signalling. Glutamatergic deficits have been shown to be 
related to resting-state brain activity in depression (Engert and Bonhoeffer, 1999), with 
abnormal glutamatergic modulation related to the functional connectivity between spACC and 
anterior insula and depression severity (Horn et al., 2010). Glutamate plays a key role in 
neuronal plasticity, which is a fundamental mechanism of neuronal adaptation. Neuronal 
plasticity has been shown to be disrupted in mood disorders and in animal models of stress, 
resulting in enhanced glutamate release, altered synaptic transmission, dendritic remodelling, 
synaptic spine reductions and glial loss (Heldt et al., 2007, Bodnoff et al., 1995, Cook and 
Wellman, 2004, Liston et al., 2006). These data suggest that abnormal glutamatergic 
neurotransmission will result in the imbalance in excitation and inhibition, commonly observed 
in mood disorders. 
Glutamatergic agents have shown antidepressant potential, with compounds such as ketamine, 
an NMDA receptor antagonist, proposed as a promising therapeutic intervention for treatment 
resistant depression, with other agents, including metabotropic glutamate receptor modulators, 
glycine transporter 1 inhibitors and glutamate release inhibitors, also being explored (Abdallah 
et al., 2015, Rotroff et al., 2016, Abdel-Magid, 2016). Ketamine has been shown to have 
clinical efficacy in antidepressant drug therapies producing rapid relief of depressive symptoms 
(Abdallah et al., 2015, Downey et al., 2016, Rotroff et al., 2016), acting by strengthening 
excitatory synapses in brain regions involved in the regulation of mood and reward in animal 
models (Zanos et al., 2016, Li et al., 2010). Esketamine, an isomer of ketamine, given 
intranasally, has been approved by the European Commission for use in treatment resistant 
MDD (Jauhar and Morrison, 2019). 
A large body of clinical and preclinical evidence supports the role of GABA dysfunction in the 
pathophysiology of MDD (Marin, 2012, Brambilla et al., 2003). It has been hypothesised that 
MDD related epigenetic and stress-induced changes are due to deficits in GABAergic 
transmission, and currently available antidepressants involve downstream alterations in 
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GABAergic transmission. Reduced GABA levels are found in plasma and CSF of patients with 
MDD (Petty and Schlesser, 1981, Gerner and Hare, 1981), which may reflect decreased levels 
of extracellular GABA in the brain or decreased turnover. An increase in plasma GABA levels 
was observed in treated patients with MDD (Kucukibrahimoglu et al., 2009), which may 
indicate that monoaminergic compounds are directly involved in modulation of GABAergic 
neurotransmission. An MRS study has demonstrated reduced GABA concentrations in 
occipital and ACC in MDD (Gabbay et al., 2012), correlating with reduced amygdala and PFC 
mRNA for glutamic acid decarboxylase 67 (GAD67), a key enzyme for the synthesis of 
GABA, in post-mortem tissue (Cotter et al., 2002, Karolewicz et al., 2010). Reduced GABA 
and GAD67 levels are also consistent with reduced densities of specific subtypes of 
GABAergic interneurones in MDD, especially those containing specific calcium binding 
proteins, such as calbindin D-28K (CB), calretinin (CR) and parvalbumin (PV) (Berridge et 
al., 2000, Cotter et al., 2002, Beasley et al., 2006, Maciag et al., 2010). Significant reductions 
in CB neurone density in the ACC has been observed in schizophrenia, bipolar disorder and 
MDD (Cotter et al., 2002, Rajkowska et al., 2007, Maciag et al., 2010), which may suggest 
selective vulnerability of these neurones in affective disorders and involvement of GABA.  
A downregulation of several GABA-related genes in sgACC has been reported in patients with 
MDD (Tripp et al., 2011), potentially affecting somatostatin (STT) dendritic targeting 
interneurones, with reduced SST expression in sgACC observed across all cortical layers in 
MDD cases (Tripp et al., 2011, Seney et al., 2015). GABAergic activity in sgACC is thought 
to be involved in isolating the memories of sad events and stopping them from ‘over-
participating’ in conscious perception. Reduced levels of GABA in sgACC has been observed 
in unmedicated recovered depressed subjects (Bhagwagar et al., 2008), which may suggest that 
while some restoration of GABA levels in clinically recovered patients with depression occurs, 
detectable deficiency remains. This may be due to reductions in glial cell numbers in the ACC 
in MDD (Ongur et al., 1998), with astrocytes being an important source of the GABA 
precursor, glutamine, to GABA nerve terminals (Shulman et al., 2004). 
As current monoaminergic pharmacological treatments for MDD display latency to achieve a 
therapeutic effect, with half of patients not responding to treatment, more effective and faster-
acting therapies are needed. GABA acts through ionotropic GABAA and metabotropic GABAB 
receptors. GABAA receptors contain binding sites for ligands such as GABA agonists (e.g. 
muscimol), antagonists (e.g. bicuculline), barbiturates, benzodiazepines, anticonvulsants and 
neurosteroids (Sieghart, 1995). GABAB receptors have binding sites for GABAB receptor 
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agonists (e.g. baclofen), antagonists (e.g. phaclofen) and allosteric positive modulators (e.g. 
CGP7930, GS39783) (Urwyler et al., 2001, Urwyler et al., 2003)(Bowery et al., 2002)(Kerr 
and Ong, 1992). The use of GABA analogs (e.g. valproate, beta-phenyl-GABA), GABA 
agonists, and neurosteroids (e.g. allopregnanolone) reduces depression like behaviours in 
animal models (Frank and Sagratella, 2000, Gajwani et al., 2005, Lapin, 2001, Lloyd et al., 
1983). Negative allosteric modulators of GABAA receptor α5 subunits (e.g. MRK-016) have 
been shown to reverse anhedonia in animal models by restoration of excitatory synaptic 
strength (Fischell et al., 2015). Similar to ketamine, MRK-016 induced a significant increase 
in coherent EEG γ frequency oscillations (Zanos et al., 2017). GABAAα5 expression is less 
widespread compared to ketamine binding sites, predominantly in the hippocampus and frontal 
cortex in mouse brain (Malherbe et al., 1990), which may result in the fewer observed side 
effects. Negative allosteric modulators of GABAAα5 have also been shown to have cognition-
enhancing actions (Rudolph and Knoflach, 2011), and may be a target for memory-enhancing 
drugs (Ballard et al., 2009). GABAB receptors are highly expressed in the limbic system 
involved in regulating emotional behaviour (McDonald et al., 2004). Neurophysiological 
GABAB deficits have been shown to be involved in the pathophysiology of MDD in post-
mortem tissue (Fatemi et al., 2005), with up-regulation of GABAB receptors shown to be 
essential for antidepressant drug action (Pilc et al., 2008). 
1.1.5 The cingulate cortex 
While there are multiple brain regions involved in the pathophysiology of depression, one 
region in particular, the cingulate cortex, plays a key role. The cingulate cortex lies immediately 
above the corpus callosum from which it is separated by the callosal fissure. It curves around 
anterior to the genu of the corpus callosum, extends along the dorsal surface of the callosal 
body, and turns ventrally behind the splenium. The cingulate cortex is a heterogeneous brain 
structure that has a number of structurally and functionally distinct subregions involved in 
cognitive, emotional and motor processes, as well as attention, pain and autonomic responses 
(Vogt et al., 1995, Vogt et al., 2006). There are multiple nomenclatures for the cingulate cortex, 
which was originally divided by Brodmann (1909) into precingulate (areas 24, 25, 32, and 33) 
and postcingulate (areas 23, 29, 30, and 31) divisions. Distinct subregions within the cingulate 
cortex differ in terms of cytoarchitecture, receptor organization, anatomical and functional 
connectivity (Palomero-Gallagher et al., 2008, Shackman et al., 2011, Vogt et al., 1995). A 
four-region neurobiological model of the cingulate cortex was proposed by (Vogt, 2005), 
which encompasses the ACC, mid-cingulate cortex (MCC), PCC and retrosplenial cortex 
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(RSC). The ACC can be further subdivided into sgACC and supragenual anterior cingulate 
(spACC) areas, the MCC into anterior (aMCC) and posterior (pMCC) regions, whereas the 
PCC can be divided into dorsal (dPCC) and ventral (vPCC) areas (Figure 1.4) (Gittins and 
Harrison, 2004, Palomero-Gallagher et al., 2009). 
Figure 1.4 Cingulate subregions. 
The major cingulate subdivisions are based on regional differences in microanatomy, 
connectivity and physiology. A four-region neurobiological model of the cingulate cortex 
includes the ACC, MCC, PCC and RSC areas. Anterior and ventral to the corpus callosum is 
the ACC, which is divided into sgACC (BA25) and spACC (BA24). The MCC has anterior 
(BAa24’) and posterior (BAp24’) subdivisions, whereas the PCC has dorsal (BAd23) and 
ventral (BAv23) subdivisions. The sgACC receives primary afferent projections from 
amygdala (AMY), hypothalamus (HT), insula (IN), orbitofrontal cortex (OFC) and 
periaqueductal grey (PAG), with primary efferent projections to AMY, PAG, lateral 
hypothalamus (LH) and parabrachial nucleus (PBN) (Palomero-Gallagher et al., 2009). 
1.1.5.1 Anterior cingulate cortex 
The ACC is a structurally and functionally heterogeneous brain region, which has motor, 
cognitive and affective subdivisions. In the ACC, pyramidal cells are more spinous than in 
PCC, which is important in functional specialization of the cortex, as higher branching and 
spine density may result in an increase of excitatory inputs (Elston et al., 2005a). This might 
suggest that pyramidal cells in the ACC are involved in more complex information processing 
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(Elston et al., 2005b). The ACC is an agranular cortex, with two major functional subdivisions 
– sgACC and spACC (Barrett and Simmons, 2015).
1.1.5.1.1 Subgenual anterior cingulate 
Anatomically, early research defines the term ‘‘subgenual’’ to describe the entirety of the 
ventral anterior cingulate cortex, whereas more recent research defines the term ‘subgenual’ to 
include only a small volume of the posterior ventral ACC (BA25), and the anterior section of 
the ventral ACC (BA24) termed ‘subcallosal’ (Baeken et al., 2015). The cytoarchitecture in the 
human sgACC varies along the rostrocaudal extent. The more rostral area 25 has a narrower 
and less prominent layer II compared to caudal area 25, with an undifferentiated layer III, and 
with layer V pyramidal cells larger than in layer VI. The more caudal area 25 has a dense and 
broad layer II and the thinnest layer III of all cingulate areas, with sparsely distributed small 
pyramidal cells, with layers V and VI almost indistinguishable (Palomero-Gallagher et al., 
2008).  The neurones in layer II are globular rather than elongated in shape with small basal 
dendrites and receive primary inputs from the amygdala (Vogt and Pandya, 1987).  
Neurotransmitter binding presents distinct laminar patterns throughout the sgACC. GABAA, 
GABAB, nicotinic, α1, α2 and 5-HT2 receptors are homogeneously distributed in all the layers 
(Varnas et al., 2004). Muscarinic M3 and 5-HT1A receptor densities are however higher in the 
superficial layers of caudal area 25, whereas kainate and M2 receptors show highest densities 
in the deep layers. 5-HT1A, GABAA and GABAB receptor density also appears to be 
significantly higher in sgACC than in pregenual ACC regions, suggesting regional and possibly 
functional differences in cingulate subregions (Palomero-Gallagher et al., 2009). AMPA and 
NMDA receptors are located preferentially in the superficial layers of sgACC, and it is 
suggested these represent the glutamatergic input from the amygdala (Zhuo, 2007). 
Furthermore, the high density of 5-HT1A receptors in layers I–II suggests that serotonin may 
amplify the signal from the amygdala and further drive output from layer III neurones 
(Palomero-Gallagher et al., 2009). The thin layer III in sgACC suggests that cortico-cortical 
projections are relatively weak in comparison to cortico-cortical connections of other cingulate 
regions (Palomero-Gallagher et al., 2008).  
The sgACC has direct projections to autonomic regulatory centres, including the lateral 
hypothalamus, periaqueductal grey and parabrachial nucleus, and is implicated in the 
modulation of autonomic responses to stress, including heart rate, digestion and respiratory 
rate.  It also receives direct input from the amygdala, involved in “fight or flight” response 
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(Drevets et al., 2008b, Vogt, 2014). Functional magnetic resonance imaging (fMRI) studies 
have shown sgACC to be activated during feelings of sadness (Smith et al., 2011), suggesting 
its pivotal role in the emotional processing of negative stimuli (Gotlib et al., 2005), and 
involvement in MDD (Kumano et al., 2007). The sgACC may be a key regulator of amygdala 
activity and autonomic responsivity, important in emotional conflict resolution (Etkin et al., 
2011). Under physiological conditions, activation of the amygdala during emotional stimuli is 
followed by activation of the sgACC, which exerts an inhibitory effect on the amygdala, 
resulting in suppression of the amygdala response (Etkin et al., 2006). This may suggest that 
dysfunction of the sgACC may result in hyperactivity of the amygdala, which is commonly 
observed in depression (Kumari et al., 2003), therefore the inability to deal with emotional 
conflict might be due to deficient amygdala inhibition by the sgACC.  
1.1.5.1.2 Supragenual anterior cingulate 
The spACC (area 24) lacks a granular layer IV, and has three subdivisions (24a, 24b and 24c) 
(Vogt et al., 1995). Area 24a has differentiated layers II and III, with layer II much broader and 
more cell-dense compared to the sgACC, whereas layer III is wider than layer II, with evenly 
distributed medium-sized pyramidal neurones, with a relatively thin layer V. Area 24b has a 
more dense layer II, and a broad and neurone dense layer V composed of small and large 
pyramidal neurones. Area 24c is cytologically one of the most heterogeneous areas in the 
cingulate cortex, and has a broader layer II compared to area 24b, with layer III containing 
medium-sized and uniformly distributed pyramidal neurones, and much thinner layer V 
(Palomero-Gallagher et al., 2008). GABAB and D1 receptor densities are significantly higher 
in layers I–III, whereas α1 adrenoreceptor densities are higher in all layers of area 24c 
(Palomero-Gallagher et al., 2009). Area 24c sends direct projections to the facial motor nucleus 
(Morecraft et al., 1996) and plays a role in facial expression and in the expression of emotion. 
Layer III of spACC provides the primary output to other cortical areas including DLPFC, 
orbitofrontal and ventral PCC (Vogt and Pandya, 1987), whereas layer V is the origin for spinal 
and brainstem motor output (Dum and Strick, 1991). Dopamine receptors are highly expressed 
throughout the ACC, with dopaminergic innervation of the spACC arising from the cell bodies 
of the SN and VTA. Dopaminergic modulation of GABAergic transmission in layer V 
pyramidal cells in the ACC has been shown to be through D1 receptors (Satoh et al., 2018). 
Low DA levels have been shown to act via D1 receptors, resulting in the enhanced GABAergic 
response, whereas high extracellular DA levels preferentially activate D2 receptors and reduce 
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GABA (Trantham-Davidson et al., 2004), which may suggest that this bidirectional modulation 
of inhibition is dependent on DA levels in the brain. 
The spACC has the highest von Economo neurone (VEN) density in the cingulate cortex 
(Santillo et al., 2013). VEN are large bipolar neurones, characterized by a large spindle-shaped 
soma that gradually tapers into an apical axon in one direction, and a single large basal dendrite 
facing opposite, distinguishing them from pyramidal neurones. VEN cell bodies in the ACC 
are over four times larger than the layer V pyramidal neurones (Nimchinsky et al., 1995). These 
neurones have fewer dendrites, which could make them particularly vulnerable to 
synaptodendritic pathology, as well as fewer dendritic spines, which might suggest that they 
receive and integrate fewer inputs (Watson et al., 2006). The large, rapidly firing axons of VEN 
may also suggest increased metabolic demands (Watson, 2008). As VEN are not labelled by 
calcium binding proteins, which are normally co-localised with GABA, and highly express 
non-phosphorylated neurofilament protein epitopes, much like large pyramidal cells, they are 
not considered to be inhibitory neurones, but rather excitatory glutamatergic projection 
neurones (Nimchinsky et al., 1995). VEN also express higher levels of D3 receptors compared 
to typical pyramidal neurones, with D3 receptors being implicated in reward seeking 
behaviour. VEN also express high levels of serotonin 1b and 2b receptors involved in decision 
making specific to social interactions. High levels of vasopressin 1a receptors, which have been 
strongly linked to the formation of social bonds, are also seen on VEN (Viskontas et al., 2007a). 
They are found in layer V of the ACC and anterior insula cortex in humans and great apes, but 
not other primates, which may support complex higher-order cognitive functions of VEN, 
including formation of social and emotional bonds (Watson et al., 2006). VEN appear later in 
brain development than other pyramidal neurones, which suggest that they may also play a role 
in social and emotional behaviour(Viskontas et al., 2007b).  
The spACC plays a key role in reward circuitry, particularly in reward based decision making 
and learning, suggesting substantial influence by dopaminergic circuitry, due to extensive 
connections with the VTA  (Bush et al., 2002). The spACC has strong interconnections with 
the DLPFC, hippocampus, insula, NAcc and orbitofrontal cortex (Fujihara et al., 2015), and 
plays a role in cognitive and emotional processing. It is part of the default mode network 
(DMN) due to the high neuronal activity in the resting state, showing predominant deactivation 
in response to tasks (Enzi et al., 2012). The spACC, along with the insula, amygdala and medial 
thalamus comprise the fear and anxiety network (von Leupoldt et al., 2009), and patients with 
lesions in the spACC show an increase in anxiety and panic attacks (Shinoura et al., 2011). The 
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spACC is activated by a conditioned fear stimulus (Milad et al., 2007), as well as in response 
to strong threat (Straube et al., 2009), which suggests that spACC  is highly important in mood 
disorders. 
1.1.5.2 Mid-cingulate cortex 
The MCC is an agranular cortex, with distinct morphological differences observed between 
anterior MCC (aMCC) and posterior MCC (pMCC) (Vogt et al., 2003). The aMCC has a poorly 
differentiated layer III with few neurofilament protein expressing neurones. The pMCC in 
comparison has a very dense layer V, with more neurofilament protein expressing neurones in 
layers III and V compared to the aMCC (Palomero-Gallagher et al., 2009). The MCC has high 
densities of glutamate, muscarinic M1, serotonin and α-adrenoceptors, compared with, for 
example, the supplementary motor areas (Zilles et al., 1995).  
The MCC is involved in skeletomotor regulation and response selection (Devinsky et al., 
1995), and is also one of the most frequently activated regions during acute pain (Derbyshire 
et al., 1994). The MCC has two separate cingulate motor areas that directly project to the spinal 
cord and motor cortices. This dichotomy suggests that two circuits differentially regulate the 
two cingulate motor areas. More nociceptive inputs from the midline and intra-laminar 
thalamic nuclei terminate in the aMCC than in the ACC or pMCC (Vogt, 2005). Activation of 
the aMCC by nociceptive inputs from the thalamus induces fear and memories of similar 
events, which drives the aMCC to enhance avoidance responses via layer V projections to 
motor structures (Bush et al., 2002). The aMCC has the greatest numbers of connections with 
the dorsal striatum, DLPFC, primary, premotor and supplementary motor areas, and has been 
strongly implicated in motor control in response to emotional stimuli (Asemi et al., 2015). The 
aMCC is also involved in processing cognitive information (Matthews et al., 2004), possibly 
playing an important role in integrating cognition and action (Wenderoth et al., 2005). The 
pMCC has strong connections with parietal cortex, DLPFC and motor regions (Beckmann et 
al., 2009). The pMCC circuit is not significantly driven by emotion and is poorly engaged by 
noxious stimulation, which may be due to less input from thalamic nuclei that receive 
spinothalamic and spinoreticular inputs (Vogt et al., 2003). The pMCC is more closely linked 
to motor output, as it projects to a part of the striatum that also receives primary motor input 
(Takada et al., 2001) and may be involved in the avoidance of potentially painful or harmful 
stimuli (Bentley et al., 2003).  
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1.1.5.3 Posterior cingulate cortex 
Unlike other cingulate cortex divisions, the PCC is a granular cortex, which has six 
differentiated layers, with layer IV containing granule excitatory spiny stellate  and small 
pyramidal neurones that amplify and distribute thalamo-cortical inputs (Barrett and Simmons, 
2015). The structural dichotomy of PCC is derived from anatomical and functional studies, 
demonstrating the unique cytological organization of the dorsal (dPCC) and ventral (vPCC) 
subdivisions. The vPCC has a neurone dense layer III and IV, and more neurofilament-
expressing layer V neurones compared to the dPCC (Vogt et al., 2006). The dPCC contains 
higher GABAB, M3 and 5-HT1A, but lower M1 receptor densities than its ventral counterpart 
(Palomero-Gallagher et al., 2008, Palomero-Gallagher et al., 2009).  
PCC is a highly anatomically interconnected brain region with strong reciprocal connections 
to the entorhinal cortex, parahippocampal gyrus, parietal cortex, precuneus, thalamus, caudate, 
orbitofrontal and ACC. It has a high baseline metabolic rate and is a central part of the default 
mode network (DMN). It also interacts with executive, attentional, motor and language 
networks (Leech et al., 2012). The PCC is part of a network that mediates visuospatial 
orientation and related memories, which together with the parietal operculum, is involved in 
visual motion stimuli, and may play a role in visual motion perception (Antal et al., 2008). The 
PCC involvement in motion onset and processing of eye movement related signals has been 
observed in human and non-human primates (McCoy et al., 2003, Stebbins et al., 2004). The 
inputs to the dPCC and vPCC are associated with the dorsal and ventral visual pathways, where 
dPCC receives inputs from the mediodorsal, ventral anterior and lateral thalamic nuclei and is 
involved in visuospatial and body orientation (Vogt et al., 2006). The dPCC, although it is also 
part of the DMN, becomes less integrated with the DMN as the attentional load increases, and 
more associated with cognitive control networks involved in the executive control of behaviour 
(Leech et al., 2011, Leech and Sharp, 2014). The vPCC is integrated with the DMN and is 
activated during tasks that require an internal focus of attention, such as autobiographical 
memory retrieval, showing greater temporal lobe functional connectivity. The vPCC shows 
strong interaction with sgACC (Shibata and Yukie, 2003, Vogt et al., 2006), showing reciprocal 
and monosynaptic connections in monkey (Vogt and Pandya, 1987). The vPCC is activated 
during simple emotions driven by faces or scripts (Mayberg et al., 1999, Vogt et al., 2003), 
although it does not have direct autonomic connections. It is proposed that vPCC evaluates 
emotional content of visual information through direct interaction with the sgACC (Vogt et al., 
2006). 
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1.1.6 The role of cingulate cortex in depression and dementia 
The cingulate gyrus is intimately involved with emotional processing. The ACC is integral in 
mood regulation, as well as in the symptomatic expression of depression, displaying structural, 
functional and metabolic abnormalities (Drevets et al., 2008b, Rodriguez-Cano et al., 2014). 
The sgACC is activated during simple emotions, such as sadness, and DBS has been shown to 
partially alleviate the symptoms of sadness (Mayberg et al., 2005). DBS of the sgACC has 
significant antidepressant effects in the short and long term (Berlim et al., 2014), although its 
mechanism of action is unknown. It has been hypothesised that DBS works by restoring the 
overall network function (Berlim et al., 2014, Rizvi et al., 2011). One study argued that DBS 
works by altering conscious perception of the symptoms of depression, such as sadness or 
anhedonia, but does not address the basic disease process, having only temporary effect 
(Eggers, 2014), which may suggest the role of multiple systems in the aetiology of MDD.  
Age and gender differences have been reported within different cingulate cortex divisions. 
With ageing, a significant grey matter loss occurs in the ACC, whereas the PCC shows relative 
structural preservation. Therefore, susceptibility of the ACC to age related grey matter loss 
may potentially contribute to cognitive decline with age (Vaidya et al., 2007). The prevalence 
of MDD is higher in women than in men, with women having higher number of symptoms, a 
more severe type of depression, and greater risk of recurring episodes (Perugi et al., 1990). 
Women have a relatively larger ACC grey matter volume compared to men (Brun et al., 2009, 
Mann et al., 2011). Gender differences have also been observed in structural and functional 
connectivity of the sgACC. The sgACC shows structural connections to the periaqueductal 
grey, amygdala, hypothalamus, thalamus, MCC and anterior insula in both genders. Structural 
connectivity of sgACC with the hypothalamus was greater in men than in women (Wang et al., 
2014). Women show stronger functional connectivity of the sgACC with the affective regions, 
such as periaqueductal grey, raphe and MCC compared to men, whereas sgACC functional 
connectivity in men is stronger with anterior insula and temporoparietal junction compared to 
women (Wang et al., 2014). Therefore, the higher prevalence of MDD in women may be due 
to stronger functional connectivity of the sgACC with other affective regions.   
Decreased functional connectivity has been reported in the spACC in elderly individuals with 
subthreshold depression using resting state fMRI (Li et al., 2014b). An abnormally elevated 
resting state activity in spACC was shown in patients with MDD (Enzi et al., 2012). Changes 
in resting state activity and connectivity, as well as glutamatergic modulation in spACC have 
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been linked to a number of psychiatric disorders, including MDD (Duncan et al., 2011). The 
high density of glutamatergic receptors in spACC suggests a relationship between glutamate 
and resting state activity (Bozkurt et al., 2005). Increased metabolism in the sgACC has been 
shown to be involved in MDD (Greicius et al., 2007, Mayberg et al., 2005), with decreased 
activity in the sgACC observed in response to antidepressant medication and ECT in treatment 
resistant depression (Baeken et al., 2015). 
VEN are distinct population of cells characteristic to the ACC and insula, and are implicated 
in several neuropsychiatric conditions, including schizophrenia (Brune et al., 2010)  and autism 
(Allman et al., 2010, Allman et al., 2005). A significant reduction in VEN has been observed 
in agenesis of the corpus callosum, which has a major effect on social and emotional behaviours 
(Kaufman et al., 2008). Studies have shown that in individuals with a clinical diagnosis of 
psychosis who die following self-harm, greater densities of VEN in the ACC are seen (Brune 
et al., 2011), and in autistic individuals (Uppal et al., 2014), which possibly underlies 
heightened anxiety and avoidance behaviours seen in these disorders. Selective, but variable 
loss of VEN within the ACC has also been shown in behavioural variant of FTD patients, who 
show behavioural and personality changes (Tan et al., 2014). This suggest that selective 
vulnerability of specific cell types within the ACC may be important in emotional and 
behavioural function. 
Grey matter atrophy in the ACC has been observed in prodromal DLB patients compared to 
controls (Blanc et al., 2016). Decreased grey matter volume of the ACC was associated with 
neuropsychological impairment in DLB compared to PDD patients (Sanchez-Castaneda et al., 
2009). The PCC shows metabolic and perfusion deficits in early AD (Lim et al., 2009). PCC 
hypometabolism has been shown to be a useful marker of AD pathology, independent of 
atrophy or volume loss (Graff-Radford et al., 2014). FDG and PiB PET scans of AD and DLB 
brains shows preservation of PCC metabolism in DLB, and this preservation is not associated 
with Aβ load, but rather lower Braak NFT stage (Graff-Radford et al., 2014, Iizuka et al., 2017). 
This could be partly attributed to functional deafferentation, where primary pathological lesion 
sites in AD, especially the entorhinal cortex, affect other distinct, but associated brain regions 
due to functional connectivity (Yoshida et al., 2011). The PCC is involved in memory retrieval, 
therefore the hypometabolism in this region seen in early stages of AD, may play an important 
role in the progression of the disease (Valla et al., 2001). It has been hypothesised that the MTA 
seen in early AD and MCI partially explains the PCC hypofunction due to the degeneration of 
the cingulum bundle that connects the PCC with the MTA (Choo et al., 2010). Additionally, 
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increased functional connectivity of PCC with frontal cortex may be as a result of a 
compensatory mechanism due to DMN dysfunction (Bai et al., 2009). Decreased functional 
connectivity of PCC and MTA has been shown in PD patients, with PDD patients showing 
decreased PCC and parahippocampal gyrus functional connectivity, which may lead to an 
increased vulnerability to early cognitive impairment and progression from PD to PDD (Chen 
et al., 2015).  
In DLB, the ACC is a predilection site for LB formation showing early and extensive pathology 
(Thal et al., 2004, Toledo et al., 2016). However, it is not known how pathological or 
neurochemical abnormalities in cingulate cortex may relate to clinical symptoms in DLB. 
Severe cholinergic deficits are observed in DLB patients, often associated with 
neuropsychiatric symptoms (Perry et al., 1990). An increase in M2 muscarinic receptor binding 
in the cingulate cortex has been shown in DLB cases (Teaktong et al., 2005), which may be 
due to a decrease in acetylcholine (ACh) release, with upregulation of M2 receptor being a 
compensatory response to preserve ACh function from on surviving cholinergic nerve 
terminals. The increase in M2 receptor binding in cingulate cortex in DLB was shown to be 
associated with neuropsychiatric symptoms, including delusions and hallucinations (Teaktong 
et al., 2005). This may suggest that downregulation of specific neurotransmitters within the 
cingulate cortex may directly contribute to neuropsychiatric symptoms in DLB. 
1.1.7 Summary and overview 
Depression is a complex phenomenon, affecting multiple systems and pathways. Depressed 
individuals display structural and functional brain abnormalities, as well as changes in multiple 
neurotransmitter systems. Although the diversity of depressive symptoms suggests widespread 
alterations in brain function, as supposed to specific regional dysfunction, the sgACC has been 
shown to be integral in mood regulation, with abundant evidence of its involvement in MDD, 
with the DBS of the sgACC showing good clinical outcomes as a treatment for long standing 
refractory MDD (Mayberg et al., 2005). The ACC divisions show early and extensive 
pathology, as well as biochemical changes in MDD, although little is known how these 
abnormalities contribute to the aetiology of depression. Depression is a common psychiatric 
symptom in DLB, often observed in prodromal stages of the disease (Fujishiro et al., 2015), 
and is associated with faster cognitive decline and a poor clinical outcome (Ritchie et al., 1998). 
The basis of depression in DLB is therefore of major importance in understanding the 
underlying cause and identifying treatments. 
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1.1.8 Research aims 
To investigate pathological and neurochemical changes within sgACC, in order to understand 
its role in depression in DLB, with a direct relevance for treatment. 
1.1.8.1 Hypotheses 
The hypothesis is that there are biochemical and pathological changes in specific anatomical 
locations within the cingulate cortex, notably the sgACC, which lead to depressive symptoms 
in DLB. 
1.1.8.2 Objectives 
 To assess pathological changes of α-synuclein, tau and Aβ in cingulate subregions
overall, as well as the sgACC in DLB cases with and without depression, as well as
controls, using quantitative immunohistochemistry and biochemical analysis.
 To investigate GABAergic and glutamatergic changes in sgACC by assessing:
a) Cell density using adapted stereological analysis.
b) Synaptic changes using confocal analysis.
c) Protein changes using biochemical analysis.
 To investigate monoaminergic changes in sgACC by assessing:
a) Fibre densities using adapted stereological analysis
b) Synaptic changes using STED analysis
c) Protein changes using biochemical analysis.
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2.1 Methods and Materials 
2.1.1 Post-mortem human brain tissue 
All post-mortem human brain tissue was obtained from the Newcastle Brain Tissue Resource 
(NBTR), a UK Human Tissue Authority regulated research tissue bank. The ethical approval 
for the study was granted by Newcastle and North Tyneside National Health Service (NHS) 
Research Ethics Committee (ref: 09/H0908/42). All participants had received detailed clinical 
assessments during their life and had consented to the use of their brain tissue for research 
purposes. The consent for the donation of brain tissue was also confirmed by their next of kin 
following death.  
2.1.2 Study cohort 
DLB and control cases were selected based on clinical and neuropathological criteria. 
Neuropathological assessment was carried out according to standardised neuropathological 
diagnostic procedures, which together with clinical data was used to make a clinico-
pathological diagnosis (Braak et al., 2006, McKeith et al., 2005, Thal et al., 2002). Of note, 4 
DLB cases also fulfilled the neuropathological criteria for high AD neuropathological change 
and could therefore be classified as neuropathologically mixed AD/DLB with a Lewy body 
disease (LBD) clinical phenotype (Montine et al., 2012, Walker et al., 2015). All cases were as 
closely matched as possible for age, sex and post-mortem delay. For immunohistochemical 
analysis the cases were selected with shorter time in fixative, and for biochemical analysis with 
higher pH (as a surrogate for agonal state). The case selection for this study was based on the 
availability of clinical information, including sequential Mini-Mental State Examination 
(MMSE) and Unified Parkinson's Disease Rating Scale (UPDRS) scores. The inclusion criteria 
for depression diagnosis was made using the Cornell Scale for Depression in Dementia (CSDD) 
(≥8), as a validated rating scale for depression in dementia (Alexopoulos et al., 1988). 
Alternatively, the Geriatric Depression Scale (GDS) (≥10) was used (Figure 2.1), which while 
less sensitive, is shown to retain acceptable qualities when applied to a population of demented 
elderly patients (Korner et al., 2006). In the absence of clinical diagnosis of depression by a 
consulting psychiatrist, retrospective analysis of clinical records was used to verify the 
presence or absence of depression. The size and characteristics of each cohort is detailed in 
individual chapters. 
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Figure 2.1 Case selection criteria. 
DLB case selection for this study was based on the availability of the Mini-Mental State 
Examination (MMSE), Unified Parkinson's Disease Rating Scale (UPDRS), Cornell Scale for 
Depression in Dementia (CSDD) and the Geriatric Depression Scale (GDS). 
2.1.3 Formalin fixed tissue acquisition and preparation 
At autopsy, the brain weight and post-mortem delay were recorded. The right hemisphere was 
fixed in 10% neutral-buffered formalin for 4-6 weeks. Following fixation, the right hemisphere 
was cut into 7 mm coronal slices, then sub-dissected into blocks for diagnostic and research 
purposes. Paraffin-embedded blocks selected for analysis corresponded to the sgACC (block 
U, coronal level 9), spACC (block V, coronal level 10), MCC (block AB, coronal level 16) and 
PCC (block AE, coronal level 20; Figure 2.2). The sgACC (Brodmann area: BA25) was 
sampled at the level of the rostrum of the corpus callosum, spACC (BA24) at the level of the 
genu of the corpus callosum, MCC (BA24’) at the level of the primary motor cortex and PCC 




















cut into 10μm sections using a HM340E rotary microtome with a z-axis monitor (Thermo 
Scientific, MA, USA) and mounted onto charged slides (Superfrost Plus, Thermo Scientific, 
UK) using a 45°C water bath. The sections were dried for 48 hours at 37°C, followed by 30 
minutes at 60°C, then cooled and stored at room temperature prior to staining.  
2.1.4 Histological staining 
To assess cell density, sections from sgACC were stained with Cresyl Fast Violet (CFV), used 
to stain Nissl substance in the cytoplasm of neurones, which appears dark blue due to staining 
of ribosomal RNA. The 10μm sections were heated in a 60°C oven for 30 minutes, dewaxed 
in xylene for 15min, then rehydrated through a graded series of ethanol solutions (absolute and 
95% ethanol). The sections were then immersed in 1% hydrochloric acid in 70% ethanol for 
5min, washed in distilled water, then incubated in pre-heated CFV solution in a 60°C oven for 
5min. Following a 5min cooling period in CFV solution, the sections were differentiated in 
95%, then absolute ethanol, cleared in xylene and mounted using DPX (CellPath, Newtown, 
UK). 
2.1.5 Immunohistochemistry 
Formalin-fixed 10μm tissue sections were heated in a 60°C oven for 30 minutes. Following 
paraffin wax removal through xylene, the sections were rehydrated with decreasing 
concentrations of ethanol (100%, 95%, 70%, 50% and deionised water). To unmask epitopes 
cross-linked as a result of fixation, antigen retrieval was carried out according to optimised 
protocols for specific antibodies. Citrate buffer heat-induced antigen retrieval (using trisodium 
citrate pH 6.0) was carried out by pre-heating the buffer for 10 minutes in an 800 watt 
microwave, then heating the slides on full power for 10 minutes, followed by a cooling period 
of 20 minutes at room temperature. Ethylenediamine tetra-acetic acid (EDTA) heat-induced 
antigen retrieval pH 8.0 was carried out by immersing slides in boiling buffer and pressure 
cooking for two minutes. Formic acid antigen retrieval was carried out by immersing slides in 
absolute formic acid at room temperature for the optimised time period.  
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Figure 2.2 NBTR protocol for brain dissection. 
Coronal dissection map of the right hemisphere. Slice 1 corresponds to the frontal pole and slice 33 to the occipital pole. The brain regions with the purple 
coloured blocks are used for diagnostic and the blue blocks for research purposes. The sgACC corresponded to block U, spACC to block V, MCC to AB and 





2.1.5.1 Chromogenic immunohistochemistry 
Following antigen retrieval, sections were incubated with three percent hydrogen peroxide in 
deionised water for 20 minutes to block endogenous peroxidase activity. After quenching, the 
sections were washed in water, followed by three washes in 10mM tris-buffered saline 
containing 0.1% v/v Tween 20 (TBST) pH 7.6. An ImmEdge hydrophobic barrier pen (Vector 
Laboratories, Burlingame, CA, USA) was used to contain primary antisera by outlining tissue 
sections. Tissue sections were incubated with the primary antibodies diluted in TBST for one 
hour at room temperature. Following three washes in TBST, the sections were incubated with 
horseradish peroxidase (HRP) polymer conjugated universal probe (MenaPath, Menarini 
Diagnostics UK) for 30 minutes at room temperature. After three washes in TBST the tissue 
sections were incubated for 30 minutes with HRP reagent, followed by three TBST washes. 
Visualisation of the antibody was attained by using the Menarini X-Cell-Plus HRP Detection 
Kit (Menarini, UK), using Diaminobenzidine (DAB) substrate for two minutes. The sections 
were then washed in running water for five minutes, counterstained with Mayer’s haematoxylin 
solution for 30 seconds, differentiated with 1% hydrochloric acid in 70% ethanol, blued with 
1% ammonia in water and dehydrated through increasing concentrations of ethanol (90%, 95% 
and 100%). The sections were then cleared in xylene and mounted using DPX (Cell Path, UK). 
2.1.5.2 Fluorescent immunohistochemistry 
Following antigen retrieval, the sections were washed in water and blocked in TBS containing 
10% normal goat serum (NGS: Sigma G9023) for one hour at room temperature. The tissue 
sections were then incubated with the primary antibodies diluted in TBS and 10% NGS 
overnight at 4°C. After three washes in TBS for 5 minutes, the sections were incubated with 
secondary fluorescent antibodies in TBS and 10% NGS for 1 hour at room temperature, 
followed by three TBS washes. To stain the nuclei, the sections were incubated with TO-PRO-
3 Iodide (1 mM Solution in DMSO, Thermo Fisher, UK) for 15 min, then washed three times 
in TBS.  Prior to and following an incubation in Sudan Black B (0.3%w/v in 70% ethanol in 
deionised water) for 10 minutes to quench autofluorescence, sections were immersed in 70% 
ethanol for 5 seconds, then washed in deionised water. Sections were mounted using ProLong 
Diamond Antifade Mountant (Thermo Fisher, UK) and stored at -30°C to preserve the 
fluorescent signal prior to imaging. 
Adjustments were made to the previously outlined protocol for stimulated emission depletion 
(STED) microscopy. Higher primary and secondary antibody concentrations (2-3 fold) were 
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used to ensure optimal labelling density. The Sudan Black B step was omitted. The sections 
were mounted with ProLong Glass Antifade Mountant (Thermo Fisher, UK) using high 
precision coverslips (0.170 ± 0.01 mm thick; Roth, Germany, LH25.1) to enhance image 
quality.  
2.1.6 Imaging 
2.1.6.1 Light microscopy  
Images were captured using a Zeiss Z1 microscope with a motorised stage and MRc camera 
(Zeiss, Germany) coupled to a PC. Stereologer software (Stereologer, Bethesda, MD, USA) 
was used to ensure adequate and unbiased sampling. The region of interest was drawn at 1.25X 
magnification and a randomly oriented point grid was superimposed over the observed image 
(Figure 2.3 A). Within the delineated region of interest 10-15 frames were captured at 10X 
magnification for the densitometric analysis, whereas 25-30 frames were used for the 
estimation of neuronal cell number using a 63X oil immersion objective. 
2.1.6.2 Confocal imaging  
Fluorescent quadruple labelled sections were imaged using Nikon A1R confocal microscope 
and NiS elements software using 60X oil immersion objective. The settings for laser power, 
gain and offset were optimised for each fluorophore (405nm, 488nm, 546nm and 647nm). Ti 
ZDrive construction of the Z-stacks was attained by determining the lower and upper thresholds 
of the section depth, with multiple images captured at 0.17μm intervals through the depth of 
the tissue. Image averaging was set to 16X to reduce background interference and give a more 
accurate depiction of the tissue stain. Four images were acquired per case within the region of 
interest, and images analysed using IMARIS software (Bitplane, Oxford Instruments). 
2.1.6.3 STED Imaging 
Stimulated emission depletion microscopy (STED) creates super-resolution images by using 
two laser beams, an excitation laser and a doughnut-shaped STED laser beam. STED is a point 
scanning method that uses an excitation laser being focused on a sample to a diffraction limited 
volume. The second depletion laser modulates fluorescence emission in the periphery, which 
produces a restricted central emission area that is smaller than the diffraction limited volume 
(Figure 2.4). STED 3D images were acquired using Leica SP8 STED microscope and 
Application Suite X software (LAS X; Leica Microsystems; Figure 2.5) with 100x oil 
immersion objective. Images of 256 × 256 pixels were obtained using 35x optical zoom, 
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resulting in a pixel size of 13 × 13 nm. The gating parameters were set to 1.5-6.0 for the 532nm 
laser, and 0.5-6.0 for the 594nm and 647nm lasers. Atto647N was imaged with 652nm 
excitation and 750nm depletion wavelengths, Alexa Fluor 532 with 505nm excitation and 
581nm depletion wavelengths, whereas Alexa Fluor 594 with 533nm excitation and 591nm 
depletion wavelengths. All images were deconvolved using Huygens Essential Software 
(Scientific Volume Imaging, Netherlands). 
2.1.7 Imaging analysis 
2.1.7.1 Densitometric analysis 
Densitometric analysis was used to assess the percentage area stained of immunoreactivity 
within the region of interest. The images were captured at 10X magnification and imported into 
Fiji Image J analysis software (Windows 64-bit: https://fiji.sc) for densitometric analysis 
(Figure 2.6Figure 2.3). The Red-Green-Blue (RGB) thresholds were adjusted manually for 
each antibody to eliminate the detection of non-specific background staining. The percentage 
area stained for each antibody was quantified overall, as well as in cortical layers II, III and V. 
The mean percentage area stained per case was calculated from the mean values obtained across 
all images taken. 
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Figure 2.3 Stereological sampling. 
A) A region of interest was drawn at 1.25X. A point grid was superimposed over the area, with
green points representing the coordinates of sampling. B) Randomly sampled frames in the x-
y axis taken at 63X, with neurones counted within a disector frame of known dimensions. C)
For the estimation of monoaminergic fibres within the outlined reference space, the fibres








Figure 2.4 The principle of STED microscopy. 
STED functions by depleting fluorescence in specific regions of the sample while leaving a 
central focal spot active to emit fluorescence. The depletion laser has a doughnut shaped 
intensity distribution, with zero intensity in the middle and high intensity in a circular region 
around the central position. Superimposing this depletion beam on the excitation beam prevents 
spontaneous emission (fluorescence) anywhere except in a very small central region (PSF), 
therefore the information can be acquired at a much higher resolution compared to standard 




Figure 2.5 STED imaging. 
3D confocal and super-resolution STED image of dopaminergic fibres (DAT; green) and 
presynaptic terminals (SNAP25; yellow). 
2.1.7.2 Analysis of neuronal density 
An adapted stereological method was used to estimate the number of neurones within the 
sgACC. Within each coronal section, a region of interest was drawn at low magnification 
(1.25X) using the Zeiss Z1 microscope with a motorised stage. A randomly oriented point grid 
was superimposed over the observed image ensuring the sampling of the structure in a 
systematic and unbiased manner through its x-y axis. The distance between points on the grid 
was determined based on the pilot study. The neurones were counted within the disector frame 




within the sgACC was determined automatically by the Stereologer software (cells per µm2), 
with values converted to cells per mm2.  
2.1.7.3 Analysis of monoaminergic fibers 
Estimation of serotonergic (5HTT) and dopaminergic (DAT) fibres within sgACC was 
assessed using stereology software, by counting the number of intersections between the linear 
probe and lines that represent the surface feature within the dissector frame of known 
dimensions. The isotropic interaction between the linear probes and the surface feature was 
achieved through the use of VUR (vertical uniform random) sections in combination with sine-
weighted line probes called cycloids (West, 2013). The green colour coded points indicate 
selected points where cycloids intersect with the objects of interest (Figure 2.3 C). 
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Figure 2.6 Densitometric analysis. 
A) Image of α-synuclein (KM51) stained section from sgACC at 10X magnification; B) A colour threshold applied using Image J software to label
Lewy body and Lewy neurite immunoreactivity; C) The selected threshold applied to quantify the percentage area stained.
A B C
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2.1.7.4 Confocal analysis 
To analyse GABAergic and glutamatergic synaptic volumes in relation to α-synuclein, 
IMARIS software was used to generate 3D representative images from the imported Z-stacks, 
with individual surfaces created for each fluorescent signal (Figure 2.7). 3D surfaces were 
created for Nuclei (647nm, purple), GAD65/67 positive GABAergic surfaces (488nm, green) 
or VGLUT1 positive glutamatergic surfaces (488nm, green), SNAP25 positive pre-synaptic 
terminals (546nm, red) and s129 positive α-synuclein surfaces (405nm, blue; Figure 2.7). The 
staining intensity boundaries were optimised for each laser channel (405nm 500-3500, 488nm 
600-3500, 546nm 400-3000), whereas background subtraction of 1.0 and smoothness of 0.1
was applied to all the channels respectively. The number and the average volume of individual
surfaces for different laser channels was calculated and averaged across four Z stacks. The
number and average volume of GABAergic and glutamatergic synapses was determined based
on the co-localisation between GAD65/67 or VGLUT1 positive surfaces and SNAP25. The
GABA and glutamate positive surfaces were masked on to SNAP25, creating the new surface
representative of a synapse. The synaptic surface was then masked onto α-synuclein, which
allowed synapses containing α-synuclein to be selected, creating surfaces for the α-synuclein
positive synapses.
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Figure 2.7 Confocal analysis. 
Confocal images were acquired at 60X magnification with each fluorophore representing different laser channels. Cell nuclei (TO-PRO-3 Iodide) 
imaged using 647nm, glutamatergic (VGLUT1) and GABAergic (GAD65/67) surfaces with 488nm, presynaptic terminals (SNAP25) with 546nm 
and phosphorylated α-synuclein (s129) with 405nm. 3D surfaces were created from imported Z stacks for each laser channel using Imaris software. 
The surfaces for different fluorophores were overlaid to assess co-localisation.
s129SNAP25Nuclei VGLUT1 Merged
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2.1.7.5 STED analysis 
3D STED images were deconvolved using Huygens Essential Software. Deconvolution is a 
combination of optical and computational techniques used to improve the contrast and 
resolution of images. Deconvolution settings were optimised to increase the final quality of the 
image. The number of iterations were set at 40, and the signal to noise ratio at 7. The quality 
threshold was set at 0.05, which is a restoration parameter that makes deconvolution stop when 
the change in the quality criterion between two consecutive iterations is below its value. The 
Object Analyzer Advanced tool was used to create 3D surfaces for each channel and obtain the 
quantitative measures of individual particles. A size threshold was applied to remove objects 
that were too small, with “garbage” volume set at 10 voxels. The seed and threshold criteria 
were optimised for individual channels. For the 488nm channel the seed was set at 5% and 
threshold at 30%, for 594 the seed was set at 5% and threshold at 15%, and for 647nm the seed 
set at 10% and the threshold at 25%. Colocalisation measurements were used to assess spatial 
overlap between structures in different data channels. 
2.1.8 Protein isolation and quantification 
2.1.8.1 Frozen tissue acquisition and protein extraction 
The left hemisphere was sliced into coronal slices at approximately 1cm intervals, sealed in 
plastic bags, frozen at -120°C and stored at -80°C. Frozen tissue slices were brought to -20°C 
in a freezing cabinet, and cingulate subregions corresponding to sgACC, spACC, MCC and 
PCC were removed. Approximately 50mg of grey matter tissue was homogenised using a rotor-
stator homogeniser in ice cold lysis buffer containing 0.2M triethylammonium bicarbonate 
(TEAB) pH 7.2 (Sigma-Aldrich, MO, USA), and 1X EDTA free protease inhibitor cocktail 
(Complete, Roche, UK). The crude samples were stored at -80°C.  
2.1.8.2 Tissue fractionation 
Total protein homogenate was fractionated to extract soluble and insoluble proteins (Culvenor 
et al., 1999). The tissue from sgACC was homogenized in 0.2M TEAB buffer containing 
EDTA free protease inhibitors with no detergent. The soluble protein fraction containing 
supernatant (containing proteins such as GAPDH) was extracted following high speed 
centrifugation (20,000 x g for 45min at 4°C), and the pellet re-suspended in 500μl of 0.1% 
Tween20 in 0.2M TEAB. The soluble membrane bound protein fraction (containing proteins 
such as SNARE proteins) was stored at -30C°. The remaining sample was centrifuged to extract 
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Tween20 soluble membrane bound proteins (containing proteins such as APP). The pellet was 
re-suspended in 500μl of 2% sodium dodecyl sulphate (SDS), and the insoluble membrane 
bound protein fraction (including GPCR coupled receptors) was stored at -30C°. The remaining 
sample was centrifuged further to extract SDS soluble membrane bound proteins, and the pellet 
containing highly insoluble aggregated proteins including aggregated α-synuclein, was re-
suspended in 500μl of 6M Urea. The highly insoluble protein fraction was taken before further 
centrifugation to extract insoluble aggregated proteins (Figure 2.8). Due to the small amounts 
of material remaining in the Urea fraction, it was not possible to run all antibodies for this 
fraction. All protein fractions were stored at -30C° prior to use.  
2.1.8.3 Protein quantification using Bradford assay 
Two percent of SDS was added to the samples prior to sonication on ice in a sonic bath for 
40min. Protein concentration was determined using Bradford assay (Bradford, 1976). The 
standards of known protein concentration ranging from 0 μg/ml to 1 mg/ml were prepared 
using bovine serum albumin (BSA; Sigma-Aldrich, UK), diluted in homogenising buffer (1:4 
in MilliQ water). Sonicated samples were diluted 1:20 in MilliQ H2O prior to analysis. Five μl 
of BSA standards and samples were pipetted into wells in triplicates to a flat-bottom 96-well 
plate. Two hundred and fifty microliters of Bradford reagent (Sigma-Aldrich, UK) was added 
to each well and incubated for 10min at room temperature. The absorbance was measured at 
595nm using a microplate reader (TECAN, UK). The protein concentration of unknown 
samples was quantified from a standard curve produced from the absorbance of the BSA 
standard concentration. 
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Figure 2.8 Tissue fractionation. 
Crude tissue homogenates were centrifuged to extract cytoplasmic and membrane bound 
protein fractions using high speed centrifugation. The pellet was gradually dissolved by 
sequentially using 0.1% Tween20, 2% SDS and 6M Urea to extract insoluble protein fractions. 
Adapted from (Culvenor et al., 1999). 
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2.1.8.4 Western blotting 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate proteins according 
to their molecular weight and to measure changes in protein expression. Protein samples were 
prepared at 1 µg/µl with 4X NuPAGE LDS Sample Buffer, 10X NuPAGE Sample Reducing 
Agent and homogenising buffer. Denaturation of proteins was achieved by heating the samples 
at 70°C for 10min on a heated block, followed by brief spinning. Ten microliters of denatured 
samples were loaded into wells of a NuPAGE 4-12% Bis-Tris Gel (Invitrogen) alongside 
Chameleon 800 pre-stained protein ladder (LI-COR). The gel was electrophoresed in 1X 
NuPAGE MOPS SDS running buffer with each chamber containing 435μl of antioxidant 
(Invitrogen) at 120V for 20 minutes, followed by 160V for an hour. The transfer of proteins 
from the polyacrylamide gel to a nitrocellulose membrane was performed using a semi-dry 
electro-transfer using an iBlot2 device (Invitrogen) at 20V for 1min, 24V for 4min and 27V for 
5min.  
2.1.8.5 Dot blotting 
The dot blot technique was used as a quantitative and semi-quantitative method for detection 
of proteins, with samples applied directly onto a membrane. The samples are pulled through 
the membrane by a vacuum, where proteins bind to the membrane and the other sample 
components pass through. Protein samples for dot blot were prepared at 1 µg/µl with 4X 
Orange G Loading Buffer, 10X NuPAGE Sample Reducing Agent and homogenising buffer. 
The standards ranging from 0 μg/μl to 120 μg/μl were prepared using pooled samples from all 
disease groups. The samples were denatured at 70°C for 10min on a heated block prior to 
loading. Vacuum-assisted 96-well Bio-dot Microfiltration apparatus (BioRad) was used to blot 
the samples. The nitrocellulose membrane (AmershamTM, 0.2μm NC) was assembled on top 
of thick filter paper (0.5cm) in between a sealing gasket and sample template with attached 
sealing screws. A tight seal between the sample wells ensured maximum suction force and that 
there was no dispersion of samples into adjacent wells. During continuous suction, the 
membranes were washed with 100μl of TBS per well delivered using a multichannel pipette. 
Fifty μl of samples and standards were pipetted into each well in duplicate. The membrane was 
then washed with TBS (100μl per well), left to dry on a flat surface for 15min, fixed in 70% 
methanol for 20min under agitation, rinsed in MilliQ water and washed in TBS prior to 
blocking. 
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2.1.8.6 Near Infrared (NIR) Western and Dot blot detection 
The proteins on nitrocellulose membrane were stained with Revert Total Protein Stain (LI-
COR) for 2min under agitation. The membrane was washed twice with MilliQ water and 
imaged using near-infrared (NIR) fluorescence detection at 680nm for 2 min using LI-COR 
Odyssey Fc imaging system. After 3X 5min washes with TBS to remove the stain, the 
membranes were blocked using Odyssey blocking buffer (LI-COR) for 1 hour at room 
temperature under light agitation, then incubated with primary antibodies diluted in Odyssey 
blocking buffer and 0.2% Tween20 (Sigma-Aldrich) overnight at 4°C. To remove excess 
primary antibody the membranes were washed in TBS with 0.1% Tween20 3X for 5min on a 
platform shaker at room temperature, then incubated with IRDye 800WC secondary antibodies 
diluted in Odyssey blocking buffer and 0.2% Tween20 for 1 hour at room temperature while 
protected from light. Following 3X TBST washes the membranes were incubated with IRDye 
conjugated GAPDH 680nm (Santa Cruz Biotechnology) diluted in Odyssey blocking buffer 
and 0.2% Tween20 for 1 hour at room temperature. Prior to imaging, the membranes were 
washed 3X in TBST for 5min, followed by 2X 5min washes with TBS to remove residual 
Tween20 and imaged while wet. 
2.1.8.7 Near Infrared (NIR) imaging analysis 
The membranes were imaged using an Odyssey NIR imaging system (LI-COR Odyssey FC). 
Each membrane was scanned at 700nm (GAPDH) and 800nm (protein of interest) for 2 min. 
The protein intensity bands were quantified using Image Studio Lite (LI-COR; Figure 2.9). The 
brightness and contrast for each scanned image was adjusted to produce the best image quality 
(this does not alter the fluorescent signal). The Lane Normalisation Factor was calculated by 
dividing GAPDH signal for each lane by the highest GAPDH signal. The signal for protein of 
interest was then divided by the Lane Normalisation Factor to normalise the protein of interest. 
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Figure 2.9 Near Infrared (NIR) imaging. 
(Top) Western blot membrane imaged at 700nm (GAPDH) and 800nm (PSD95 and Chameleon 
800 ladder) using control and DLB cases with depression. (Middle) Dot blot membrane imaged 
at 700nm (GAPDH) and 800nm (3R Tau) using controls and DLB cases with and without 
depression, as well as pooled standards. (Bottom) Plot of total protein value against absorbance 
(800nm) of the protein of interest to provide a standard curve for the pooled standards. 
2.1.8.8 Enzyme-Linked Immunosorbent Assay (ELISA) 
ELISA was used to measure the levels of total and fibrillar α-synuclein in a fractionated sgACC 
tissue samples from DLB cases with and without depression and normal controls. For both total 
and fibrillar α-synuclein “Sandwich” ELISA (Figure 2.10), a 96 well plate (IMULON, Thermo 
Fisher Scientific) was coated (100μl per well) with 10D2 α-synuclein antibody (2.9 mg/ml 
stock concentration; Analytic Jena, Germany; 1:2000) diluted in Carbonate Bicarbonate Buffer 
(50mM; pH 9.6; Sigma Aldrich, UK), and incubated overnight at 4°C. Phosphate-Buffered 
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PBST washes, the plates were blocked with 1% BSA in PBST (200μl per well) for 1 hour at 
room temperature on an orbital shaker. Standards ranging from 0-60 μg/μl for fibrillary and 0-
40 μg/μl for total α-synuclein were prepared using serially diluted recombinant proteins 
(Proteos, USA) in 1% BSA in PBST, with samples of 2.5 μg/μl protein prepared in PBST. 
Following a single wash with PBST, the standards and samples were pipetted in triplicate 
(100μl per well), and incubated for two hours on a shaker at room temperature. After 3X PBST 
washes, 100μl of detection antibody (for total α-synuclein: α-β synuclein (Abcam, EP1646Y, 
1:1500); for fibrillar α-synuclein: filament (Abcam, MJFR-14-6-4-2, 1:2000)) diluted in 1% 
BSA in PBST was pipetted in triplicate and incubated for 1 hour, followed by 3X PBST washes. 
The plate was incubated with alkaline phosphatase (AP) conjugated goat anti-rabbit secondary 
antibody 1:1000 in 1% BSA in PBST (100μl per well) for 1 hour, followed by 3X PBST 
washes. A 1 mg/ml AP substrate solution was prepared by dissolving p-nitrophenyl phosphate 
(pNPP) in a solution consisting of 0.05M Sodium Carbonate, 0.001M magnesium chloride and 
0.05M Sodium Bicarbonate (Sigma Aldrich), which was prepared 30min before use and the 
plate incubated at room temperature.  One hundred microliters of substrate solution was added 
to each well and the plate incubated at 37°C in an incubator. The plate was read at 412nm 
absorbance at 15, 30, 45 and 60min time points.  
Figure 2.10 “Sandwich” ELISA. 
The capture antibody 10D2 was used to coat a 96 well plate prior to incubation with antigen 
(recombinant non-aggregated or fibrillary α-synuclein), which was recognised by detection 
antibodies (α-β or fibrillar synuclein). The detection antibody was detected by the secondary 
AP conjugated antibody. The exposure to substrate resulted in the colour change, which was 








2.1.9 Statistical analyses 
Statistical analyses were performed using SPSS Statistics version 22.0. The normal distribution 
across samples was assessed using Shapiro–Wilk test, with homogeneity of variance 
determined using Levene’s test. If the assumptions of normality were met, analysis of variance 
(ANOVA) was used to analyse the data sets between the groups, followed by Bonferroni post-
hoc analysis to correct for multiple comparisons. A paired-samples t-test was used for pairwise 
comparisons within groups. Where the normal distribution criteria was not fulfilled, a non-
parametric Kruskal-Wallis test was used to compare multiple groups, with adjusted p-values to 
correct for multiple comparisons, so that the overall error rate remained at 5%. Friedman’s 
ANOVA was used for pairwise comparisons within groups. The effect sizes for group 
differences was calculated using Wilcoxon test. Correlation analyses were carried out using 
Spearman’s correlation coefficient ρ (rho). The relationship between imaging, pathological and 





















In DLB, the cingulate cortex, and in particular the ACC, shows extensive LB pathology that 
can be observed at an early disease stage along with grey matter atrophy and metabolic 
abnormalities (Blanc et al., 2016, Braak et al., 2002, Yong et al., 2007). Decreased grey matter 
volume of the ACC was shown to be associated with neuropsychological impairment in DLB 
(Sanchez-Castaneda et al., 2009). Metabolic and perfusion deficits within the cingulate cortex 
are commonly observed in DLB patients, suggesting that the cingulate cortex is susceptible to 
functional changes (Lim et al., 2009). Co-occurring AD associated Aβ and tau pathological 
changes occur in 50-80% of DLB patients and may contribute to clinical features of disease 
(Halliday et al., 2011). The ACC is integral to emotional processing and symptomatic 
expression of depression (Drevets et al., 2008b), with the sgACC showing structural, functional 
and metabolic abnormalities in MDD (Li et al., 2014b). The sgACC is the primary target in the 
treatment of depression using DBS, producing an effective antidepressant effect in treatment 
resistant depression (Berlim et al., 2014). Depression is a common feature of DLB (Ballard et 
al., 2004), associated with higher mortality rates and a poor response to treatment (Ritchie et 
al., 1998). However, little is known about how pathological burden in cingulate subregions, 
particularly the sgACC, influences development of depression in DLB.  
3.1.2 Aims 
The aim of this study was to investigate pathological changes within the cingulate cortex and 
particularly in the sgACC in relation to depression in DLB.  
3.1.2.1 Objectives 
 To assess pathological changes of α-synuclein, p-Tau and Aβ within cingulate cortex
subregions in relation to depression using post-mortem tissue from DLB cases with and
without depression, and normal controls.
 To quantify overall and layer specific pathological changes of α-synuclein, p-Tau and
Aβ in sgACC in relation to depression in DLB using post-mortem fixed tissue.
 To quantify protein levels of α-synuclein, p-Tau and Aβ markers in sgACC using
fractionated frozen post mortem tissue samples.
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 To assess neuronal cell numbers in sgACC in DLB cases with and without depression
and controls.
3.2 Methods 
The cohort for the neuropathological analysis consisted of 16 DLB cases with depression, 20 
DLB cases without depression and 17 neurologically and psychiatrically normal controls 
(Table 3.1).  Of note, 4 DLB cases also fulfilled the neuropathological criteria for high AD 
neuropathological change and could therefore be classified as neuropathologically mixed AD/
DLB with a Lewy body disease (LBD) clinical phenotype (Montine et al., 2012, Walker et al., 
2015). The inclusion criteria for depression diagnosis was made using CSDD (>8) or GDS 
(>10). In the absence of clinical diagnosis of depression, retrospective analysis of clinical 
records was used to verify the presence or absence of depression including use of 
antidepressant medication. Ten micron thick sections were sampled from fixed tissue blocks 
corresponding to sgACC, spACC, MCC and PCC (Figure 3.1), and stained with antibodies 
against α-synuclein (KM51), p-Tau (AT8) and Aβ (4G8) (Table 3.2) for densitometric analysis 
(see Methods Section 2.7.1 for full details). The cohort for biochemical analysis consisted of 
12 DLB cases with depression, 12 DLB cases without depression and 12 normal controls (Table 
3.3).  Cases were identified with relatively short PM delay and were selected for analysis, as 
autolysis and protein degradation is a potential concern when working with post mortem 
tissues. For the biochemical analysis, with the focus on sgACC, tissue samples were 
fractionated to extract soluble and insoluble proteins (see section 2.8.2 for fractionation 
method), which were then quantified using western blotting (WB) and dot blotting (DB) 
techniques (see sections 2.8.4 and 2.8.5).  
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Table 3.1 Demographic information for neuropathological cohort. 
Case ID Diagnosis Depression Gender Age at death PM delay McKeith NFT Braak stage CERAD
1 DLB yes Male 71 22 Neocortical 3 Moderate
2 DLB yes Male 76 13 Neocortical 2 Sparse
3 DLB yes Female 91 10 Neocortical 3 Moderate
4 DLB yes Female 81 44 Neocortical 4 Moderate
5 DLB yes Male 77 29 Neocortical 2 Moderate
6 DLB yes Female 77 23 Neocortical 3 Moderate
7 DLB yes Male 84 72 Neocortical 4 None
8 DLB yes Female 73 99 Neocortical 3 None
9 DLB yes Male 72 89 Neocortical 3 None
10 DLB yes Male 78 83 Limbic 1 None
11 DLB yes Female 91 84 Limbic 5 Frequent
12 DLB yes Female 75 64 Diffuse 6 Frequent
13 DLB yes Male 77 65 Neocortical 3 Sparse
14 DLB yes Female 75 51 Limbic 5 Frequent
15 DLB yes Male 89 88 Neocortical 3 Sparse
16 DLB yes Female 57 40 Brain stem 0 N/A
17 DLB no Male 81 24 Neocortical 4 Sparse
18 DLB no Male 78 8 Neocortical 3 Moderate
19 DLB no Male 77 8 Neocortical 2 Moderate
20 DLB no Male 71 8 Neocortical 2 Sparse
21 DLB no Female 88 16 Neocortical 3 Moderate
22 DLB no Male 92 20 Neocortical 4 n/a
23 DLB no Male 74 60 Neocortical 2 None
24 DLB no Female 87 90 Neocortical 2 None
25 DLB no Male 73 47 Neocortical 3 None
26 DLB no Male 81 81 Neocortical 3 Moderate
27 DLB no Male 77 46 Neocortical 3 None
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‘PM delay’ represents the interval between death and post-mortem examination; ‘Braak NFT stage’ evaluates the density and distribution of NFT 
pathology (Braak et al., 2006); ‘McKeith’ criteria represents global LB pathology stage (McKeith et al., 2005), ‘CERAD’ consortium to establish 
a registry of AD, assesses neuritic plaques (Gearing et al., 1995). N/A, data not available.
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28 DLB no Male 74 42 Neocortical 4 Sparse
29 DLB no Male 71 68 Neocortical 3 Sparse
30 DLB no Female 75 78 Neocortical 6 Frequent
31 DLB no Female 78 96 Neocortical 3 Sparse
32 DLB no Female 78 120 Diffuse 5 Frequent
33 DLB no Male 84 56 Neocortical 3 Moderate
34 DLB no Female 84 127 Neocortical 2 None
35 DLB no Male 81 51 Neocortical 3 Sparse
36 DLB no Male 79 110 Neocortical 3 None
37 Control no Female 78 23 No LB pathology 2 Sparse
38 Control no Male 90 161 No LB pathology 3 Sparse
39 Control no Female 93 12 No LB pathology 3 None
40 Control no Female 93 101 No LB pathology 3 Sparse
41 Control no Male 94 39 No LB pathology 2 Sparse
42 Control no Male 71 25 No LB pathology 1 None
43 Control no Female 90 63 No LB pathology 2 None
44 Control no Female 76 86 No LB pathology 2 None
45 Control no Male 85 45 No LB pathology 1 none
46 Control no Male 96 16 No LB pathology 2 None
47 Control no Male 85 57 No LB pathology 3 sparse
48 Control no Male 99 5 No LB pathology 2 None
49 Control no Female 97 21 No LB pathology 2 Sparse
50 Control no Female 94 15 No LB pathology 2 None
51 Control no Female 85 95 No LB pathology 2 None
52 Control no Female 72 27 No LB pathology 1 sparse




Figure 3.1 Cingulate subregions. 
Scanned coronal cingulate sections of a DLB case with depression (case ID-14) stained with 
α-synuclein (KM51). The red boxes demonstrate the regions of interest. 
 
Table 3.2 Antibodies used for pathological study. 
 
DB – dot blot; IHC – immunohistochemistry; m – monoclonal; p – polyclonal; Ms – mouse; 





Antigen Host/IgG Dilution Source Product Code
α-synuclein fillament mRb (IgG) 1:500 (DB) Abcam ab209938
α-synuclein (KM51) mMs l (IgG1) 1:500 (DB)1:50 (IHC) Leica Biosystems ASYN-L
α-synuclein (5G4) mMs (IgG1) 1:500 (DB) 1:4500 (IHC) Analytik Jena 847-0102004001
α-synuclein (s129) pRb (IgG) 1:500 (DB) Abcam ab168381
α-synuclein (α-β) mRb (IgG) 1:500 (DB) Abcam ab51252
α-synuclein (pY125) mMs (IgG2b) 1:500 (DB) BD Biosciences 558246
Amyloid-beta (4G8) mMs (IgG2b) 1:500 (DB)1:12000 (IHC) BioLegend 800701
Amyloid-beta (1-40) mMs (IgG) 1:500 (DB) Sigma-Aldrich 05-799
Amyloid-beta (1-42) mMs (IgG1) 1:500 (DB) Sigma-Aldrich 05-831-I
Tau (AT8) mMs (IgG1) 1:500 (DB)1:8000 (IHC) Thermo Fisher MN1020
Tau (3R) mMs (IgG) 1:500 (DB) Sigma-Aldrich 05-803
Tau (4R) mMs (IgG) 1:500 (DB) Sigma-Aldrich 05-804
NeuN mRb (IgG) 1:1000 (IHC) Abcam ab207279
74 
 
Table 3.3 Demographic information for sgACC biochemical cohort. 
Pathological protein levels were assessed in 12 DLB cases with, 12 DLB cases without 
depression and 12 normal controls. The cases that were also included in immunohistochemical 
analysis are in bold. ‘PM delay’ represents the interval between death and post-mortem.
Case ID Diagnosis Depression Sex pH PM delay Age at death
1   DLB yes Male 6.09 22 71
2  DLB yes Male 6.12 13 76
3 DLB yes Female 6.51 10 91
4 DLB yes Female 6.14 44 81
5 DLB yes Male 6.36 29 77
6 DLB yes Female 6.24 23 77
7 DLB yes Male 6.06 19 69
8 DLB yes Female 6.07 21 75
9 DLB yes Male 6.45 18 75
10 DLB yes Male 6.36 29 77
11 DLB yes Female 6.64 48 70
12 DLB yes Female 5.77 40 57
13 DLB no Male 6.66 26 79
14 DLB no Male 5.7 22 71
15 DLB no Female 6.27 10 72
16 DLB no Male 6.54 31 66
17 DLB no Male 6.15 24 81
18 DLB no Male 6.4 8 78
19 DLB no Male 6.41 8 77
20 DLB no Male 6.33 8 71
21 DLB no Female 5.92 16 88
22 DLB no Male 6.19 20 92
23 DLB no Male 6.29 18 72
24 DLB no Female 6.02 4 70
25 Control no Female 6.47 23 78
26 Control no Female 6.39 21 88
25 Control no Male 6.24 24 85
26 Control no Male 6.78 30 66
29 Control no Male 6.89 22 67
30 Control no Male 6.13 17 72
31 Control no Female 6.35 34 78
32 Control no Male 6.45 25 73
33 Control no Female 6.2 29 96
34 Control no Female 6.57 26 82
35 Control no Male 6.66 9 66




3.3.1 Pathological changes in cingulate subregions 
There was no significant difference in gender (p=0.109), post-mortem delay (p=0.790) or age 
at death (p=0.464) between controls or either of the DLB groups. No α-synuclein 
immunoreactivity was observer in control cases in all cingulate subregions. The KM51 α-
synuclein pathological burden was highest in spACC, followed by sgACC in DLB cases, with 
MCC and PCC showing relatively low levels of LB and LN pathology (Figure 3.2). In DLB 
cases, 5G4 α-synuclein immunoreactivity in cingulate subregions was higher compared to 
KM51, with spACC and sgACC showing highest, and MCC and PCC moderate pathological 
burden (Figure 3.3). A significant main effect of diagnosis on α-synuclein pathological burden 
(KM51 and 5G4) was observed in sgACC, spACC, MCC and PCC, with significant increase 
found in all cingulate subregions in DLB cases with and without depression compared to 
controls (p<0.001, Figure 3.4). Using paired within subjects analysis, DLB cases with 
depression showed significantly higher α-synuclein (KM51) burden in spACC compared to the 
PCC (p=0.001) and MCC (p=0.039), whereas DLB cases without depression had higher α-
synuclein levels in spACC compared to the PCC (p=0.001). No significant regional differences 
in α-synuclein (5G4) burden were observed between the groups. 
The control cases showed p-Tau immunoreactivity in the form of NFT and NT in sgACC, with 
low levels of NT observed in the spACC, whereas MCC and PCC showing the absence of p-
Tau pathology. DLB cases without depression had highest p-tau levels in sgACC, moderate 
levels of pathology in spACC and MCC, whereas low levels in PCC. The highest p-Tau burden 
in DLB cases with depression was observed in MCC and PCC (Figure 3.5). Tau pathological 
burden was significantly different in sgACC (H(2)=7.899, p=0.019), spACC (H(2)=15.414, 
p<0.001), MCC (H(2)=13.837, p=0.001) and PCC (H(2)=6.849, p=0.033) between the groups. 
DLB cases with depression showed significantly higher p-Tau burden in spACC (p=0.001), 
MCC (p=0.001) and PCC (p=0.027) compared to controls, however DLB cases without 
depression showed significant changes only in sgACC (p=0.028) and spACC (p=0.005) 
compared to controls (Figure 3.6 A). Within group paired analysis showed higher tau burden 
in sgACC compared to the MCC (p=0.045) and PCC (p=0.008) in controls, as well as in sgACC 
compared to PCC in DLB cases with depression (p=0.027), but no regional differences in tau 




Figure 3.2 α-synuclein (KM51) pathology in cingulate subregions. 
Photomicrographs of α-synuclein (KM51) pathology in sgACC (BA25), spACC (BA24), MCC 
(BA24’) and PCC (BA23) in controls, DLB cases without (DLB-D) and DLB cases with 





















Figure 3.3 α-synuclein (5G4) pathology in cingulate subregions. 
Photomicrographs of α-synuclein (5G4) pathology in sgACC (BA25), spACC (BA24), MCC 
(BA24’) and PCC (BA23) in controls, DLB cases without (DLB-D) and DLB cases with 




















Figure 3.4 Densitometric analysis of α-synuclein pathological burden within cingulate 
subregions. 
α-synuclein (A) KM51 and (B) 5G4 pathology (% area stained) was assessed within sgACC, 
spACC, MCC and PCC between DLB cases with and without depression and controls; (*** 
p<0.001, compared to control group). 

























































Figure 3.5 Tau (AT8) pathology in cingulate subregions. 
Photomicrographs of tau (AT8) pathology in sgACC (BA25), spACC (BA24), MCC (BA24’) 
and PCC (BA23) in controls, DLB cases without (DLB-D) and DLB cases with depression 































Figure 3.6 Densitometric analysis of tau and Aβ pathological burden within cingulate 
subregions. 
(A) Tau (AT8) and (B) Aβ (4G8) pathology (% area stained) was assessed within sgACC, 
spACC, MCC and PCC between DLB cases with and without depression and controls; 
(*p<0.05, **p<0.01 and *** p<0.001, compared to control group). 
 
 
















































Figure 3.7 Aβ (4G8) pathology in cingulate subregions. 
Photomicrographs of Aβ (4G8) pathology in sgACC (BA25), spACC (BA24), MCC (BA24’) 
and PCC (BA23) in controls, DLB cases without (DLB-D) and DLB cases with depression 
(DLB+D); magnification X10; scale bars represent 100μm. 
All groups showed Aβ immunoreactivity in all cingulate subregions. The highest Aβ 
pathological burden in DLB cases was observed in spACC and PCC (Figure 3.7). Aβ burden 
was significantly different between the groups in spACC (H(2)=9.203, p=0.010), and PCC 
(H(2)=12.803, p=0.002). A significant increase in Aβ pathology was found in DLB cases 
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without depression compared to controls in spACC (p=0.012) and PCC (p=0.009). 
Significantly elevated Aβ burden was observed in PCC in DLB cases with depression 
compared to controls (p=0.005) (Figure 3.6 B). Paired analysis showed higher Aβ burden in 
spACC compared to the MCC in DLB cases without depression (p=0.023), but no regional 
differences in Aβ distribution in DLB cases with depression or controls. No significant 
difference in α-synuclein, tau or Aβ burden was observed between DLB cases with and without 
depression in any cingulate subregions analysed. 
3.3.2 Pathological changes in sgACC in relation to depression in 
DLB 
3.3.2.1 Immunohistochemical changes 
Using immunohistochemical analysis, pathological changes within main cortical input and 
output laminae (layers II, III and V) were assessed in sgACC. In DLB cases KM51 α-synuclein 
pathology was present in all laminae, with moderate LN pathology observed in layers II and 
III, and sparse in layer V.  LB in layer III were less frequently observed and were smaller in 
size compared to layer V LB. Severe LN pathology was observed in all layers using 5G4 α-
synuclein, with medium/large LB in layers III and V. Non-parametric Kruskal-Wallis analysis 
was used to assess overall and layer specific pathological changes between the groups in 
sgACC. Both KM51 and 5G4 α-synuclein pathological burden was significantly different 
between the groups, with higher α-synuclein immunoreactivity observed in DLB cases with 
and without depression compared to controls (p<0.001) in all cortical layers within sgACC, but 
no differences were seen between depressed and non-depressed DLB cases (Figure 3.8 A-B).  
While NFT were primarily observed only in layer V, moderate NT distribution was seen in all 
the layers. Tau pathology in sgACC was significantly different between the groups overall 
(H(2)=9.936, p=0.007), layer II (H(2)=9.106, p=0.011), layer III (H(2)=10.130, p=0.006) and 
layer V (H(2)=8.798, p=0.012), with higher tau immunoreactivity observed in DLB cases 
without depression compared to controls overall (p=0.008), layer II (p=0.017), layer III 
(p=0.005) and layer V (p=0.011) (Figure 3.8 C). Aβ plaques were present in all three layers, 
with similar topographical distribution across all laminae. No significant difference in overall 
or layer specific Aβ pathology burden was observed between disease subgroups in sgACC 
(Figure 3.8 D).   
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Figure 3.8 Densitometric analysis of pathology within sgACC. 
Overall and layer specific pathological changes of  α-synuclein (A) KM51 and (B) 5G4, (C) p-Tau (AT8) and (D) Aβ (4G8) (% area stained) were 
assessed within sgACC between DLB cases with (DLB+D) and without (DLB-D) depression and controls; (*p<0.05, **p<0.01 and ***p<0.001, 
compared to control).




























































































The neuronal specific marker (HuD) raised against amino acids 1-300 of human HuD (Szabo 
et al., 1991) was used to assess neuronal cell density within sgACC between the groups. There 
was no significant difference observed in neuronal density overall (F(2, 48)=0.393, p=0.677), 
as well as layers II/III (F(2, 48)=0.018, p=0.982) and layer V (F(2, 48)=1.183, p=0.315) of the 
sgACC between the groups (Figure 3.9). 
Figure 3.9 Neuronal cell density in the sgACC. 
Overall, layer II/III and layer V cell numbers (cells per mm2) within sgACC were assessed in 
DLB cases with and without depression, as well as controls. Tissue sections were stained with 
HuD (neuronal specific marker) and analysed using adapted stereological method. The 
micrograph above was taken at 20X magnification. The scale bar represents 100μm. 

















3.3.2.2 Biochemical changes 
As pathological changes demonstrated using immunohistochemical approaches shows 
structural pathology, biochemical analysis of pathological proteins was used to determine 
differences, and if these could be correlated with clinical findings. These biochemical changes 
might include partitioning of proteins within specific subcellular compartments, such as 
synapses, reductions in the level of endogenous or normal protein species representing loss of 
normal function, or different pathological species such as oligomeric or fibrillar forms 
(Culvenor et al., 1999, Li et al., 2014a, Espindola et al., 2018). The sgACC was chosen as the 
region of interest owing to its role in depression and the high pathology burden in LBD, 
particularly DLB. Several α-synuclein (Figure 3.10), tau and Aβ antibodies were used to assess 
protein levels in the sgACC using fractionated tissue. 
The biochemical analysis of α-synuclein pathological burden in sgACC generally supports the 
immunohistochemical data, which shows no significant difference in α-synuclein levels in 
sgACC between DLB cases with and without depression. Biochemical total (α-β) synuclein 
burden was determined using an antibody mapped to amino acids 1-70 of α-synuclein (Li et 
al., 2019). Significant differences between the groups were observed in the crude sample 
(H(2)=17.780, p<0.001), supernatant (H(2)=10.925, p=0.004), 0.1% Tween pellet 
(H(2)=20.820, p<0.001), 0.1% Tween supernatant (H(2)=23.227, p<0.001), 2% SDS pellet 
(H(2)=19.117, p<0.001) and 2% SDS supernatant fraction (H(2)=21.520, p<0.001). DLB cases 
with and without depression showed significantly higher total α-synuclein burden compared to 
controls in crude, 0.1% Tween pellet, 2 % SDS pellet and supernatant (p<0.001). DLB cases 
with depression also showed higher total α-synuclein immunoreactivity compared to controls 
in supernatant (p=0.003) and 0.1% Tween supernatant (p<0.001), whereas DLB cases without 
depression had higher total α-synuclein burden compared to controls in 0.1% Tween 
supernatant fraction of tissue homogenate (p=0.002; Figure 3.11). 
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Figure 3.10 α-synuclein structure and antibody reagent mapping. 
Several α-synuclein antibodies were used to detect pathological changes within the sgACC. Each antibody recognises specific amino acid (aa) 
sequence of the α-synuclein protein: fibrillar (120-126 aa), α-β synuclein (1-70 aa), s129 α-synuclein (129 aa), KM51 α-synuclein (full length 
protein– epitope not mapped), BD α-synuclein (15-100 aa) and 5G4 α-synuclein (45-58 aa). 
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Figure 3.11 Total α-synuclein protein levels in tissue fractions of sgACC. 
Dot blotting was used to assess changes in total α-synuclein protein levels in sgACC within 
different tissue fractions of DLB cases with (DLB+D) and without (DLB-D) depression and 
controls: crude, supernatant (cytoplasmic soluble proteins), 0.1% Tween pellet (soluble 
membrane bound proteins), 0.1% Tween supernatant (Tween soluble membrane proteins), 2% 
SDS pellet (insoluble membrane bound proteins), 2% SDS supernatant (SDS soluble 
membrane proteins) and 6M Urea supernatant (highly insoluble proteins). (**p<0.01 and *** 
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Using the fibrillar α-synuclein antibody, which recognises a conformational epitope within the 
120-126 amino acid (aa) sequence of α-synuclein protein (Lassen et al., 2018), demonstrated
significantly different changes between the groups in the crude tissue sample (H(2)=7.265,
p=0.026), supernatant (H(2)=9.015, p=0.011), 0.1% Tween supernatant (H(2)=17.350,
p<0.001) and 6M Urea fraction of tissue homogenates (H(2)=8.437, p=0.015). Significantly
higher fibrillar α-synuclein reactivity was found in DLB cases with depression compared to
controls in the crude (p=0.041), supernatant (p=0.010), 0.1% Tween supernatant (p<0.001) and
6M urea (p=0.013) fraction (Figure 3.12).
Analysis of tissue fractions using an antibody against α-synuclein phosphorylated at residue 
serine 129 (s129) (Delic et al., 2018) showed significantly altered levels between the groups in 
the crude sample (H(2)=16.826, p<0.001), supernatant (H(2)=7.115, p=0.029), 0.1% Tween 
pellet (H(2)=11.988, p=0.002), 0.1% Tween supernatant (H(2)=16.122, p<0.001), 2% SDS 
pellet (H(2)=6.504, p=0.039), 2% SDS supernatant (H(2)=9.159, p=0.028) and urea fraction of 
tissue homogenates (H(2)=20.523, p<0.001). DLB cases with depression showed significantly 
higher s129 α-synuclein burden compared to controls in crude (p=0.001), supernatant 
(p=0.029), 0.1% Tween pellet (p=0.003), 0.1% Tween supernatant (p<0.001), 2 % SDS 
supernatant (p=0.020) and urea (p=0.001). DLB cases without depression showed higher s129 
α-synuclein immunoreactivity compared to controls in the crude (p=0.002), 0.1% Tween pellet 
(p=0.045), 2% SDS pellet (p=0.010) and 2% SDS supernatant (p=0.035) and 6M Urea tissue 
fraction (p<0.001). There was no significant difference between DLB cases with or without 
depression in s129 immunoreactivity (see Figure 3.13). 
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Figure 3.12 Fibrillar α-synuclein protein levels in tissue fractions of sgACC. 
Dot blotting was used to assess changes in fibrillar α-synuclein protein levels in sgACC within 
different tissue fractions of DLB cases with (DLB+D) and without (DLB-D) depression and 
controls: crude, supernatant (cytoplasmic soluble proteins), 0.1% Tween pellet (soluble 
membrane bound proteins), 0.1% Tween supernatant (Tween soluble membrane proteins), 2% 
SDS pellet (insoluble membrane bound proteins), 2% SDS supernatant (SDS soluble 
membrane proteins) and 6M Urea supernatant (highly insoluble proteins). (*p<0.05, **p<0.01 
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Figure 3.13 s129 α-synuclein protein levels in tissue fractions of sgACC. 
Dot blotting was used to assess changes in protein levels of α-synuclein phosphorylated at 
position serine 129 in sgACC within different tissue fractions of DLB cases with (DLB+D) 
and without (DLB-D) depression and controls: crude, supernatant (cytoplasmic soluble 
proteins), 0.1% Tween pellet (soluble membrane bound proteins), 0.1% Tween supernatant 
(Tween soluble membrane proteins), 2% SDS pellet (insoluble membrane bound proteins), 2% 
SDS supernatant (SDS soluble membrane proteins) and 6M Urea supernatant (highly insoluble 
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Two antibodies used in immunohistochemical analysis, KM51 and 5G4, were also used to 
probe tissue fractions. A significant difference in KM51 (raised against full length recombinant 
α-synuclein – epitope not mapped) immunoreactivity was observed between the groups in 2% 
SDS pellet (H(2)=16.290, p<0.001) and 2% SDS supernatant (H(2)=19.668, p<0.001) fractions 
of tissue homogenate. Control cases showed significantly higher KM51 α-synuclein burden 
compared to DLB cases with depression in the 2% SDS pellet (p=0.001) and supernatant 
(p<0.001), as well as compared to DLB cases without depression in 2% SDS pellet (p=0.002) 
and supernatant (p=0.021; Figure 3.14). No changes in KM51 reactivity were seen between 
DLB cases with and without depression. A significantly higher 5G4 (mapping to amino acids 
45-58) (Kovacs et al., 2012) α-synuclein immunoreactivity between the groups was only
observed in the 0.1% Tween supernatant (H(2)=6.132, p=0.047) fraction of tissue
homogenates, with higher a 5G4 burden in DLB cases without depression compared to controls
trending on significance (p=0.054; Figure 3.15).
No significant difference was observed using the BD α-synuclein (raised against amino acids 
15-99 of α-synuclein and mapping to amino acids 15-100 (Lassen et al., 2018) in any of the
tissue fractions from control or DLB (Figure 3.16).
Data generated from ELISA determination of total and fibrillar α-synuclein analysis in total 
and fractionated samples showed similar, but non-significant changes, to dot blot approaches 
(data not shown in this thesis). 
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Figure 3.14 α-synuclein (KM51) protein levels in tissue fractions of sgACC. 
Dot blotting was used to assess changes in KM51 α-synuclein immunoreactive protein levels 
in sgACC within different tissue fractions of DLB cases with (DLB+D) and without (DLB-D) 
depression and controls: crude, supernatant (cytoplasmic soluble proteins), 0.1% Tween pellet 
(soluble membrane bound proteins), 0.1% Tween supernatant (Tween soluble membrane 
proteins), 2% SDS pellet (insoluble membrane bound proteins) and 2% SDS supernatant (SDS 
soluble membrane proteins). (Significance levels set at *p<0.01, **p<0.01 and *** p<0.001, 
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Figure 3.15 α-synuclein (5G4) protein levels in tissue fractions of sgACC. 
Dot blotting was used to assess changes in α-synuclein (5G4) immunoreactive protein levels 
in sgACC within different tissue fractions of DLB cases with (DLB+D) and without (DLB-D) 
depression and controls: crude, supernatant (cytoplasmic soluble proteins), 0.1% Tween 
supernatant (Tween soluble membrane proteins) and 2% SDS supernatant (SDS soluble 
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Figure 3.16 α-synuclein (BD) protein levels in tissue fractions of sgACC. 
Dot blotting was used to assess changes in α-synuclein protein levels in sgACC using an 
antibody raised against amino acids 15-123 of α-synuclein (BD Biosciences) within different 
tissue fractions of DLB cases with (DLB+D) and without (DLB-D) depression and controls: 
crude, supernatant (cytoplasmic soluble proteins), 0.1% Tween pellet (soluble membrane 
bound proteins), 0.1% Tween supernatant (Tween soluble membrane proteins), 2% SDS pellet 
(insoluble membrane bound proteins) and 2% SDS supernatant (SDS soluble membrane 
proteins).  
The microtubule (MT) associated protein tau regulates the axonal transport of proteins, vesicles 
and organelles and is the principal component of neurofibrillary tangles in AD and related 
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gives rise to tau isoforms with three (3R) or four (4R) MT-binding repeats (Goedert et al., 
1989). These isoforms are expressed at similar levels within the brain (Goedert and Jakes, 
1990). The 3R/4R isoform imbalance is thought to play a role in axonal transport impairment 
and neuronal dysfunction in many neurodegenerative disorders. In AD, both isoforms are 
present in the Tau fibrils (Goedert et al., 1992), whereas in PSP only 4R Tau is present (Flament 
et al., 1991). Therefore, p-Tau, 3R, 4R expression and 3R/4R ratios were assessed in soluble 
and insoluble fractions of sgACC samples in relation to depression in DLB.  
The AT8 antibody is routinely used to demonstrate NFT pathology in tissue sections and 
recognises a phosphorylated epitope in Tau at amino acids 202–205 (Goedert et al., 1995). A 
significantly higher AT8 p-Tau pathological burden was observed in the supernatant 
(H(2)=6.892, p=0.032), 0.1% Tween supernatant (H(2)=9.701, p=0.008) and in the 2% SDS 
pellet fraction (H(2)=7.049, p=0.029) between the groups. DLB cases with depression showed 
significantly higher AT8 p-Tau burden compared to controls in supernatant (p=0.037) and 
0.1% Tween supernatant (p=0.046), whereas  DLB cases without depression showed higher p-
Tau immunoreactivity compared to controls in 0.1% Tween supernatant (p=0.010) and the 2% 
SDS pellet (p=0.044; Figure 3.17). 
Antibodies to the repeat domains of Tau are available, with amonoclonal antibody against the 
3R region of Tau used to demonstrate immunoreactivity in tissue fractions (de Silva et al., 
2003). A significantly higher 3R Tau pathological burden was observed in the crude 
(H(2)=6.695, p=0.035) and 2% SDS supernatant fraction (H(2)=7.101, p=0.029) between the 
groups. Control cases shower significantly higher 3R Tau burden compared to DLB cases with 
depression in crude (p=0.033) and 2% SDS supernatant fractions (p=0.024; Figure 3.18). 
Using a specific 4R Tau antibody (de Silva et al., 2003), a significantly higher 4R p-Tau 
pathological burden was observed in the 2% SDS pellet (H(2)=11.866, p=0.003) and 2% SDS 
supernatant (H(2)=9.747, p=0.008) between the groups. Control cases shower significantly 
higher 4R p-Tau immunoreactivity compared to DLB cases with depression in 2% SDS pellet 
(p=0.005) and 2% SDS supernatant (p=0.038), as well as compared to DLB cases without 
depression in 2% SDS pellet (p=0.017) and 2% SDS supernatant (p=0.013; Figure 3.19). 
A significantly higher 3R/4R p-Tau ratio was observed in the 2% SDS pellet (H(2)=9.869, 
p=0.007) and 6M Urea fraction (H(2)=9.165, p=0.010) between the groups. DLB cases with 
depression had significantly higher 3R/4R p-Tau ratio compared to controls in 2% SDS pellet 
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(p=0.005) and 6M Urea fractions (p=0.025), whereas DLB cases without depression showed 
higher 3R/4R p-Tau ratio in 6M Urea (p=0.032; Figure 3.20). 
Figure 3.17 AT8 p-Tau protein levels in tissue fractions of sgACC. 
Dot blotting was used to assess changes in AT8 p-Tau protein levels in sgACC within different 
tissue fractions of DLB cases with (DLB+D) and without (DLB-D) depression and controls: 
crude, supernatant (cytoplasmic soluble proteins), 0.1% Tween pellet (soluble membrane 
bound proteins), 0.1% Tween supernatant (Tween soluble membrane proteins), 2% SDS pellet 
(insoluble membrane bound proteins), 2% SDS supernatant (SDS soluble membrane proteins) 
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Figure 3.18 3R p-Tau protein levels in tissue fractions of sgACC. 
Dot blotting was used to assess changes in 3R p-Tau protein levels in sgACC within different 
tissue fractions of DLB cases with (DLB+D) and without (DLB-D) depression and controls: 
crude, supernatant (cytoplasmic soluble proteins), 0.1% Tween pellet (soluble membrane 
bound proteins), 0.1% Tween supernatant (Tween soluble membrane proteins), 2% SDS pellet 
(insoluble membrane bound proteins), 2% SDS supernatant (SDS soluble membrane proteins) 
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Figure 3.19 4R p-Tau protein levels in tissue fractions of sgACC. 
Dot blotting was used to assess changes in 4R p-Tau protein levels in sgACC within different 
tissue fractions of DLB cases with (DLB+D) and without (DLB-D) depression and controls: 
crude, supernatant (cytoplasmic soluble proteins), 0.1% Tween pellet (soluble membrane 
bound proteins), 0.1% Tween supernatant (Tween soluble membrane proteins), 2% SDS pellet 
(insoluble membrane bound proteins), 2% SDS supernatant (SDS soluble membrane proteins) 
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Figure 3.20 3R/4R p-Tau ratios in tissue fractions of sgACC. 
Dot blotting was used to assess changes in 3R/4R p-Tau ratio in sgACC within different tissue 
fractions of DLB cases with (DLB+D) and without (DLB-D) depression and controls: crude, 
supernatant (cytoplasmic soluble proteins), 0.1% Tween pellet (soluble membrane bound 
proteins), 0.1% Tween supernatant (Tween soluble membrane proteins), 2% SDS pellet 
(insoluble membrane bound proteins), 2% SDS supernatant (SDS soluble membrane proteins) 
and 6M Urea supernatant (highly insoluble aggregated proteins). (*p<0.05 and **p<0.01, 
compared to control). 
The Aβ peptide is the major component of senile plaques in AD and related disorders and 
represents a core feature of AD pathology. A significantly higher level of Aβ immunoreactivity 
was observed in the 2% SDS supernatant fraction between the groups (H(2)=8.488, p=0.014), 
with significantly higher Aβ levels in DLB cases with depression compared to controls 
(p=0.010; Figure 3.21). 
Using an epitope specific Aβ antibody, a significantly higher Aβ (1-40) level was observed in 
2% SDS pellet (H(2)=12.565, p=0.002) and 2% SDS supernatant between the groups 
(H(2)=6.173, p=0.046), with significantly higher Aβ (1-40) levels in the 2% SDS pellet found 
in controls compared to DLB cases with depression (p=0.006) and without depression 
















































in DLB cases with depression compared to controls (p=0.041; Figure 3.22). Material from the 
Urea fractions was not available for analysis. 
Figure 3.21 Aβ peptide levels in tissue fractions of sgACC. 
Dot blotting was used to assess changes in Aβ peptide levels in sgACC within different tissue 
fractions of DLB cases with (DLB+D) and without (DLB-D) depression and controls: crude, 
supernatant (cytoplasmic soluble proteins), 0.1% Tween pellet (soluble membrane bound 
proteins), 0.1% Tween supernatant (Tween soluble membrane proteins), 2% SDS pellet 
(insoluble membrane bound proteins), 2% SDS supernatant (SDS soluble membrane proteins) 
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Figure 3.22 Aβ(1-40) peptide levels in tissue fractions of sgACC. 
Dot blotting was used to assess changes in Aβ (1-40) peptide levels in sgACC within different 
tissue fractions of DLB cases with (DLB+D) and without (DLB-D) depression and controls: 
crude, supernatant (cytoplasmic soluble proteins), 0.1% Tween pellet (soluble membrane 
bound proteins), 0.1% Tween supernatant (Tween soluble membrane proteins), 2% SDS pellet 
(insoluble membrane bound proteins), 2% SDS supernatant (SDS soluble membrane proteins). 
(*p<0.05 and **p<0.01). 
A significantly higher Aβ (1-42) pathological burden was observed in 0.1% Tween supernatant 
(H(2)=12.375, p=0.002) and 2% SDS pellet (H(2)=11.210, p=0.004) between the groups. In 
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(p=0.006) and DLB cases with depression (p=0.007) compared to DLB cases without 
depression. Control cases had significantly higher Aβ (1-42) burden in 2% SDS pellet fraction 
compared to DLB cases with depression (p=0.007; Figure 3.23). Urea fractions were not 
available for Aβ (1-42) analysis. 
Figure 3.23 Aβ(1-42) peptide levels in tissue fractions of sgACC. 
Dot blotting was used to assess changes in Aβ (1-42) protein levels in sgACC within different 
tissue fractions of DLB cases with (DLB+D) and without (DLB-D) depression and controls: 
crude, supernatant (cytoplasmic soluble proteins), 0.1% Tween pellet (soluble membrane 
bound proteins), 0.1% Tween supernatant (Tween soluble membrane proteins), 2% SDS pellet 
(insoluble membrane bound proteins), 2% SDS supernatant (SDS soluble membrane proteins). 
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A significantly higher Aβ 1-40/1-42 ratio was observed in the 2% SDS supernatant between 
the groups (H(2)=19.352, p<0.001). DLB cases with depression had significantly higher Aβ 1-
40/1-42 ratio in 2% SDS supernatant compared to controls (p<0.001) and DLB cases without 
depression (p=0.013), whereas DLB cases without depression showed higher Aβ 1-40/1-42 
ratio compared to controls (p=0.004; Figure 3.24). 
Figure 3.24 Aβ 1-40/1-42 ratio in tissue fractions of sgACC. 
Dot blotting was used to assess changes in Aβ 1-40/1-42 ratio in sgACC within different tissue 
fractions of DLB cases with (DLB+D) and without (DLB-D) depression and controls: crude, 
supernatant (cytoplasmic soluble proteins), 0.1% Tween pellet (soluble membrane bound 
proteins), 0.1% Tween supernatant (Tween soluble membrane proteins), 2% SDS pellet 
(insoluble membrane bound proteins), 2% SDS supernatant (SDS soluble membrane proteins). 


















































Depression is a common psychiatric symptom in DLB, associated with faster cognitive decline 
and a poor clinical outcome. The association between depression and dementia, which is not 
mutually exclusive, needs further clarification. It is not clear whether depression and dementia 
are manifestations of the same underlying neuropathology, if depression is a consequence of 
dementia, or if there is an independent association between these two conditions. The present 
study assessed pathological changes within four main functional divisions of the cingulate 
cortex to understand its role in depression in DLB, with a focus on the sgACC given its role in 
depression. DLB cases without depression were included in this study in order to separate those 
pathological changes, which are specifically due to depression, from those that are ‘disease’ 
related. This is the first post-mortem study to assess neurodegenerative pathology in cingulate 
subregions using a large cohort. 
The present findings indicate that neurodegenerative pathology in the cingulate cortex does not 
directly relate to depression in DLB. Studies examining neuropathological changes in relation 
to depression in patients without dementia or in AD are scarce, often presenting contradictory 
results. In line with the present findings, one study found no association between depressive 
symptoms in DLB or AD and severity of cortical or subcortical LB pathology (Samuels et al., 
2004). Similarly, a large scale longitudinal study demonstrated an association between 
depressive symptoms and cognitive decline, but this was independent of any neuropathological 
hallmarks of dementia such as Aβ plaques, NFT and LB (Wilson et al 2014). Previous studies 
have suggested the involvement of neurodegeneration in the pathogenesis of MDD (Burgut et 
al., 2006). The presence of LB in amygdala has been shown to be associated with psychiatric 
morbidity and increased risk for MDD in AD (Lopez et al., 2006). Higher levels of NP and 
NFT were found in the hippocampus in AD patients with depression compared to non-
depressed AD patients (Rapp et al., 2006), as well as a positive correlation between depressive 
states and NP density in AD (Meynen et al., 2010). Later life MDD is frequently associated 
with cognitive impairment and has been linked to AD pathological changes (Sweet et al 2004), 
suggesting interactions between MDD and AD lesions (Rapp et al 2006). The current results 
do not however support these findings in DLB for the cingulate, and it is possible that the 
substrates of depression in DLB are independent of pathology, with neuropathology being an 
initiator of this cascade, which once activated is self-sustaining and relatively independent of 
amyloid and tau pathology. 
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Several studies have shown that the cingulate cortex is severely affected by α-synuclein 
pathology compared to other cortical regions in DLB (Colom-Cadena et al., 2013). The present 
findings show that the pathological burden of α-synuclein is most severe in ACC compared to 
MCC and PCC in DLB cases, although despite the considerable pathological burden, no major 
changes in neuronal density were observed in ACC. While some studies have observed cortical 
thinning and grey matter atrophy of the ACC in DLB based on MRI (Blanc et al., 2016, Blanc 
et al., 2015), other studies have shown no marked reduction in grey matter volume in ACC in 
DLB (Patterson et al., 2019, Harper et al., 2017). This may suggest that higher pathological 
burden may not necessarily result in neuronal loss, but rather dysfunction. The current results 
support this, showing an absence of significant neuronal loss despite considerable pathological 
changes. Furthermore, imaging studies show reduced functional activity in the ACC based on 
PET, SPECT and fMRI in depression (Fu et al., 2018, Ongur et al., 2003). Reduced metabolic 
activity in the ACC has also been observed in DLB patients compared to MCC and PCC, which 
is thought to relate to higher α-synuclein burden in ACC (Patterson et al., 2019). While that 
study found no direct relationship between α-synuclein pathology and reduced perfusion in the 
ACC, this may indicate that there is a threshold effect, once certain levels of pathology are 
reached, metabolism begins to decline, and metabolic imaging changes can be observed. 
Occipital hypometabolism is also a common feature in DLB (Ishii et al., 1998, Colloby et al., 
2002). This region does not show significant atrophy (Burton et al., 2004), and typically, does 
not show major pathological changes (Khundakar et al., 2016), which may suggest that factors 
other than pathological burden, cell loss or atrophy play a role in the reduced metabolism in 
specific brain structures. More direct markers of metabolism that are downstream 
consequences of pathological change will be required to observe these metabolic changes and 
allow the relationships between pathology and metabolism to be explored. Metabolic changes 
in the cingulate cortex may therefore better reflect the presence or absence of depression. 
Similarly, given that there is an extensive literature indicating neurochemical changes 
associated with depression (see section 1.4.3-1.4.4), direct determination of neurochemical 
changes such as monoaminergic, glutamatergic, or GABAergic markers in the cingulate may 
be more relevant indicators of depression.  
The biochemical analysis of pathology within the sgACC largely reiterate the 
immunohistochemical results, showing no association between pathology in sgACC and 
depression in DLB. In sgACC the highest level of α-synuclein was detected in insoluble 
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membrane bound fractions, which may suggest that the majority of α-synuclein in DLB is 
sequestered in insoluble pathological aggregates. Similar observations were made regarding 
tau pathology in sgACC, with no differences observed in tau expression between DLB with 
and without depression. Higher 3R/4R ratios were observed in DLB cases compared to 
controls. Tau can be expressed with three repeat domains (3R) or four (4R), which arise from 
alternative splicing of MAPT exon 10. The abnormal increase in 4R tau expression is observed 
in many tauopathies, such as FTD, PSP and AD, with 4R tau present in NFT and NT (de Silva 
et al., 2003, Arai et al., 2001). The increases in the 4R to 3R ratio have been described in many 
neurodegenerative disorders, including FTD, PSP and AD (Ginsberg et al., 2006, Ingelsson et 
al., 2007). The higher 3R/4R ratios in DLB may indicate dysfunction in axonal transport, which 
may contribute to neuronal dysfunction in sgACC. The altered 3R/4R ratio may also represent 
the shift in tau expression associated with tau related neurodegeneration in AD considering that 
many DLB cases have a considerable burden of tau related neuropathology (Ginsberg et al., 
2006, Ingelsson et al., 2007). 
In AD, a reduced CSF level of Aβ42 is thought to be associated with the deposition of Aβ42 
in senile plaques, with studies showing a strong correlation between low CSF Aβ42 and high 
density of plaques in the neocortex and hippocampus (Strozyk et al., 2003). This is also 
demonstrated by a high retention of PIB that reflects plaque pathology in the brain (Forsberg 
et al., 2008). Some studies have also suggested that the ratio of Aβ42/Aβ40 may be more 
important to the neurobiology of AD than the absolute level of Aβ42 (Kumar-Singh et al., 
2006, Bentahir et al., 2006). In this study, higher Aβ40 and lower Aβ42 levels were observed 
in the SDS soluble fraction of sgACC in DLB cases with depression compared to controls, as 
well as higher Aβ40/Aβ42 ratio in DLB cases with depression compared to controls and also 
DLB cases without depression. Many studies have examined plasma levels of Aβ in AD with 
mixed results (Irizarry, 2004), although decreased CSF Aβ42 levels were observed in DLB 
patients (Kanemaru et al., 2000, Tschampa et al., 2001), with higher Aβ40/Aβ42 ratios in DLB 
patients compared to AD (Lewczuk et al., 2015). Some studies have reported lower plasma 
concentrations of Aβ42 in depression in the elderly, leading to a higher Aβ40/Aβ42 ratio (Sun 
et al., 2008), whereas others have found higher Aβ42 plasma concentrations in late onset 
depression (Blasko et al., 2010, Moon et al., 2011). Other studies have also shown higher 
plasma Aβ40, but not higher Aβ42 nor Aβ40/Aβ42 ratio in depressed patients with MCI, which 
was associated with parahippocampal atrophy and poor cognitive prognosis (Yamazaki et al., 
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2017). Aβ levels appear therefore, to be variably changed depending on both disease state and 
sampling region. 
In conclusion, these results demonstrate that neurodegenerative neuropathological changes 
within the cingulate cortex do not appear to influence appreciably the development of 
depression in DLB. While the ACC is a predilection site for the development of α-synuclein 
pathology, pathological changes including neuronal loss do not directly associate with 
depression. The underlying biochemistry of LB, NFT, and Aβ pathology also do not associate 
with depression. These findings do however suggest that, since there are metabolic changes 
associated with depression and neurodegeneration in the cingulate cortex (Drevets et al., 2008a, 
Drevets et al., 2008b, Rodriguez-Cano et al., 2014), that study of metabolic changes or 
neurochemical imbalance in the cingulate gyrus may be more relevant in relation to depression 
in DLB. 
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 Chapter 4. 
GABAergic and glutatergic 
changes in the sgACC 
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4.1 Introduction 
The monoamine hypothesis is well established and has dominated the field of research into 
depression for some time, although increasing attention has been placed on other potential 
changes. Neurobiological abnormalities responsible for depression, such as dysregulation of 
the HPA axis, neurotrophins and multiple neurotransmitter systems may suggest that 
depression is not a single entity, with a variable underlying cause. This may explain why no 
single treatment approach, such as enhancement of monoaminergic transmission, would be 
effective in all patients. With recent advances in the development of fast-acting antidepressants 
that can overcome current therapeutic limitations of monoaminergic drugs, there is a clear 
indication that other neurochemical mechanisms are significant in MDD, and increasing 
interest has been placed on the development of more selective glutamatergic and GABAergic 
agonists, antagonists and modulators, which appear to be effective. 
A growing body of evidence supports an impairment of glutamatergic and GABAergic 
neurotransmission in the pathophysiology of depression (Sanacora et al., 2012, Lener et al., 
2017, Cryan and Kaupmann, 2005). The majority of cortical neurones and synapses use 
glutamate as a neurotransmitter, therefore it has been suggested that the glutamatergic system 
is a primary mediator of depression, and may represent a common pathway for the therapeutic 
action of antidepressant drugs (Sanacora et al., 2012). Evidence from clinical studies 
demonstrates abnormal glutamatergic transmission in limbic and cortical areas involved in 
emotional processing in depressed individuals (Zanos et al., 2016, Downey et al., 2016). 
Abnormal glutamatergic signalling has also been observed in post mortem and MRI studies in 
patients with MDD, contributing to cytoarchitectural and volumetric changes (Konarski et al., 
2008, Lorenzetti et al., 2009, Koolschijn et al., 2009). Enhanced glutamate release, altered 
synaptic transmission, structural and morphological changes in limbic brain regions have also 
been observed in animal models of stress (Gorman and Docherty, 2010, Pittenger and Duman, 
2008, Musazzi et al., 2011). Glutamatergic abnormalities have additionally been identified in 
plasma (Mitani et al., 2006, Bocchio-Chiavetto et al., 2010), and CSF in MDD, indicating 
widespread glutamatergic changes (Levine et al., 2000, Frye et al., 2007).  
Functional and structural alterations of GABAergic circuits have been shown to contribute to 
the pathophysiology of anxiety and MDD (Marin, 2012, Brambilla et al., 2003). Reduced 
GABA levels in ACC in patients with MDD have been observed using PET imaging (Gabbay 
et al., 2012, Godfrey et al., 2018). A downregulation of several GABA related genes in sgACC 
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has also been reported in patients with MDD, demonstrating altered GABAergic circuitry in 
key regions associated with depression (Tripp et al., 2011). Reduced GABA levels have also 
been shown in plasma (Petty and Sherman, 1984) and the CSF (Gerner and Hare, 1981, Gold 
et al., 1980) in patients with depression. There is therefore significant evidence implicating 
GABAergic changes in MDD. 
Disrupted balance in excitatory and inhibitory (E/I) neurotransmission is thought to contribute 
greatly to the development of mood disorders (Gabbay et al., 2012), possibly through impaired 
synaptic function (Zhao et al., 2012, Feyissa et al., 2009). Abnormalities of glutamatergic and 
GABAergic neurotransmission in the sgACC in MDD are well established (Tripp et al., 2012, 
Tripp et al., 2011, Ongur et al., 1998), but how these changes relate to depression in DLB is 
unknown.  
4.2 Aims 
The aim of this study was to investigate changes in glutamatergic and GABAergic 
neurotransmission in the sgACC in relation to depression in DLB. 
4.2.1 Objectives 
 To assess glutamatergic and GABAergic cell numbers in sgACC using an adapted
stereological method in post-mortem tissue from DLB cases with and without
depression and in normal controls.
 To assess whether the presence of aggregated phosphorylated α-synuclein (s129)
induces changes in glutamatergic and/or GABAergic synapses in the sgACC in relation
to depression in DLB using confocal analysis.
 To quantify protein levels of pre- and postsynaptic markers associated with
glutamatergic and GABAergic synaptic function and neurotransmission in the sgACC
using frozen post mortem tissue samples from DLB cases with and without depression
and in normal controls.
 To assess mitochondrial changes in sgACC in DLB cases with and without depression
and normal controls using frozen post mortem tissue.
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4.3 Methods 
The cohort for confocal and stereological analysis consisted of 17 DLB cases with depression, 
20 DLB cases without depression and 17 neurologically and psychiatrically normal controls 
(see section 3.3; Table 3.1). The cohort for protein analysis consisted of 12 DLB cases with 
depression, 12 DLB cases without depression and 12 normal controls (see section 3.3; Table 
3.3). 
Fixed tissue sections corresponding to the sgACC were stained with GABA (GAD67) and 
pyramidal (CRYM) cell markers for assessment of cell density and analysed using an adapted 
stereological method (see section 2.1.7.2). Quadruple immunofluorescence was used to stain 
sgACC tissue sections for confocal analysis of glutamatergic and GABAergic synapses (see 
sections 2.1.5.2, 2.1.6.2 and 2.1.7.4). To quantify changes in neurotransmitter receptors and 
pre- and postsynaptic proteins involved in GABAergic and glutamatergic neurotransmission, 
western blot and dot blot techniques were employed, using Near Infrared (NIR) detection (see 
sections 2.1.8.4-2.1.8.6). The proteins were quantified using Image Studio Lite (see section 
2.1.8.7) and normalised against GAPDH. All of the antibodies used in this study can be found 
in Table 4.1. 
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Table 4.1 Antibodies used for GABAergic and glutamatergic study. 
DB – dot blot; IHC – immunohistochemistry; m – monoclonal; p – polyclonal; Ms – mouse; 
Rb – rabbit, Gt – goat. 
Antigen Host/IgG Dilution Source Product Code
α-synuclein (s129) pRb (IgG) 1:500 (DB)       1:500 (F-IHC) Abcam ab168381
Donkey Anti-Sheep, 546 conjugate Sheep (IgG) 1:200 (F-IHC) Life Technologies (AF) A21098
GABARAP mRb(IgG) 1:500 (DB) Abcam ab109364
GABAR3 pRb (IgG) 1:500 (DB) Abcam ab33299
GABAARα5 mMs (IgG1) 1:500 (DB) Santa Cruz Biotechnology sc393921
GABRG1 pRb (IgG) 1:500 (DB) GeneTex GTX66238
GAD 65/67 mMs (IgG1) 1:500 (DB) Enzo Life Sciences ADI-MSA-225-E
GAD 67 mMs (IgG1) 1:500 (DB)     1:1000 (IHC) Santa Cruz Biotechnology sc58531
GAP-43 pRb (IgG) 1:1000 (DB) GeneTex GTX1015355
Gephyrin mMs (IgG1) 1:1000 (DB) Synaptic Systems 147011
GLUR1/5 mMs (IgG1) 1:500 (DB) Neuromab N75/3
GLUR5 pRb (IgG) 1:500 (DB) Abcam ab27190
GLUR6/7 mRb(IgG) 1:500 (DB) Millipore MAB5683
Goat Anti-Mouse, 488 conjugate Gt (IgG1) 1:200 (F-IHC) Life Technologies (AF) A21121
Goat Anti-Mouse, 488 conjugate Gt (Ig2b) 1:200 (F-IHC) Life Technologies (AF) A21141
Goat Anti-Mouse, 546 conjugate Gt (IgG1) 1:200 (F-IHC) Life Technologies (AF) A21123
Goat Anti-Rabbit, 405 conjugate Gt (IgG) 1:200 (F-IHC) Life Technologies (DyLight) 35550
μ-crystallin (CRYM) mMs (IgG2b) 1:500 (DB)     1:1000 (IHC) Santa Cruz Biotechnology sc376687
MTCO2 mMs (IgG2a) 1:1000 (DB) Abcam ab110258
NDUFB8 mMs (IgG1) 1:500 (DB) Abcam ab110242
Neuroligin-2 pRb (IgG) 1:250 (DB) Santa Cruz Biotechnology sc50394
NMDAR2B mMs(IgG2b) 1:500 (DB) BD Biosciences 610416
Parvalbumin pRb (IgG) 1:1000 (DB) Abcam ab11427
PSD-95 mMs (IgG2a) 1:500 (DB) EMD Millipore MAB1598
SNAP25 mMs (IgG1) 1:500 (WB)1.500 (F-IHC) Santa Cruz Biotechnology sc20038
SNAP25 pSheep (IgG) 1:500 (F-IHC) LifeSpan BioSciences LS-C94834
Synaptogamin I mMs (IgG1) 1:500 (DB) Santa Cruz Biotechnology sc136480
Synaptophysin mMs (IgG1) 1:1000 (DB) EMD Millipore MAB368
Syntaxin Ia pRb (IgG) 1:1000 (DB) Abcam ab41453
Ubiquinol-Cytochrome C 
Reductase Core Protein I mMs (IgG1) 1:1000 (DB) Abcam ab110252
VDAC1/Porin mMs (IgG2b) 1:500 (DB) Abcam ab14734
VGLUT1 mMs (IgG1) 1:500 (DB)        1:500 (F-IHC) Sigma-Aldrich AMAb91041
VGLUT2 mMs (IgG2b) 1:250 (DB) EMD Millipore MAB5504
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4.4 Results 
4.4.1 GABAergic and glutamatergic cell density in the sgACC 
A pilot study was carried out to verify μ-crystallin (CRYM) as a reliable pyramidal cell marker 
(Maruoka et al., 2011, Arlotta et al., 2005). Temporal cortical sections from six controls were 
stained using dual immunofluorescence (Figure 4.1). The captured images (15-20 frames per 
case) were analysed by counting CRYM and GAD67 positive neurones. The co-localisation 
between CRYM and GAD67 was less than two percent, which suggested CRYM to be a 
reliable pyramidal cell marker. 
Figure 4.1 Co-localisation of CRYM and GAD 67 markers in the temporal cortex. 
The nuclei were labelled using DAPI (405nm). Co-localisation of CRYM (pyramidal cell 
marker; 488nm) and GAD67 (GABAergic cells marker; 594nm) was assessed in the temporal 
cortex in six control cases (20x magnification). Scale bar represents 100μm. 
Overall (F(2, 48)=1.038, p=0.362) or layer V (F(2, 48)=1.452, p=0.244) pyramidal cell density 





layers II/III was significantly different between the groups (F(2, 48)=3.940, p=0.026), and was 
higher  in controls compared to DLB-D (p=0.022; Figure 4.2 A). No significant difference was 
observed in overall GABAergic cell density (H(2)=2.997, p=0.223), or in layers II/III 
(H(2)=4.473, p=0.107). GABAergic cells density in layer V was significantly different 
between the groups, with significantly higher cell density observed in controls compared to 
DLB+D (p=0.004; Figure 4.2 B).  
4.4.2 Glutamatergic synaptic changes in the sgACC 
Glutamatergic synapses were assessed in the sgACC in controls, DLB cases with and without 
depression (Figure 4.3). The total number of glutamatergic surfaces (VGLUT1 positive) was 
significantly different between the groups (F(2, 40)=4.887, p=0.013), and was higher in DLB 
cases with depression compared to controls (p=0.048) and DLB cases without depression 
(p=0.019). The average volume of glutamatergic surfaces was also significantly different 
between the groups (F(2, 40)=3.965, p=0.040), with significantly higher volumes observed in 
DLB cases with depression compared to controls (p=0.049; Figure 4.4 A-B). The number (F(2, 
40)=1.781, p=0.181), as well as total volume of presynaptic surfaces (SNAP25 positive) (F(2, 
40)=1.799, p=0.178) was not significantly different between the groups (Figure 4.4 C-D). The 
total number of α-synuclein surfaces (s129 positive) was not significantly different between 
the groups (H(2)=5.660, p=0.059), although it was trending towards significance. The average 
volume of α-synuclein surfaces was significantly different between the groups (H(2)=27.099, 
p<0.001), with DLB cases with and without depression showing higher s129 average volume 
compared to controls (p<0.001; Figure 4.4 E-F). 
The number of glutamatergic synapses (VGLUT1 and SNAP25 positive) was not significantly 
different between the groups (F(2, 40)=1.789, p=0.180), whereas changes were observed in the 
synaptic volume between the groups (F(2, 40)=7.592, p=0.002), which was significantly higher 
in DLB cases with depression (p=0.002) and DLB cases without depression (p=0.011) 
compared to controls (Figure 4.5 A-B). The percentage of glutamatergic synapses containing 
s129 α-synuclein surfaces was significantly different between the groups (H(2)=13.529, 
p=0.001), and was significantly higher in DLB cases with depression compared to controls 
(p=0.001; Figure 4.5 C). The average volume of glutamatergic synapses containing s129 α-
synuclein surfaces was significantly different between the groups (F(2, 40)=7.228, p=0.002), 
and was significantly higher in DLB cases with depression compared to controls (p=0.002; 
Figure 4.5 D). 
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Figure 4.2 Glutamatergic and GABAergic cell density in sgACC. 
(A) CRYM  positive pyramidal neurones and (B) GAD-67 positive GABAergic cells were
assessed in sgACC overall, as well as in layers II/III and layer V in controls (n=17), DLB cases
without depression (DLB-D; n=20) and DLB cases with depression (DLB+D; n=17). The
images were captured at 20X magnification. *p<0.05 and **p<0.01compared to control. Box
plots represent the median (midline) and quartile ranges, with error bars representing the
minimum and maximum values. Scale bar represents 100μm.
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Figure 4.3 Confocal imaging of glutamatergic synapses. 
Representative images of glutamatergic synaptic immunoreactivity (VGLUT1+SNAP25) in relation to s129 α-synuclein in the sgACC in age 
matched controls and DLB cases with (DLB+D) and without (DLB-D) depression. The nuclei were visualised using TO-PRO-3 Iodide (blue, 
647nm), glutamatergic synaptic terminals were visualised using VGLUT1 (green, 488nm), presynaptic terminals demonstrated using SNAP25 













TO-PRO-3 VGLUT1 SNAP25 s129 Merged
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Figure 4.4 Analysis of VGLUT1, SNAP25 and s129 positive surfaces. 
The number and the average volume (μm³) of glutamatergic (VGLUT1; A-B), presynaptic 
(SNAP25; C-D) and α-synuclein (s129; E-F) immunoreactive structures in the sgACC was 
assessed in age matched controls and DLB cases with (DLB+D) and without (DLB-D) 
depression. There was a significant increase in the number and average volume of 
glutamatergic surfaces in DLB cases with depression compared to controls, as well as the 
number of glutamatergic surfaces in DLB cases with compared to without depression. The 
average volume of α-synuclein was significantly higher in DLB cases compared to controls. 
(*p<0.05 and ***p<0.001, compared to appropriate group). Box plots represent the median 
(midline) and quartile ranges, with error bars representing the minimum and maximum values. 
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Figure 4.5 Analysis of glutamatergic synapses. 
Analysis of the number and volume of glutamatergic synapses (VGLUT1 + SNAP25; A-B), as 
well as the percentage and volume of glutamatergic synapses containing α-synuclein (s129; C-
D) in sgACC in age matched controls, DLB cases with (DLB+D) and without (DLB-D) 
depression. (*, p<0.05, **, p<0.01, or *** p<0.001, compared to control). Box plots represent 
the median (midline) and quartile ranges, with error bars representing the minimum and 
maximum values. 
4.4.3 Biochemical analysis of glutamatergic changes in the sgACC 
To complement histological assessment of glutamatergic synapses, various biochemical 
markers of glutamatergic function were assessed. CRYM protein level in sgACC was 
significantly different between the groups (H(2)=17.754, p<0.001), with significantly lower 
CRYM levels detected in DLB cases with (p<0.001) and without depression compared to 
controls (p=0.012; Figure 4.6 A). Vesicular glutamate transporter is a marker of vesicular 
glutamate uptake, with VGLUT1 primarily expressed in the cortex, hippocampus and 
cerebellum, and VGLUT2 in brainstem and deep cerebellar nuclei (Fremeau et al., 2001). 
VGLUT1 levels in the sgACC were significantly different between the groups (F(2, 
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34)=13.984, p<0.001), with significantly lower VGLUT1 levels observed in DLB cases with 
(p<0.001) and without depression compared to controls (p=0.001; Figure 4.6 B). No significant 
difference between the groups was observed in VGLUT2 levels in sgACC (F(2, 34)=2.104, 
p=0.139; Figure 4.6 C).  
Postsynaptic density protein 95 (PSD95), a marker of postsynaptic glutamate receptors, was 
significantly different between the groups (F(2, 34)=6.620, p=0.004), with a significant 
decrease in levels observed in DLB with (p=0.008) and without depression (p=0.014) 
compared to controls (Figure 4.7 A). Neuroligin-2 is a postsynaptic protein primarily located 
at inhibitory synapses, which interacts with PSD-95 and regulates E/I ratio. Neuroligin-2 was 
significantly different between the groups (H(2)=12.069, p=0.002), with significant increase in 
levels observed in DLB cases with (p=0.012) and without depression (p=0.006) compared to 
controls (Figure 4.7 B). The PSD95/Neuroligin-2 (E/I) ratio was significantly different 
between the groups (H(2)=15.193, p=0.001), with a significant decrease in the ratio observed 
in DLB with (p=0.003) and without depression (p=0.002) compared to controls (Figure 4.7 C). 
Ionotropic ligand gated NMDA receptor 2B subunit protein concentration in sgACC was 
significantly different between the groups (F(2, 34)=4.800, p=0.015), with a significant 
decrease in levels observed in DLB with depression (p=0.018) compared to controls (Figure 
4.8 A). No significant change in metabotropic glutamate receptor levels in sgACC was 
observed between the groups, including GLUR 1/5 (F(2, 34)=0.021, p=0.979), GLUR 5 (F(2, 
34)=2.351, p=0.112) and GLUR 6/7 (F(2, 34)=2.552, p=0.093; Figure 4.8 B-D).  
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Figure 4.6 Dot blot analysis of CRYM, VGLUT1 and VGLUT2 glutamatergic markers. 
μ-Crystallin (CRYM; A), vesicular glutamate transporter 1 (VGLUT1; B) and 2 (VGLUT2; C) 
protein concentrations in sgACC were assessed in age matched controls, DLB cases with 
(DLB+D) and without (DLB-D) depression. (*, p<0.05 and ***, p<0.001 compared to control). 
Box plots represent the median (midline) and quartile ranges, with error bars representing the 
minimum and maximum values. 
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Figure 4.7 Dot blot analysis of PSD95, Neuroligin 2 and E/I ratio. 
Postsynaptic density protein 95 (PSD95; A) and Neuroligin 2 (B) protein levels were assessed 
using in sgACC in age matched controls, DLB cases with (DLB+D) and without (DLB-D) 
depression. PSD95/Neuroligin ratio (C) was used to assess changes in excitation and inhibition 
(E/I) (*p<0.05, **p<0.01 and ***p<0.001 compared to control). Box plots represent the 
median (midline) and quartile ranges, with error bars representing the minimum and maximum 
values. 
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Figure 4.8 Dot blot analysis of NMDA2B, GLUR1/5, GLUR5 and GLUR6/7 
glutamatergic receptors. 
Ionotropic (NMDA 2B; A) and metabotropic (GLUR 1/5, GLUR 5 and GLUR 6/7; B-D) 
glutamatergic receptor levels were determined using Near Infra-Red dot blots in sgACC in age 
matched controls, DLB cases with (DLB+D) and without (DLB-D) depression. (* p<0.05 
compared to control). Box plots represent the median (midline) and quartile ranges, with error 
bars representing the minimum and maximum values. 
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Table 4.2 Summary Table for Glutamatergic Markers. 
Summary of significant glutamatergic changes after post hoc Bonferroni corrections; ns - no 
significant difference after corrections for multiple comparisons; DLB-D<Controlsa and 
DLB+D<Controlsb. 
4.4.4 GABAergic synaptic changes in the sgACC 
GABAergic synapses were assessed in the sgACC in controls, DLB cases with and without 
depression using four colour confocal microscopy (Figure 4.9). The total number of 
GABAergic surfaces (GAD65/67 positive) was significantly different between the groups (F(2, 
40)=3.513, p=0.040), although no significant differences were seen after post hoc analysis 
(Figure 4.10 A). The average volume of GABAergic surfaces was significantly different 
between the groups (F(2, 40)=5.216, p=0.010), with a significant reduction in average volume 
observed in DLB cases with depression compared to controls (p=0.008; Figure 4.10 B). No 
changes were observed in the number (F(2, 40)=0.250, p=0.780) or the average volume of 
presynaptic surfaces (SNAP25 positive) between the groups (F(2, 40)=0.54, p=0.579; Figure 
4.10 B-C). The total number of α-synuclein surfaces (s129 positive) was significantly different 
between the groups (F(2, 40)=24.759, p<0.001), with control cases having a significantly 
higher number of individual α-synuclein surfaces compared to DLB cases with or without 
depression (p<0.001; Figure 4.10 E). The average volume of individual α-synuclein surfaces 
was significantly different between the groups (F(2, 40)=15.695, p<0.001), with DLB cases 
with or without depression showing higher s129 average volumes compared to controls 
(p<0.001; Figure 4.10 F). 
Controls DLB-D DLB+D
CRYM — ns p<0.001
VGLUT1 — p=0.001 p<0.001
VGLUT2 — — —
PSD95 — ns ns
NMDA2B — — ns
GLUR1/5 — — —
GLUR5 — — —




Figure 4.9 Confocal imaging of GABAergic synapses. 
Representative images of GABAergic synaptic (GAD65/67+ SNAP25) immunoreactivity in relation to s129 α-synuclein in the sgACC in age 
matched controls and DLB cases with (DLB+D) and without (DLB-D) depression. The nuclei were visualised using TO-PRO-3 Iodide (blue, 
647nm), GABAergic synaptic terminals were visualised using GAD 65/67 (green, 488nm), presynaptic terminals identified using SNAP25 (red, 













TO-PRO-3 GAD 65/67 SNAP25 s129 Merged
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Figure 4.10 Analysis of GAD67, SNAP25 and s129 positive surfaces. 
Analysis of the number and the average volume (μm³) of the GABAergic (GAD 65/67; A-B), 
presynaptic (SNAP25; C-D) and α-synuclein (s129; E-F) immunoreactive structures in the 
sgACC in age matched controls and DLB cases with (DLB+D) and without (DLB-D) 
depression. (**p<0.01 and ***p<0.001, compared to control group). Box plots represent the 
median (midline) and quartile ranges, with error bars representing the minimum and maximum 
values. 
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The number (F(2, 40)=2.082, p=0.139) and average volume (F(2, 40)=0.812, p=0.451) of 
GABAergic synapses was not significantly different between the groups (Figure 4.11 A-B). 
The percentage of GABAergic synapses containing 129 α-synuclein was significantly different 
between the groups (H(2)=13.881, p=0.001), and was significantly higher in DLB cases with 
(p=0.003) or without depression compared to controls (p=0.005; Figure 4.11 C). The average 
volume of GABAergic synapses containing 129 α-synuclein surfaces was significantly 
different between the groups (F(2, 40)=14.755, p<0.001), and was significantly higher in DLB 
cases with (p=0.001) or without depression (p<0.001) compared to controls (Figure 4.11 D). 
Figure 4.11 Analysis of GABAergic synapses. 
Analysis of the number and volume of GABAergic synapses (GAD 65/67 + SNAP25; A-B), 
as well as the percentage and volume of GABAergic synapses containing α-synuclein (s129; 
C-D) in sgACC in age matched controls, DLB cases with (DLB+D) and without (DLB-D)
depression. (*, p<0.05, **, p<0.01 and ***, p<0.001, compared to control). Box plots represent
the median (midline) and quartile ranges, with error bars representing the minimum and
maximum values.
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4.4.5 Biochemical analysis of GABAergic changes in the sgACC 
To complement confocal analysis of GABergic synapses, biochemical analysis of GABAergic 
proteins in post mortem tissue was determined using western blotting or dot blotting 
approaches. No significant change in GAD 65/67 (H(2)=0.920, p=0.631) was detected in 
sgACC between the groups (Figure 4.12 A). Gephyrin levels were significantly different 
between the groups (F(2, 34)=16.277, p<0.001), with a significant decrease observed in DLB 
cases with (p<0.001) and without depression compared to controls (p=0.001; Figure 4.12 B). 
Parvalbumin levels in sgACC were significantly different between the groups (F(2, 
34)=10.035, p<0.001), with a significant decrease in levels observed in DLB with (p=0.003) 
or without depression (p=0.001) compared to controls (Figure 4.12 C). Calbindin levels were 
significantly different between the groups (F(2, 34)=4.118, p=0.025), with a significant 
decrease observed in DLB cases with depression compared to without (p=0.027; Figure 4.12 
D).  
GABAA receptor α3 subunit levels were significantly different between the groups (F(2, 
34)=4.185, p=0.025), with a significant reduction observed in DLB cases with depression 
compared to controls (p=0.024; Figure 4.13 A). GABAA receptor α5 subunit levels in sgACC 
was significantly different between the groups (F(2, 34)=7.265, p=0.002), with a significant 
decrease observed in DLB cases with depression compared to controls (p=0.002; Figure 4.13 
B). No significant change was observed between the groups in GABAAγ1 (F(2, 34)=1.695, 
p=0.199) or GABARAP proteins (F(2, 34)=1.115, p=0.340; Figure 4.13 C-D).  
128 
Figure 4.12 Dot blot analysis of GAD65/67, Gephyrin, Parvalbumin and Calbindin 
GABAergic markers. 
GABAergic markers were assessed using NIR blotting in sgACC of age matched controls, or 
DLB cases with (DLB+D) or without (DLB-D) depression, including GAD 65/67 (A), 
Gephyrin (B), Parvalbumin (C) and Calbindin (D); (*p<0.05, **p<0.01 and ***p<0.001 
comparing appropriate groups). Box plots represent the median (midline) and quartile ranges, 
with error bars representing the minimum and maximum values. 
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Figure 4.13 Dot blot analysis of GABAAα5, GABAAα3, GABAAγ1 and GABARAP 
GABAergic markers. 
GABAergic receptor markers were assessed in sgACC in age matched controls, DLB cases 
with (DLB+D) and without (DLB-D) depression, including GABAAα3 (A), GABAAα5 (B), 
GABAAγ1 (C) and GABARAP (D); (*p<0.05 or ***p<0.001, compared to control). Box plots 
represent the median (midline) and quartile ranges, with error bars representing the minimum 
and maximum values. 
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Table 4.3 Summary Table for GABAergic Markers. 
Summary of significant GABAergic changes after post hoc Bonferroni corrections; ns - no 
significant difference after corrections for multiple comparisons; DLB-D<Controlsa, 
DLB+D<Controlsb. 
4.4.6 Biochemical analysis of synaptic and mitochondrial changes 
in the sgACC 
Since changes were identified in both glutamatergic and GABAergic synapses using confocal 
microscopy, overall levels of synaptic marker proteins, known to be involved in synaptic 
function were determined in sgACC. SNAP25 protein level was significantly different between 
the groups (F(2, 34)=18.214, p<0.001), with a significant decrease observed in DLB cases with 
depression (p<0.001) and also DLB cases without depression (p=0.010) compared to controls. 
SNAP25 was also significantly reduced in DLB cases with depression compared to DLB cases 
without depression (p=0.021; Figure 4.14 A). Synaptophysin levels in the sgACC were 
significantly different between the groups (F(2, 34)=4.762, p=0.015), with a significant 
decrease observed in DLB cases with depression compared to controls (p=0.018),  whereas a 
trend towards significance was observed in DLB cases without depression compared to 
controls (p=0.081; Figure 4.14 B). No significant changes were observed in Synaptogamin I 
(F(2, 34)=3.217, p=0.053), Syntaxin Ia (H(2)=2.190, p=0.335) or Synapsin IIa (F(2, 
34)=1.229, p=0.306) between the groups (Figure 4.14 C-E). GAP-43, a synapse/growth cone 
Controls DLB-D DLB+D
GAD65/67 — — —
PV — p=0.001 p=0.003
CB — — ns
Gephyrin — p=0.001 p<0.001
GABARAP — — —
GABAAα5 — — p=0.002
GABAAα3 — — ns







marker, was also significantly different between the groups (F(2, 34)=9.868, p<0.001), with a 
significant reduction observed in DLB cases with depression (p<0.001) and also DLB without 
depression compared to controls (p=0.024; Figure 4.14 F).  
Synaptic activity is a highly energy dependent process and intimately linked to functional 
metabolism, therefore, select mitochondrial markers as indicators of energy metabolism 
associated with synaptic activity were determined in sgACC. No significant change was 
observed in NDUFB8, a marker of Complex I (F(2, 34)=2.008, p=0.150; Figure 4.15 A) or in 
Ubiquinol-Cytochrome C Reductase Core Protein I expression, a marker of Complex III,  in 
sgACC between the groups (F(2, 34)=2.740, p=0.079; Figure 4.15 B). MTCO2, a complex IV 
cytochrome oxidase subunit marker, determined in sgACC was significantly different between 
the groups (F(2, 34)=15.446, p<0.001), with a significant decrease observed in DLB cases with 
depression (p<0.001) and also DLB cases without depression compared to controls (p<0.001; 
Figure 4.15 C). VDAC1/Porin, a mitochondrial mass marker, was significantly different 
between the groups (F(2, 34)=9.248, p=0.001), with significant reduction observed in DLB 
cases with depression (p=0.001) and in DLB without depression (p=0.020) compared to 
controls (Figure 4.15 D).  
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Figure 4.14 Dot blot analysis of synaptic markers. 
Synaptic changes were assessed in sgACC in age matched controls, DLB cases with (DLB+D) 
and without (DLB-D) depression, using NIR based dot blots for SNAP25 (A), Synaptophysin 
(B), Synaptotagmin I (C), Syntaxin Ia (D), Synapsin IIa (E) and GAP-43 (F) markers; (* 
p<0.05 and ***p<0.001 compared to appropriate group). Box plots represent the median 
(midline) and quartile ranges, with error bars representing the minimum and maximum values. 
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Figure 4.15 Dot blot analysis of mitochondrial markers. 
Mitochondrial protein levels in sgACC were assessed in age matched controls, DLB cases with 
(DLB+D) and without (DLB-D) depression, using complex I (NDUFB8; A), complex III 
(Ubiquinol-Cytochrome C Reductase Core Protein I; B), complex IV marker (MTCO2; C), and 
general mitochondrial marker (VDAC1/Porin; D); (*p<0.05 and ***p<0.001 compared to 
control). Box plots represent the median (midline) and quartile ranges, with error bars 
representing the minimum and maximum values. 
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4.5 Discussion 
Abnormalities of glutamatergic and GABAergic neurotransmission in the sgACC in MDD are 
well established (Tripp et al., 2012, Tripp et al., 2011, Ongur et al., 1998), but it is unclear how 
these changes relate to depression in DLB. This study investigatedglutamatergic and 
GABAergic changes in the sgACC in relation to depression in DLB. The present findings 
suggest that an imbalance in excitatory and inhibitory neurotransmission may contribute to the 
development of depression in DLB. Furthermore, metabolic, neurotransmitter receptor, and 
synaptic protein changes in the sgACC may contribute to synaptic dysfunction in DLB, 
possibly due to accumulation of aggregated α-synuclein within presynaptic terminals.  
Imaging studies in MDD have provided consistent evidence of a reduced volume of cortical 
and limbic regions involved in the regulation of emotions, mood and cognition (Hercher et al., 
2009, Price and Drevets, 2010), with structural, functional and metabolic abnormalities 
observed particularly in the sgACC (Li et al., 2014b, Coryell et al., 2005). At a cellular level, 
these imaging changes are consistent with the finding of reduced neuronal soma size and 
increased neuronal density in layer V of the ACC in MDD (Chana et al., 2003, Cotter et al., 
2001), although other studies have found no such changes (Ongur et al., 1998, Hercher et al., 
2009, Bouras et al., 2001). A reduction in the size of pyramidal neurones has also been observed 
in the PFC in MDD (Rajkowska et al., 1999), with altered dendritic branching in the ACC in 
MDD (Hercher et al., 2010). PFC superficial layer II/III pyramidal neurones have been shown 
to be critical for moderation of stress in the context of depressive behaviours, since deletion of 
wolframin (the protein encoded by WFS1 gene), which is exclusively expressed in superficial 
layer pyramidal cells causes depression-like behaviour in mice (Shrestha et al., 2015). In this 
current study, no pyramidal cell loss was observed overall or in layer V in the sgACC in DLB. 
A small but significant reduction in pyramidal cell numbers was however observed in layers 
II/III in DLB cases without depression compared to controls. These findings, although 
superficially similar to those seen in MDD, where reduced cell volume was seen (Rajkowska 
et al., 1999), differ in that significant loss of layer II/III pyramidal neurones was observed in 
DLB cases without depression. Whilst it is not clear why this would be the case, it is tempting 
to speculate that in cases with more severe neurodegenerative pathology, there is reduced 
ability to demonstrate depressive behaviours or that these are more difficult to communicate. 
Indeed, in this case series, higher (although not significantly) levels of AT8 (phospho-tau) 
reactivity are seen in non-depressed DLB donors in the sgACC (see chapter 3). 
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As a correlate of pyramidal neurone density, a blotting approach was used to determine the 
protein levels of μ-crystallin (CRYM) (Figure 4.6), a pyramidal cell marker, and this was 
significantly reduced in DLB cases overall compared to controls and was slightly more severe 
in DLB cases with depression. CRYM depletion is suggested to make neurones more 
vulnerable to mutant huntingtin protein (Francelle et al., 2015), and it is possible that loss of 
CRYM in DLB patients may make neurones more vulnerable to cellular stress. Therefore, 
while mild pyramidal cell loss was observed in DLB without depression, molecular changes 
may suggest functional pyramidal cell abnormalities. This is also seen with other glutamatergic 
pyramidal neurone markers including the vesicular glutamate transporter isoforms VGLUT1 
and VGLUT2 that mediate glutamate uptake into synaptic vesicles of excitatory neurones, and 
are differentially expressed in the brain, with VGLUT1 more abundantly expressed in the 
cortex (Fremeau et al., 2001). In this study, as with CRYM expression, a significant reduction 
in VGLUT1 was observed in the sgACC in DLB cases with depression compared to controls, 
similar to the findings in PD with reduced VGLUT1 expression (Kashani et al., 2007). VGLUT 
levels have been shown to be critical in determining the balance between excitation and 
inhibition (Erickson et al., 2006), and have been shown to be implicated in mood disorders, 
with reduced VLGUT1 expression in the hippocampus observed in animal models of 
depression (Tordera et al., 2007, Zink et al., 2010). In PD, an increase in VGLUT1 and 
VGLUT2 expression has been shown in putamen, whereas a decrease in VGLUT1 has been 
seen in the temporal cortex and PFC, suggesting the existence of profound alterations of 
glutamatergic transmission in PD (Kashani et al., 2007). The findings of the current study may 
suggest a more pronounced glutamatergic deficits in DLB cases with depression, possibly 
contributing to a greater imbalance in excitation/inhibition (E/I). 
To further explore a potential change in excitatory neurone activity in DLB, PSD-95 and 
Neuroligin-2 levels were assessed in sgACC, which provide a possible measure of the E/I 
balance. Postsynaptic density 95 (PSD-95) protein, is a major glutamatergic receptor scaffold 
protein present at excitatory synapses, and has been shown to be elevated in the lateral 
amygdala of MDD patients (Karolewicz et al., 2009). This may be a specific change in MDD 
since other studies have shown no changes in PSD-95 levels in the striatum (Kristiansen and 
Meador-Woodruff, 2005), hippocampus and orbitofrontal cortex in depressed patients (Toro 
and Deakin, 2005). In DLB, disease, but not depression specific changes were observed in 
PSD-95 levels in sgACC, which may suggest that PSD-95 involvement in depression in DLB, 
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as with MDD (Karolewicz et al., 2009), may be limited to specific brain regions involved with 
emotional processing, such as the amygdala. PSD-95 has been shown to be involved in 
modulating Neuroligin-2 localisation at the synapse, and regulation of the E/I ratio (Levinson 
and El-Husseini, 2005). An increase in the excitation/inhibition synaptic current was observed 
in neurones overexpressing PSD-95, whereas knockdown of PSD-95 reduced the E/I ratio 
(Prange et al., 2004), therefore, PSD95 may directly affect E/I balance and synaptic strength. 
The PSD95/Neuroligin-2 ratio was significantly reduced in DLB in this study, although again 
disease, but not depression changes were observed. This change in the E/I ratio would appear 
to favour abnormal inhibition in DLB. Pre- and postsynaptic proteins involved in anchoring 
receptors and adhesion molecules are important in maintaining the E/I balance, which is 
disrupted in neuropsychiatric disorders (Yizhar et al., 2011). Abnormalities in Neuroligin-2 
expression have been shown to be one of the factors contributing to chronic changes in the E/I 
balance in PFC and behavioural impairments in neuropsychiatric patients (Liang et al., 2015). 
Neuroligin-2 is a cell adhesion protein on the postsynaptic membrane, that interacts with β-
neurexins located presynaptically, mediating the formation of synapses between neurones. 
Neuroligin-2 is primarily located at inhibitory synapses and is important in function of 
GABAergic synapses (Sudhof, 2008). Neuroligin-2 knock-out mice show increased anxiety-
like behaviour (Blundell et al., 2009), with Neuroligin-2 overexpressing mice also showing 
anxiety-like behaviour, as well as enlarged synaptic contact size and reduction in the 
excitation/inhibition (E/I) ratio. In this study, elevated levels of Neuroligin-2 were found in 
DLB cases with and without depression in sgACC, whereas decreased Neuroligin-2 levels were 
observed in the NAcc in a mouse model of depression (Heshmati et al., 2018). This may suggest 
that brain regions involved in regulating emotional behaviour may be more susceptible to 
changes in Neuroligin-2 expression and that even subtle changes in Neuroligin-2 might lead to 
dysregulation of the balance between excitation and inhibition. 
A decrease in GABAergic interneurone density has been reported in the DLPFC in patients 
with MDD (Rajkowska et al., 2007). In this study no overall changes in GABAergic cell 
density within sgACC were observed, although a significant reduction in GAD67 positive cells 
in layer V was observed in DLB cases with depression compared to controls. This may suggest 
reduced inhibition of layer V pyramidal neurones, followed by an increase or imbalance in 
excitation (Naka and Adesnik, 2016). GABA is synthesized by two isoforms of the enzyme 
glutamic acid decarboxylase (GAD), GAD65 and GAD67, and reductions in GAD67 have been 
shown to decrease inhibitory network activity in cortical regions (Lazarus et al., 2015).  In this 
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study no significant changes in the protein levels of GAD65/67 were found between DLB cases 
and controls. Some studies have also found no changes in GAD65 or GAD67 cell numbers and 
mRNA levels in DLPFC in MDD (Sibille et al., 2011, Gilabert-Juan et al., 2012), whereas 
others found reduced GAD67 protein and gene expression in the DLPFC and sgACC  in MDD 
(Karolewicz et al., 2010, Tripp et al., 2012). PV expressing GABAergic neurones constitute 
the largest group of layer V interneurones (Xu and Callaway, 2009), whereas CB expressing 
interneurones are primarily expressed in layer II (Moon et al., 2002). While a decrease in PV 
gene expression in the sgACC was found in post-mortem tissue of depressed patients (Tripp et 
al., 2012), other studies failed to observe any robust changes (Sibille et al., 2011, Beasley et 
al., 2002). Reduction in CB positive neurones have also been observed in layer II of the ACC 
in MDD (Woo et al., 2008, Cotter et al., 2002). In this study, reduced PV protein levels were 
observed in DLB cases with depression compared to controls, as well as reduced CB levels in 
DLB patients with depression compared to DLB cases without depression, therefore selective 
vulnerability in specific populations of interneurones may play a role in development of 
depression in DLB.   
Alpha-synuclein 
Unlike in AD, DLB patients show no major atrophy in the brain (Burton et al., 2002), therefore 
dysfunction of synapses may play a role in the pathophysiological mechanism of the disease. 
Synaptic abnormalities in DLB have been suggested to precede neuronal loss and LB formation 
(Chung et al., 2009, Calo et al., 2016), and are closely related to clinical symptoms (Bereczki 
et al., 2016). The aggregation of α-synuclein at synapses is thought to be a major factor in the 
pathogenesis of DLB (Calo et al., 2016). Recent evidence suggests a close relationship between 
differential expression profiles of α-synuclein and selective vulnerability of certain neuronal 
populations (Taguchi et al., 2019, Li et al., 2002), with aggregation of α-synuclein thought to 
be dependent on its endogenous expression (Volpicelli-Daley et al., 2011b, Erskine et al., 
2018).  
Presynaptic α-synuclein aggregation in cortical brain regions in DLB cases was shown to 
correlate with a reduction of dendritic spines, possibly contributing to synaptic loss (Kramer 
and Schulz-Schaeffer, 2007). Phosphorylated α-synuclein has been detected in synaptic-
enriched fractions in post-mortem DLB cases (Walker et al., 2013, Muntane et al., 2008), with 
synaptic α-synuclein induced toxicity observed in animal models (Nemani et al., 2010, Garcia-
Reitbock et al., 2010). Glutamatergic neurones are known to develop LB in DLB. The 
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inhibitory neurones in the cortex show low expression of endogenous α-synuclein in the mouse 
brain (Taguchi et al., 2019), with hippocampal GAD positive inhibitory neurones suggested to 
show an absence of LB aggregates (Taguchi et al., 2014). Cortical PV interneurones are also 
suggested to show sparing of LB pathology in DLB patients (Gomez-Tortosa et al., 2001). 
However, overlap of α-synuclein expression in GAD positive inhibitory synapses is observed 
within the globus pallidus, SN and olfactory bulb, despite the suggestion of α-synuclein not 
being present in interneurones of the cerebral cortex, hippocampus or thalamus (Taguchi et al., 
2019). It is unclear therefore if only specific GABAergic neurones develop α-synuclein 
pathology. 
Synaptic α-synuclein and VGLUT1 in the current study appears to show similar patterns of 
expression within cortical regions and similarly, the majority of striatal α-synuclein is also 
localised to glutamatergic terminals, possibly derived from corticocortical and corticostriatal 
input (Emmanouilidou et al., 2016, Taguchi et al., 2019). There is potentially a differential 
expression and also differential susceptibility of specific neuronal populations to LB and α-
synuclein pathology.  
To address this issue of differential neuronal susceptibility, confocal microscopy was used to 
identify α-synuclein in neurochemically defined synapses. An increase in the average size of 
glutamatergic synapses was observed in DLB with or without depression compared to controls. 
Phosphorylated α-synuclein was observed in glutamatergic, but also GABAergic synapses. A 
significant increase in the number and size of glutamatergic synapses containing 
phosphorylated α-synuclein was found in DLB cases with depression compared to controls. No 
significant changes in the number or the average volume of GABAergic synapses were 
observed between the groups in sgACC. Similar to the findings with glutamatergic synapses, 
the size and number of GABAergic synapses containing α-synuclein was higher in the DLB 
group in general compared to controls, but showed no selective increase in relation to 
depression. 
While phosphorylated α-synuclein was present in both GABAergic and glutamatergic 
synapses, the latter were more affected. Synaptic phosphorylated α-synuclein in the form of 
small aggregates was observed in DLB cases, which has previously been associated with 
structural changes in presynaptic terminals (Colom-Cadena et al., 2017). Around 20% of 
phosphorylated α-synuclein co-localized with presynaptic terminals in the cingulate cortex 
(Colom-Cadena et al., 2017), which is similar to the observations made in the current study, 
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with about 8% of GABAergic and 15% of glutamatergic synapses containing phosphorylated 
α-synuclein. The same study also observed larger presynaptic terminal volumes in the presence 
of phosphorylated α-synuclein (Colom-Cadena et al., 2017), again in line with the present 
results, although only enlargement of glutamatergic synapses in DLB was observed in the 
present study. Enlargement of VGLUT1 terminals has been observed in SNAP25 knock-in 
mutant mice bearing a SNAP25 S187A mutation, with synapses also demonstrating 
concomitant accumulation of α-synuclein and phosphorylated α-synuclein (Nakata et al., 
2012). Other studies have shown relative preservation of presynaptic terminals, but found 
retraction of dendritic spines (Kramer and Schulz-Schaeffer, 2007, Schulz-Schaeffer, 2010), 
which may suggest synaptic dysfunction is induced by reduction of key neurotransmitters in 
DLB. While no synaptic loss in the sgACC was observed in this study, the enlarged 
glutamatergic and GABAergic synapses may indicate possible dysfunction and may be a result 
of a response involving the accumulation of pathological phosphorylated α-synuclein.  
Further investigation of synaptic protein expression in the sgACC was carried out in DLB to 
determine if the presence of α-synuclein may have a detrimental effect on synaptic function. 
Alpha-synuclein is normally localised in the presynaptic terminals and directly interacts with 
SNARE complex proteins (Burre et al., 2010). SNAP25 and syntaxin proteins are integral in 
SNARE complex function. These SNARE protein complexes are expressed on the presynaptic 
membrane, and play a role in vesicle fusion and exocytosis (Zhang et al., 2002). Deletion of 
SNAP25 in the mouse results in profound dysfunction in calcium-mediated neurotransmitter 
exocytosis (Washbourne et al., 2002). SNARE complex dysfunction has also been shown to 
result in presynaptic accumulation of endogenous α-synuclein, possibly representing the initial 
pathological event in DLB, and eventually leading to cellular dysfunction and death (Nakata et 
al., 2012). Abnormalities in SNAP25 and syntaxin expression have also been shown to be 
involved in a wide range of neuropsychiatric disorders (Houenou et al., 2017, Nakamura et al., 
2008). Using confocal analysis, no changes were found in the number and size of presynaptic 
terminals in sgACC, whereas overall SNAP25 protein level was significantly reduced in DLB 
cases with depression compared to DLB cases without depression and controls. Syntaxin Ia is 
also part of the SNARE complex, and has been shown to interact with SNAP25 facilitating 
exocytosis (Liang et al., 2013). In the present study, no changes in syntaxin Ia protein levels 
were observed between the groups. One study demonstrated that syntaxin Ib, but not syntaxin 
Ia is necessary for the regulation of synaptic vesicle exocytosis (Mishima et al., 2014), which 
may suggest functional differences in two isoforms. Synaptophysin, another presynaptic 
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protein that associates with the pre-synaptic SNARE complex to facilitate synaptic vesicle 
exocytosis (Hansen et al., 1998), is involved in regulating neurotransmitter release and 
improving efficiency of exocytosis (Gordon et al., 2016). A reduction in synaptophysin 
levelwas observed in DLB cases with depression compared to controls in the present study. 
These results suggest that both the machinery involved in synaptic vesicle exocytosis, and 
presynaptic proteins involved in efficient neurotransmitter release are altered, and this may 
play a role in the pathogenesis of depression in DLB, possibly due to the accumulation of α-
synuclein pathology. Growth associated protein 43 (GAP43), which is predominantly 
expressed on presynaptic membranes and involved in axonal growth, although does not directly 
associate with the SNARE complex, was reduced in DLB. This finding may also suggest that 
presynaptic proteins that regulate function may be affected by α-synuclein. 
Mitochondrial activity is intimately linked to synaptic function and is vital in neurotransmitter 
release given the high energy requirements to maintain vesicle exocytosis and recycling and 
membrane polarisation (Lee et al., 2018). Mitochondrial dysfunction has been observed in 
neuropsychiatric, as well as neurodegenerative disorders,therefore, the investigation of 
expression of mitochondrial markers in DLB was carried out in the current study, to determine 
if any changes may relate to synaptic function or neuropsychiatric symptoms. Reduced rates of 
mitochondrial respiration in MDD (Karabatsiakis et al., 2014), and reductions of respiratory 
chain complexes I, III and IV in cerebral cortex and cerebellum has been reported after chronic 
exposure to stress (Rezin et al., 2008). Mitochondrial enzyme activity within complex I-V in 
the frontal cortex shows significant reductions in DLB compared to controls (Garcia-Esparcia 
et al., 2017). Similarly, mRNA expression levels of mitochondrial complex V subunit are 
downregulated in DLB cases compared to controls (Garcia-Esparcia et al., 2017). Protein 
expression levels of several complex I subunits were shown to be significantly reduced in DLB 
compared to controls (Garcia-Esparcia et al., 2017), which was not observed in the present 
study based on NDUFB8 expression. Protein levels of complexes II-V have also been shown 
to be significantly decreased in DLB cases compared to controls (Garcia-Esparcia et al., 2017), 
however this is in contrast to the present results, which showed no change in the Complex III 
marker and only showed a decrease in the Complex IV marker MTCO2. The voltage dependent 
anion channel (VDAC), which is used as a marker of mitochondrial mass has been shown to 
be reduced in DLB cases compared to controls (Garcia-Esparcia et al., 2017), which is in 
agreement with present results, and may suggest a reduced numbers of mitochondria or reduced 
mitochondrial size. Regional deficits in mitochondrial function, particularly in the ACC, appear 
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to consistently differentiate patients with mood disorders from controls (Konarski et al., 2008). 
Since α-synuclein can interfere with mitochondrial function (Vicario et al., 2018), the presence 
of synaptic α-synuclein may be one factor driving alterations in mitochondrial function in the 
synapse. The current findings suggest certain mitochondrial deficits as a potential factor in 
metabolic changes in DLB, although it does not seem to influence depressive symptoms in 
DLB.  
Glutamatergic and GABAergic Synapses 
Changes in glutamate and GABA receptors have been observed in many psychiatric and 
neurodegenerative disorders. While downregulation of glutamatergic and GABAergic 
receptors is often observed in MDD, receptor deficits in DLB may be due to a loss of intrinsic 
neurones and synapses that express these receptors. Based on clinical and preclinical evidence, 
several drugs and compounds with high affinity for glutamatergic receptors have been 
identified as being effective in providing rapid relief of depressive symptoms. Ketamine, a non-
competitive high affinity NMDA receptor antagonist has been shown to have clinical efficacy 
in antidepressant drug therapies by strengthening excitatory synapses in the brain regions 
involved in the regulation of mood and reward (Zanos et al., 2016, Li et al., 2010, Zarate et al., 
2006). Negative side effects due to NMDA receptor inhibition however, pose limitations for 
the use of ketamine as an antidepressant. However, esketamine, an isomer of ketamine, has 
been approved for use in treatment resistant MDD (Jauhar and Morrison, 2019). Selective 
targeting of the NMDA receptor 2B subunit, by using the antagonists MK-0657 and CP-
101,606, has also been shown to be effective in treating depression without serious side effects 
(Preskorn et al., 2008, Ibrahim et al., 2012). A significant reduction in NMDA NR2A and 
NR2B subunit expression was observed in the PFC of patients with MDD (Feyissa et al., 2009), 
with a decrease in NMDA, but not AMPA receptors also seen in patients with depression (Scarr 
et al., 2003). These findings are compatible with present results, showing reduced NMDA 2B 
subunit levels in the sgACC in DLB cases with depression compared to controls, suggesting 
the NMDA receptor may mediate some of the depressive symptoms found in DLB. 
Metabotropic glutamate receptors (mGluR) mediate many intracellular metabolic processes, 
particularly within neurones. The mGluR5 receptor is a potential target for novel drug 
development in the treatment of MDD (Singh and Singh, 2011, Knopfel et al., 1995). mGluR5 
knockout animals and also mGluR1 knockout animals show deficits in sensorimotor gating 
(Brody et al., 2003, Brody et al., 2004), which is impaired in some psychiatric disorders, and 
can be reversed by certain mood stabilizer agents, such as the sodium channel blocker 
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lamotrigine. GluR7 exhibits a wide distribution throughout the entire brain, with mGluR7 
knockout mice showing anxiety and depression type behaviours (Cryan et al., 2003, 
Stachowicz et al., 2008). No disease or depression specific changes in the mGluR in sgACC 
were observed in this study, therefore this possibly suggests selective receptor changes, 
implicating dysfunction of glutamatergic ion-channel receptors in the pathophysiology of 
depression in DLB.   
Postsynaptic ionotropic GABAA receptors are targets of many psychotropic agents, such as 
benzodiazepines, ethanol and barbiturates (Engin et al., 2018), whereas pre- and post-synaptic 
metabotropic GABAB receptors function as autoreceptors, inhibiting GABA release (Cryan 
and Kaupmann, 2005). Decreased expression of GABAA receptor α1, α3, α4, γ1, β2 and ρ1 
subunit genes (Luscher et al., 2011, Klempan et al., 2009, Merali et al., 2004, Sequeira et al., 
2007), and increased expression of α5, γ2, β3 and δ subunits is observed in MDD (Klempan et 
al., 2009, Merali et al., 2004, Sequeira et al., 2007). This may suggest distinct roles of GABAA 
receptor subunits in the aetiology of MDD. In this study, a significant reduction in GABAA α5 
and GABAA α3 receptor subunits was seen in DLB cases with depression compared to 
controls.The evidence from preclinical, clinical or post-mortem studies show GABA receptors 
to be a promising target for MDD. Selective agonists or positive modulators of GABAAα3 
subunit such as TPA023 and eszopiclone, have been recently proposed as potential 
antidepressants (Atack, 2010, Atack, 2011, Vollenweider et al., 2011). Studies have shown that 
when co-administered with SSRIs, the preferential GABAA α3 positive modulator eszopiclone 
induced a faster onset of efficacy and greater treatment response of first line antidepressants 
(Fava et al., 2006, Fava et al., 2011). The GABAA α5 subunit has been shown to be upregulated 
in the cortex and hippocampus in human and rodent depression studies (Matsumoto et al., 2007, 
Xiong et al., 2018), with preclinical studies showing that both positive and negative allosteric 
modulators of GABAA α5 receptors produce rapid antidepressant-like effects (Xiong et al., 
2018, Zanos et al., 2017). The GABAA α5 negative allosteric modulator L-655,708 can restore 
alterations in hedonic behaviours (Fischell et al., 2015) by increasing the expression of the 
GluA1 subunit of the AMPA receptor, suggesting that it produces an indirect potentiation of 
excitatory synapses. Another GABAA α5 negative allosteric modulator MRK-016 has been 
shown to reverse anhedonia in animal models by restoration of excitatory synaptic strength 
(Fischell et al., 2015). Similar to ketamine, MRK-016 induced a significant increase in coherent 
EEG γ frequency oscillations (Zanos et al., 2017). GABAA α5 expression is less widespread 
compared to the target of ketamine the NMDA receptor, being found predominantly in the 
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hippocampus and frontal cortex in mouse brain that may result in the reduced side effects seen 
with GABAAα5 modulation (Malherbe et al., 1990). Negative allosteric modulators of 
GABAAα5 also were shown to have cognition-enhancing actions (Rudolph and Knoflach, 
2011), and may be a target for memory-enhancing drugs (Ballard et al., 2009). Similar 
antidepressant effects are observed after acute and chronic increases of GABAA α5 activity by 
a positive modulator, although this was exclusively restricted to female mice, suggesting sex-
specific effects (Piantadosi et al., 2016). This may suggest that GABAA α5 positive modulators 
interact with steroid hormones to produce an antidepressant response (Maggi and Perez, 1986, 
Maguire and Mody, 2007). The GABAA α5 subunit is therefore one possible mediator of 
depression in DLB. 
Gephyrin is a scaffolding protein, essential for GABAA receptor clustering at the post-synaptic 
sites (Tyagarajan and Fritschy, 2014). Abnormalities in gephyrin functions have been 
associated with many neuropsychiatric disorders (Lionel et al., 2013, Fritschy and Brunig, 
2003). Lithium and valproic acid have been widely used in treatment of epilepsy and bipolar 
disorder, and show enhancement of gephyrin clustering (Wang et al., 2012, Andre et al., 2001). 
A global reduction of gephyrin expression has been observed in AD (Agarwal et al., 2008), 
which may mean a reduced neuronal inhibition and increased glutamatergic excitotoxicity, 
possibly contributing to synaptic degeneration and neuronal death. Downregulation of 
gephyrin levelwas observed in DLB cases with and without depression compared to controls, 
and this was more pronounced in depressed DLB cases. Gamma-aminobutyric acid receptor-
associated protein (GABARAP) directly interacts with gephyrin (Kneussel et al., 2000), and is 
important in intracellular transport of GABAA receptors (Kittler et al., 2001). However, no 
reduction in GABARAP was observed in this study, suggesting that a downregulation of 
gephyrin may not directly result in the loss of other associated proteins at synapses.   
Pharmacological treatments using SSRIs, as well as transcranial magnetic stimulation in 
treatment of depression have shown to restore plasma and cortical GABA levels (Karolewicz 
et al., 2010, Kucukibrahimoglu et al., 2009), and act directly as an allosteric modulators of 
GABAA receptors (Robinson et al., 2003). Direct interactions between the GABAergic and 
serotoninergic systems have been reported (Llado-Pelfort et al., 2012, Celada et al., 2001), with 
the majority of serotoninergic cells in the raphe nucleus expressing GABAB receptors, which 
control serotoninergic cell firing (Abellan et al., 2000, Serrats et al., 2003). Studies have shown 
PV positive cells to express serotoninergic receptors (mainly 5HT1A and 5HT2A) (Santana et 
al., 2004), with 8-OH-DPAT, a 5HT1A receptor agonist, preferentially targeting GABA 
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interneurones, which results in pyramidal neurone disinhibition and enhancement of cell firing 
(Llado-Pelfort et al., 2012). The inhibition of pyramidal neurones has been observed by 
activation of GABA interneurones through 5HT3 receptors (Puig et al., 2004), and compounds, 
that are high affinity 5HT3 receptor antagonists such as vortioxetine, have shown antidepressant 
efficacy in treating MDD (Thase et al., 2016, Artigas et al., 2018). This evidence that 
normalization of a GABA mediated imbalance in excitation and inhibition through the action 
of antidepressants, provides further support for the involvement of GABAergic dysfunction in 
the aetiology of MDD. While GABAergic dysfunction in MDD may reflect downregulation of 
specific receptors, GABAergic deficits in DLB may be due to a selective (e.g. PV) loss of 
intrinsic neurones and synapses that express these receptors. Therefore, selective targeting of 
GABA receptors might lead to more effective psychotherapeutics for mood disorders in which 
there is a high and unmet medical need. 
To conclude, a reduction in postsynaptic proteins was observed depending on neurochemical 
composition, as well as selective loss in presynaptic proteins involved in SNARE complex 
facilitated exocytosis. This may indicate neuronal degeneration, although only mild and very 
selective neuronal loss in sgACC was observed in DLB cases with depression. Reduction in 
presynaptic proteins involved in regulation of neurotransmitter release and efficient exocytosis 
may indicate altered inputs to the sgACC, possibly due to degeneration or cell loss in the 
brainstem, amygdala and NAcc, which directly project to sgACC (Vogt et al., 1995, Vogt and 
Pandya, 1987). Patients with MDD show hyperexcitability in the sgACC (Greicius et al., 2007), 
which may suggest decreased inhibition and this correlates with the finding of changes in 
GABAergic and glutamatergic neurotransmission observed in this study, suggesting 
dysregulation in excitation and inhibition, contributing to the abnormal activity in sgACC in 
DLB. While the present findings did not show clear changes specific to DLB patients with 
depression, depressed patients show more pronounced dysfunction in GABAergic and 
glutamatergic neurotransmission, suggesting higher imbalance in excitation and inhibition 
compared to DLB cases without depression. There is therefore the potential to use selective 











The monoamine hypothesis of depression is well established, suggesting that changes primarily 
in serotonergic, but also noradrenergic and dopaminergic neurotransmission are the basis of 
depression (Stahl et al., 2003). There is considerable evidence in support of the hypothesis of 
abnormal serotonergic transmission in depression, with reduced concentrations of 5-HT in 
serum and reduced 5HIAA in CSF in patients with MDD (Bot et al., 2015, Asberg et al., 1976), 
along with decreased serotonin 5HT1A and 5HT2A binding in the ACC in depressed 
individuals (Wang et al., 2016, Baeken et al., 2012). Serotonergic neurotransmission is also 
impaired in DLB compared to AD patients with depression, with reduced 5-HT and metabolite 
concentrations in limbic regions (Vermeiren et al., 2015). However, reductions in levels of 5-
HT as a basis of depression have been challenged by several studies, primarily based on low 
and delayed response to 5-HT based therapies (Lacasse and Leo, 2005, Andrews et al., 2015, 
Ruhe et al., 2007, Karg et al., 2011).  
The noradrenergic system is involved in mediating stress responses and has been shown to be 
involved in the pathogenesis of depression (Goddard et al., 2010). Post-mortem studies in 
MDD have shown reduced noradrenaline transporter binding in the LC and other limbic 
regions, possibly due to a loss of noradrenergic innervation (Ordway and Klimek, 2001, 
Klimek et al., 1997). Elevated α2-adrenoceptor levels in platelets are seen in MDD patients 
(Kaneko et al., 1992, Garcia-Sevilla et al., 2004), with a decrease in α2-adrenoceptor density 
observed following antidepressant treatment with TCAs (Gurguis et al., 1999). The LC in DLB 
cases is severely affected by LB pathology (Jellinger, 2003a), which may also play a major role 
in the noradrenergic neuronal loss in the LC. Reduced noradrenergic innervation in ACC, 
amygdala and ventral striatum has been observed in PD patients with depression using [11C]-
RTI-32 PET imaging (Remy et al., 2005), as well as in DLB cases (Szot et al., 2006). This 
associates with an increase in the mRNA for TH and sprouting of dendrites in remaining 
neurones, potentially as a result of the compensatory changes due to noradrenergic neuronal 
loss in the LC. 
Dopamine plays a role both in reward and stress (Pignatelli and Bonci, 2015), with dysfunction 
of dopaminergic neurotransmission within the mesolimbic and mesocortical system 
contributing to anhedonia and loss of motivation in depressive disorders (Chaudhury et al., 
2013, Ben Zion et al., 2006, Berridge and Kringelbach, 2008). A significant reduction in DAT 
binding using [123I]-FP-CIT binding in the caudate and putamen was shown in anhedonic 
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depressed patients (Sarchiapone et al., 2006), as well as increased striatal D2 receptor binding 
in patients with MDD (D'Haenen and Bossuyt, 1994), which may suggest decreased dopamine 
turnover, as indicated by low HVA levels in the CSF in depressed patients (Reddy et al., 1992). 
The development of depressive symptoms in PD has been shown to be associated with 
mesolimbic dopaminergic pathway dysfunction, as demonstrated by reduced volume in VTA, 
cingulate and amygdala on MRI, as well as reduced [11C]RTI-32 dopamine and noradrenaline 
transporter binding in several limbic regions in PD patients with depression (Remy et al., 2005), 
which may relate to the loss of dopamine projections from the VTA.  
The sgACC is important in mood regulation, as well as in the symptomatic expression of 
depression, displaying structural, functional and metabolic abnormalities in depression and 
MDD (Drevets et al., 2008b, Rodriguez-Cano et al., 2014). However, little is known about how 
changes within monoaminergic neurotransmission in the sgACC might relate to development 
of depression in DLB, despite the high levels of α-synuclein pathology in the sgACC (see 
chapter 3). 
5.2Aims 
The aim of this study was therefore to investigate potential changes in monoaminergic 
neurotransmission in the sgACC in relation to depression in DLB. 
5.2.1 Objectives 
 To assess serotonergic and dopaminergic innervation in the sgACC using stereological
analysis in post-mortem tissue from DLB cases with and without depression, and in
normal controls.
 To assess whether phosphorylated α-synuclein (s129) induces changes in
monoaminergic synapses in the sgACC in relation to depression in DLB using STED
microscopy.
 To quantify protein levels of serotonergic, dopaminergic and noradrenergic markers
and receptors in the sgACC using frozen post-mortem tissue samples from DLB cases
with and without depression and in normal controls.
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5.3 Methods 
Cases with as short a post mortem interval as possible were selected from the total DLB and 
control population for STED and stereological analysis, including 11 DLB cases with 
depression, 12 DLB cases without depression and 11 neurologically and psychiatrically normal 
controls (see section 3.3; Table 3.1). The cohort for protein analysis consisted of 12 DLB cases 
with depression, 12 DLB cases without depression and 12 normal controls with similar post 
mortem interval (see section 3.3; Table 3.3). 
Fixed tissue sections of the sgACC were used to estimate the number of serotonergic (5HTT) 
and dopaminergic (DAT) fibres between the groups using an adapted stereological method (see 
section 2.7.3). Noradrenergic fibres were not assessed as the available primary antibody did 
not provide cell or fibre labelling of the required specificity. Triple-colour STED microscopy 
was applied to assess DAT or 5HTT co-localisation with a presynaptic terminal marker 
(SNAP25) and phosphorylated α-synuclein (s129) in relation to depression in DLB (see 
sections 2.5.2, 2.6.3 and 2.7.4). Immunohistochemical findings were also complemented by 
biochemical assessment of neurotransmitters synthesizing enzymes and receptors involved in 
monoaminergic neurotransmission. A dot blot technique was employed using Near Infra-Red 
(NIR) detection for protein determination (see sections 2.8.4-2.8.6). The specific proteins were 
quantified using Image Studio Lite (see section 2.8.7) and normalised against GAPDH. All of 
the antibodies used in this study can be found in (Table 5.1), and showed bands of the correct 
molecular weight on western blotting. 
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Table 5.1 Antibodies used in monoaminergic study. 
DB – dot blot; IHC – immunohistochemistry; m – monoclonal; p – polyclonal; Ms – mouse; 
Rb – rabbit, Gt – goat, Dk – donkey. 
5.4 Results 
5.4.1 Dopaminergic Projections 
The sgACC receives dopaminergic afferent projections from the VTA (Berridge and 
Kringelbach, 2008), and therefore the assessment of the number of pigmented dopaminergic 
Antigen Host/Ig Antibody Dilution Source Product Code
5HT1A pRb (IgG) 1:1000 (DB) Abcam ab227165
5HT2A pRb (IgG) 1:100 (DB) Abcam ab66049
5HT3B pRb (IgG) 1:500 (DB) Abcam ab39629
5HTT mMs (IgG1) 1:1000 (DB), 1:500 (STED) MAb Technologies ST51-2
s129 pRb (IgG) 1:50 (STED) Abcam ab168381
D2DR pRb (IgG) 1:500 (DB) Abcam ab130295
D3DR mRb (IgG) 1:1000 (DB) Abcam ab155098
D4DR mMs (IgG1) 1:500 (DB) Santa Cruz sc136169
Donkey Anti-Sheep 594 Dk (IgG) 1:50 (STED) Life Technologies A11016
DDC mMs (IgG1) 1:500 (DB) Atlas Antibodies AMAb91089
DBH pRb (IgG) 1:500 (DB) Atlas Antibodies HPA002130
DAT mMs (IgG1) 1:250 (DB),1:20 (STED) Atlas Antibodies sc32258
Goat Anti-Rabbit Atto 647N Gt (IgG) 1:50 (STED) Sigma-Aldrich 40839
Goat Anti-Mouse 532 Gt (IgG) 1:50 (STED) Life Technologies A11002
NET mMs (IgG1) 1:500 (DB) Atlas Antibodies AMAb91116
SNAP25 pSh (IgG) 1:100 (STED) LifeSpan BioSciences LS-C94834
TPH-2 mMs (IgG1) 1:500 (DB) Atlas Antibodies AMAb91108
TH pRb (IgG) 1:500 (DB) Abcam ab112
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neurones in the VTA, as well as DAT positive fibres in the sgACC between the three 
experimental groups was carried out in this study. Dopaminergic fibres compared to 
serotonergic were less abundant in the sgACC. DAT positive processes showed numerous 
"swellings" or varicosities (Figure 5.1 A). The number of DAT positive dopaminergic fibres in 
the sgACC was significantly different between the groups (F(3, 43)=9.440, p<0.001), with 
significantly lower fibre density observed in DLB cases with depression compared to controls 
(p<0.001; Figure 5.1 B). The number of neurones in the VTA was significantly different 
between the groups (F(3, 81)=3.027, p=0.034), with significantly lower neuronal counts 
observed in the DLB group overall compared to controls (p=0.043), with DLB cases without 
depression showing a trend towards significance (p=0.067; Figure 5.1 C). A weak negative 
correlation between the number of dopaminergic neurones in VTA and the number of 
dopaminergic fibres in sgACC was observed in DLB cases with depression (r=-0.580, 
p=0.048), whereas no correlations were observed in controls or DLB cases without depression 
(Figure 5.1 D). 
The above gross structural findings were extended by assessment of dopaminergic synapses 
(DAT and SNAP25 positive) in relation to phosphorylated α-synuclein (s129) in the sgACC 
using super-resolution STED microscopy (Figure 5.2). Due to the high resolution analysis 
provided by STED microscopy, a stereological approach to image analysis was not possible. 
No significant differences were observed in the percentage of dopaminergic synapses 
(p=0.582), dopaminergic axonal synapses (p=0.578), or dopaminergic synapses containing 
s129 between the groups (p=0.823; Figure 5.3). Since α-synuclein is known to interact with 
synaptic vesicle proteins (Burre et al., 2010), the volume of s129 α-synuclein was correlated 
with volumes of SNAP25 within synapses, to determine if the presence of pathological α-
synuclein affected synapses. A significant positive correlation between the volume (μm3) of 
DAT and SNAP25 was observed in DLB cases with depression (r=0.379, p=0.007), but not in 
DLB cases without depression or controls (Figure 5.4). A significant positive correlation was 
also observed between the volume (μm3) of s129 negative DAT and SNAP25 in DLB cases 
with depression (r=0.216, p=0.021), but not in DLB cases without depression or controls 
(Figure 5.5). 
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Figure 5.1 Stereological analysis of dopaminergic fibres and dopaminergic cells in sgACC. 
(A) Dopaminergic fibres (DAT positive) in sgACC and (B) pigmented dopaminergic neurones in the VTA were assessed using stereological
approaches in controls, DLB cases overall, DLB cases without (DLB-D) and DLB cases with depression (DLB+D) (Significant at * p<0.05 and
***p<0.001). (C) The relationship between neuronal number in the VTA and dopaminergic fibre density in the sgACC was assessed using
Spearman's correlation and was significant for DLB+D. (D) A micrograph of dopaminergic fibres in sgACC (X63 magnification; the error bar








Figure 5.2 STED imaging of dopaminergic synapses. 
A - STED 3D image of dopaminergic fibres (DAT; green), presynaptic terminals (SNAP25; yellow) and phosphorylated α-synuclein (s129; red); 
B - Deconvolved STED image; C and E - 3D surfaces of dopaminergic fibres and presynaptic terminals; D and F - 3D surfaces of presynaptic 
terminals and α-synuclein; G - 3D surfaces of co-localisation of all 3 channels. Scale bars represent (A-D) 0.5μm, (E-G) 0.1μm. 
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Figure 5.3 Analysis of dopaminergic synapses using Stimulated Emission Depletion (STED). 
The percentage of dopaminergic synapses present at synaptic terminals, synapses adjacent to dopaminergic axons, and synapses containing s129 
were assessed in the sgACC in age matched controls, DLB cases with (DLB+D) and without depression (DLB-D). Box plots represent the median 
(midline) and quartile ranges, with error bars representing the minimum and maximum values.
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Figure 5.4 Dopaminergic Synapse Correlation Analysis. 
The relationship between DAT and SNAP25 within synapses in the sgACC was assessed using 
STED microscopy data and Spearman’s correlation analysis in controls, DLB cases with 
(DLB+D) and without (DLB-D) depression. Significant correlations were observed between 






Figure 5.5 Effect of Phosphorylated Alpha-Synuclein (s129) Expression on Dopaminergic 
Synapses. 
A relationship between s129 negative DAT and SNAP25 volumes (μm3) within sgACC were 
assessed using Spearman’s correlation analysis in controls, DLB cases with (DLB+D) and 
without (DLB-D) depression. A significant correlation was observed between synapse DAT 
volume and SNAP25 volume in s129 containing synapses in DLB+D cases. 
To determine the impact of DLB on dopaminergic neurotransmission, a dot blot approach was 
used with validated antibodies against specific dopaminergic markers. TH (F(2, 34)=10.493, 
p<0.001), DAT (F(2, 34)=6.409, p=0.005) and DDC levels (F(2, 34)=4.224, p=0.023) were all 
significantly different between the groups in the sgACC. Significantly lower levels of TH 
(p=0.001), DAT (p=0.003) and DDC (p=0.033) were observed in DLB cases with depression 
compared to controls, as well as in DLB cases without depression compared to controls 
(p=0.002; Figure 5.6 A, C, E). No significant difference was observed in the levels of dopamine 
D2 receptors in the sgACC between the groups (F(2, 34)=0.704,  p=0.502; Figure 5.6 B). 
Dopamine D3 receptors (F(2, 34)=4.162, p=0.024) and dopamine D4 receptors (F(2, 
34)=3.338, p=0.048) were significantly different between the groups in the sgACC. A 
significantly lower dopamine D3 (p=0.034) and D4 receptor level (p=0.043) was observed in 
DLB cases with depression compared to controls (Figure 5.6 D, F). 



























Figure 5.6 Dot blot analysis of dopaminergic markers and receptors. 
Dopaminergic markers, including (A) tyrosine hydroxylase (TH), (C) dopamine transporter 
(DAT) and (E) dopamine decarboxylase (DDC), as well as dopamine D2, D3 and D4 (B, C, F) 
receptors were assessed in sgACC in age matched controls, DLB cases with (DLB+D) and 
without (DLB-D) depression. (*p<0.05, **p<0.05 and ***p<0.001, compared to appropriate 
group). Box plots represent the median (midline) and quartile ranges, with error bars 
representing the minimum and maximum values. 
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5.4.2 Serotonergic Projections 
Since serotonin neurotransmission abnormalities are thought to underpin much of the 
neurobiology of depression, serotonergic biomarkers were assessed in depression within DLB. 
The number of serotonergic fibres in the sgACC assessed using a stereological approach were 
not significantly different between the groups (F(2, 39)=1.694, p=0.197) (Figure 5.7). Using 
STED microscopy to analyse serotonergic markers, no significant difference in the percentage 
of presynaptic serotonergic terminals (F(2, 22)=1.258, p=0.299) or the proportion of 
serotonergic synapses containing α-synuclein was observed between the groups (F(2, 
22)=0.057, p=0.944). A significant difference was observed in the proportion of synapses 
adjacent to serotonergic axons between the groups (F(2, 22)=3.444, p=0.0465), with 
significantly higher proportion of axonal synapses in DLB cases with depression compared to 
DLB cases without depression (p=0.016; Figure 5.8). Using STED data, a significant positive 
correlation was observed between the volume of s129 α-synuclein within presynaptic terminals 
in DLB cases without depression (r=0.313, p=0.016) and DLB cases with depression (r=0.316, 
p=0.030) (Figure 5.9). A significant positive correlation was also observed between the volume 
(μm3) of s129 negative 5HTT and SNAP25 in DLB cases with depression (r=0.285, p=0.020), 
and DLB cases without depression (r=0.307, p=0.028) (Figure 5.10). 
Using the dot blot approach in frozen post mortem tissue from the sgACC, no significant 
changes in 5HTT (F(2, 34)=0.098, p=0.907), TPH-2 (F(2, 34)=2.149, p=0.133), 5HT1A 
receptor (F(2, 34)=0.375, p=0.690) was observed between the groups (Figure 5.11 A-C). A 
significant difference in 5HT2A receptor protein levels was observed in the sgACC between 
groups (F(2, 34)=5.093, p=0.012), with significantly lower 5HT2A receptor protein levels 
observed in DLB cases with depression compared to controls (p=0.017; Figure 5.11 D). 5HT3B 
receptor level was significantly different between the groups (F(2, 34)=3.838, p=0.032), with 
significantly lower 5HT3B receptor levels observed in DLB cases with depression compared 
to without (p=0.028; Figure 5.11 E). 
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Figure 5.7 Stereological analysis of serotonergic fibres in sgACC. 
Serotonergic fibres (5HTT positive; (A) – X10 magnification, error bar represents 100μm; (B) – X63 magnification, error bar represents 50μm) 
were assessed using a stereological approach in the sgACC in controls, DLB cases overall, cases without (DLB-D) and DLB cases with (DLB+D) 

























Figure 5.8 Analysis of serotonergic synapses using Stimulated Emission Depletion (STED). 
The percentage of (A) serotonergic synapses present at synaptic terminals, (B) synapses adjacent to serotonergic axons, and (C) synapses 
containing s129 α-synuclein were assessed in the sgACC in age matched controls, DLB cases with (DLB+D) and without (DLB-D) depression. 
(*, Significant at p<0.05). Box plots represent the median (midline) and quartile ranges, with error bars representing the minimum and maximum 
values.
160 
Figure 5.9 Effect of phosphorylated α-synuclein (s129) on Serotonergic Synapses. 
The relationship between 5HTT and SNAP25 within synapses in the sgACC was assessed 
using STED microscopy data and Spearman’s correlation analysis in controls, DLB cases with 
(DLB+D) and without (DLB-D) depression. Significant correlations were observed between 







Figure 5.10 Correlation analysis of α-synuclein negative serotonergic synapses. 
The relationship between s129 negative 5HTT and SNAP25 volumes (μm3) within sgACC was 
assessed using Spearman’s correlation analysis in controls, DLB cases with (DLB+D) and 
without (DLB-D) depression. Significant correlations were observerved between synapse 
5HTT volume and SNAP25 volume in s129 containing synapses in DLB+D and DLB-D cases. 






























Figure 5.11 Analysis of serotonergic markers and receptors in the sgACC. 
Serotonergic markers, including (A) serotonin transporter (5HTT), (B) tryptophan 
hydroxylase-2 (TPH-2), and serotonin receptors 5HT1A, 5HT2A and 5HT3B (C-E) were 
assessed using a dot blot approach with validated antibodies in post mortem frozen tissue from 
the sgACC of age matched controls, DLB cases with (DLB+D) and without (DLB-D) 
depression. (**p<0.01, compared to control group). Box plots represent the median (midline) 
and quartile ranges, with error bars representing the minimum and maximum values. 
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5.4.3 Noradrenaline 
Due to a lack of specific staining for NET, no immunohistochemical analysis of noradrenergic 
innervation into the sgACC was possible. Using dot blotting, no significant changes were 
observed in DBH levels between the groups in the sgACC (F(2, 34)=2.642, p=0.087). A 
significant difference in NET levels was observed between the groups (F(2, 34)=7.842, 
p=0.002), with significantly lower NET levels observed in DLB cases with depression 
(p=0.008) and DLB cases without depression compared to controls (p=0.003; Figure 5.12). 
Figure 5.12 Analysis of noradrenergic markers in the sgACC. 
Noradrenergic markers, including (A) noradrenaline transporter (NET) and (B) dopamine beta-
hydroxylase (DBH) were assessed in sgACC in age matched controls, DLB cases with and 
without depression. (**p<0.010, compared to control group). Box plots represent the median 
(midline) and quartile ranges, with error bars representing the minimum and maximum values. 
5.5 Discussion 
Monoaminergic abnormalities have been a mainstay of the neurobiology of depression with 
altered serotonin neurotransmission being a major theory in the aetiology and treatment of 
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depression. The sgACC shows structural and functional abnormalities in depression (Drevets 
et al., 2008b, Rodriguez-Cano et al., 2014), as well as high LB pathological burden in DLB. 
Little is known however, about how changes within monoaminergic neurotransmission within 
the sgACC relate to development of depression in DLB. The present results suggest that 
primarily there is a reduced dopaminergic drive associated with depression in DLB, with 
reduced dopaminergic innervation in the sgACC in DLB cases with depression, along with 
reduced levels of dopaminergic markers and receptors, as well as changes in dopaminergic 
synaptic function. This contrasts with little change in serotonin markers in depression in DLB, 
although noradrenergic markers are reduced. 
The mesolimbic and mesocortical dopamine pathway sends projections from the VTA to 
various cortical and subcortical regions including the ACC. Dopaminergic neurones in the 
VTA play a role in both reward and stress (Pignatelli and Bonci, 2015), with dysfunction of 
dopaminergic neurotransmission within the mesolimbic system contributing to anhedonia and 
loss of motivation in depressive disorders (Chaudhury et al., 2013). In this study, a subtle 
decrease in VTA dopaminergic neurone number was found in the DLB group overall compared 
to controls. This was not however significant when separated into DLB with and without 
depression, which may suggest that due to low numbers in each group there is insufficient 
statistical power to detect the difference. Compared to the SN, the VTA is suggested to show 
a relative preservation in terms of the cell loss in PD (Alberico et al., 2015, Gibb and Lees, 
1988). This may be due to co-expression of calbindin on VTA dopaminergic neurones, which 
is suggested to be neuroprotective and may potentially explain why VTA neurones are resistant 
to α-synuclein (Pan and Ryan, 2012, Maingay et al., 2006), but also that a subgroup of calretinin 
expressing dopaminergic neurones are protected in both the VTA and SN in PD (Mouatt-
Prigent et al., 1994). Studies have shown that counting SN neurones in PD using a single 
section provides reliable estimates of cell loss (Ross et al., 2004b, Ma et al., 1995). It is unclear 
if the similar counting approach of using a single section used in this study provides reliable 
estimates of VTA neuronal loss. Supporting present findings in DLB, some studies indicate 
loss of VTA neurones in PD (Torack and Morris, 1992, Seidel et al., 2015, Uhl et al., 1985), 
indicating that VTA neurones are not necessarily protected in Lewy body disorders, and that 
in DLB, VTA neurones are lost.  
In the nonhuman primate the sgACC dopaminergic innervation gradient is denser within the 
superficial cortical layers (Williams and Goldman-Rakic, 1993), with DAT positive processes 
showing numerous "swellings" or varicosities similar to the findings of this study (see Figure 
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5.1). In this study, dopaminergic innervation in all cortical layers in the sgACC, and reduced 
dopaminergic fibre density was observed in sgACC in DLB cases with depression compared 
to controls, which may indicate reduced innervation from the VTA, corresponding with present 
finding of reduced VTA neurone numbers in DLB overall. In PD, the first motor symptoms 
appear when about 50% of SN dopamine neurones are lost (Ross et al., 2004a), whereas the 
extent of striatal damage at the time of the onset of motor symptoms is much more severe, 
showing about 80% of dopamine loss (Bernheimer et al., 1973). The axons and their terminals 
are suggested to be the main site of pathology, with the neurodegenerative process in PD 
thought to follow a retrograde pathway originating in the striatal terminals (Hornykiewicz, 
1998). This may explain the present finding of significant dopaminergic fibre loss in DLB cases 
with depression in this study, without significant VTA neuronal loss in depressed DLB patients. 
These findings of reduced dopaminergic fibre density in DLB cases with depression are similar 
to the finding of decreased dopamine metabolites in cortical regions in PD (Scatton et al., 1982) 
and levels of dopamine (and noradrenaline) transporter determined using [11C]-RTI-32 PET 
imaging in the ACC, that has been observed in depressed PD patients (Remy et al., 2005). 
In this study,a decrease in dopaminergic neurotransmission markers was observed, almost 
selectively in DLB cases with depression compared to controls, including DAT, TH and DDC. 
This is in line with other studies suggesting a decrease in extracellular dopamine levels to be 
implicated in depression (Lambert et al., 2000), with some antidepressants shown to enhance 
neurotransmission in dopamine within the mesolimbic system (Maj et al., 1987). Reduced DAT 
binding in the striatum was observed in depressed patients with anhedonia (Sarchiapone et al., 
2006), as well as in PD and DLB, with DLB cases showing more severe loss of DAT binding 
in caudate compared to PD (Walker et al., 2004). 
STED based analysis showed the presence of α-synuclein within dopaminergic synapses in the 
sgACC (see Figure 5.3). In depressed DLB cases, the presence of α-synuclein showed a 
positive correlation with SNAP25, where elevated α-synuclein corresponded significantly with 
elevated SNAP25 (Figure 5.4), a finding also seen within serotonergic terminals (Figure 5.9). 
One possibility is that pathological α-synuclein causes sequestration of SNAP25 within 
synapses leading to synaptic dysfunction. Alpha-synuclein is a presynaptic protein that 
modulates synaptic activity through effects on vesicle recycling and release (Burre et al., 2010, 
Burre et al., 2014, Diao et al., 2013). Endogenous α-synuclein in particular, promotes synaptic 
vesicle generation by assisting with the formation of SNARE complexes (Chandra et al., 2005, 
Burre et al., 2014, Sun et al., 2019). Pathological fibrillar α-synuclein can however rapidly 
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promote aberrant synaptic activity following application to neurones (Wu et al., 2019, 
Volpicelli-Daley et al., 2011a). In forming macromolecular aggregates within synapses, 
fibrillar α-synuclein may lead to an effective depletion of the endogenous pool of functional 
SNARE proteins including SNAP25, reducing formation of a functional synaptic vesicle pool. 
Fibrillar and oligomeric α-syn also has direct effects on synaptic machinery with further 
depletion of SNARE complexes (Choi et al., 2013, Larson et al., 2017, Rockenstein et al., 
2014). This may underscore the observed increase in SNAP25 seen within α-synuclein 
containing synapses, with SNAP25 increased, but non-functional due to being sequestered in 
α-synuclein aggregates (Choi et al., 2018). 
Dopamine exerts its action by binding to dopaminergic receptors with dopamine D2 and D1 
receptors typically expressed at high levels in the striatum (Ng et al., 1994, Bates et al., 1991). 
D1 receptors are highly expressed in the striatum, as well as in mesolimbic and mesocortical 
areas (Cortes et al., 1989). PET studies on D1 receptors in affective disorders are scarce, 
however, patients with MDD show lower D1 receptor binding in frontal cortex and striatum 
(Suhara et al., 1992, Dougherty et al., 2006). A novel allosteric potentiator of the dopamine D1 
receptor (DETQ) was shown to amplify the effects of endogenous dopamine transmission 
improving when and where dopamine is released, showing promise in applications in treatment 
of PD and neuropsychiatric disorders (Bruns et al., 2018). The highest levels of D2 dopamine 
receptors are expressed in the striatum, NAcc and the olfactory tubercle, with significant levels 
in the SN, VTA, hypothalamus, amygdala, hippocampus and cortical areas. In PD, progressive 
loss of dopaminergic neurones in SN results in reduced dopamine levels in the striatum. An 
increase in D2 receptor density in the striatum has been observed in PD (Rinne et al., 1995), 
which may suggest an involvement of compensatory mechanism in response to low dopamine 
levels. Increased dopamine D2/D3 receptor binding and lower DAT activity has been shown 
in depression, possibly reflecting compensatory changes due to the impairment in mesolimbic 
dopaminergic neurotransmission (Klimek et al., 2002, Allard and Norlen, 2001).  
Dopamine D3 receptors are expressed on postsynaptic and presynaptic dopaminergic neurones, 
and have the highest affinity for dopamine and dopamine agonists (Sokoloff et al., 2006). The 
dopamine D3 receptor is a primary target within the mesolimbic dopamine system, with highest 
level of expression observed in the limbic areas (Sokoloff et al., 1992). In the amygdala, 
dopamine D3 receptor expression is primarily observed on target glutamatergic neurones as a 
postsynaptic modulatory receptor (Li and Kuzhikandathil, 2012). The dopamine D3 receptor 
has been shown to be clinically relevant as a therapeutic target for depression. A number of 
167 
relatively non-specific agonists (aripiprazole, pramipexole and ropinirole) and selective 
antagonists (SB-277011-A) of the dopamine D3 receptor have been developed that have been 
shown to have antidepressant and anxiolytic effects in humans and animals (Tadori et al., 2011, 
Zarate et al., 2004, Rogoz et al., 2004, Leggio et al., 2013, Reavill et al., 2000). Downregulation 
of the expression of dopamine D3 receptors has been shown in MDD (Leggio et al., 2013). 
While no changes were identified in dopamine D3 receptor density in the striatum in a monkey 
model of PD following loss of dopaminergic innervation (Hurley et al., 1996), a reduction in 
dopamine D3 receptors, particularly in ventral striatum, has been observed in PD cases (Joyce, 
1993). Furthermore, L-DOPA treatment has been shown to alter expression of dopamine D3 
receptors in the striatum and SN of parkinsonian primates (Sanchez-Pernaute et al., 2007). 
Other studies have shown elevated dopamine D3 receptor binding in non-demented PD cases, 
but with reduced dopamine D3 receptor binding in PD cases with dementia (Joyce et al., 2001), 
which may suggest that dopamine D3 receptors are also involved in modulating cognitive 
function. The present results suggest that reduced dopamine D3 receptor levels may play a role 
in depression in DLB patients. Therefore, the dopamine D3 receptor could be target for the 
development of more specific dopamine based treatments for depression. Dopamine D3 
receptor agonists have been used in treatment of dyskinesia in PD and the dopamine D2/D3 
agonist piribedil has been shown to reduce apathy in PD indicating potential benefits that could 
be applied to DLB (Thobois et al., 2013). 
The dopamine D4 receptor has the lowest levels of expression in the brain, with higher receptor 
densities in anterior regions of the limbic and cortical forebrain, which may suggest its function 
is in modifying executive and behavioural regulation (Rondou et al., 2010). Dopamine D4 
receptor polymorphisms in FTD have been shown to be associated with greater behavioural 
apathy and atrophy in the ACC, suggesting involvement in mood (Butler et al., 2019). The 
findings of the present study demonstrated reduced dopamine D4 receptor levels in the sgACC 
in DLB cases with depression compared to without, suggesting a possible role in depression in 
DLB. The antidepressant Roxindole is a relatively selective dopamine D4 receptor agonist with 
a known clinical safety profile and while Roxindole has been used in PD for treatment of 
dyskinesia, effects on mood were not noted (Bravi et al., 1993). 
Studies of the serotonergic system in neurodegenerative disorders and in relation to depression 
has focused on both pathological and receptor changes. The dorsal raphe, the major cell group 
involved in forebrain serotonin innervation, is severely affected by LB pathology in DLB and 
PD, which might explain the loss of serotonergic innervation to the forebrain (Ballard et al., 
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2013, Sharp et al., 2008). Neurones in the raphe are also affected by NFT pathology and 
neurone loss observed in AD, although there does not appear to be any appreciable difference 
in neuronal numbers using stereological approaches between depressed and non-depressed AD 
subjects (Hendricksen et al., 2004). This also correlates with findings in late onset depression 
where dorsal raphe neurone pathology or neurone counts do not relate to symptoms (Syed et 
al., 2005). Serotonergic neurotransmission has been suggested to be severely impaired in DLB 
compared to AD patients with depression, with reduced 5-HT and its metabolite concentrations 
observed in the PFC, temporal, limbic, occipital cortex and hippocampus (Vermeiren et al., 
2015). In the present study, no changes in serotonergic innervation in the sgACC was observed 
in DLB cases overall or in relation to depression, and additionally no changes in protein levels 
of serotonin transporter. Other studies have observed reduced 5HTT levels in the raphe nuclei 
in PD patients compared to controls using in vivo PET imaging (Guttman et al., 2007, Murai 
et al., 2001, Politis et al., 2010a), with an increase in 5HTT binding in the dorsal raphe and 
limbic regions in PD patients with depression (Politis et al., 2010b). An increase in 5-HT 
concentrations in the ACC in depressed DLB patients has been suggested (Vermeiren et al., 
2015), which may be a compensatory mechanism for the decreased serotonergic 
neurotransmission overall in DLB in neocortical and limbic projection areas. No changes in 
the levels of 5HT1A receptor were observed in the sgACC between the groups, which is in 
contrast to a previous study that found decreased serotonin 5HT1A binding in ACC in depressed 
patients using PET imaging (Wang et al., 2016). The present finding does correspond with 
previous studies in depression in DLB/PDD where there was no significant change in [3H]-
8OH-DPAT binding in the inferior temporal gyrus (BA20), although a significantly increased 
5HT1A level was found in the fusiform gyrus (BA36) in depressed DLB/PDD cases (Sharp et 
al., 2008). A decrease in 5HT2A binding in ACC and DLPFC was observed in treatment 
resistant depression (Baeken et al., 2012), which is in line with current results, showing reduced 
levels of 5HT2A  receptors in sgACC in DLB cases with depression compared to controls, 
which may suggest selective and region specific serotonergic receptor changes. This also 
correlates with ligand binding studies of the 5HT2A receptor in DLB, PD, and AD, where 
reduced binding was observed across all disease states (Cheng et al., 1991). 
Whilst studies have shown loss of neurones from the dorsal raphe in AD (Hendricksen et al., 
2004) and the presence of LB and LN pathology in Parkinson’s disease (Seidel et al., 2015), 
there appears not to be any significant neuronal loss from the dorsal raphe in PD (Frisina et al., 
2009, Cheshire et al., 2015). This absence of neuronal loss in PD is despite alterations in the 
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levels of 5-HT metabolites (Cheshire et al., 2015, Kish et al., 2008). In one large study using 
PET imaging with [123I]-FP-CIT in PD, reduced 5HTT activity in PD was not associated with 
depression or anxiety (Qamhawi et al., 2015). In early de novo PD, 5HTT was unaltered in 
cortical regions including sgACC,  as measured using [11C]DASB PET (Strecker et al., 2011), 
suggesting that changes in 5HTT may be a late event, since in established PD, 5HTT levels 
were altered predominantly in subcortical structures (Guttman et al., 2007). Treatment may 
also play a role in 5HTT expression (Strecker et al., 2011), since L-DOPA administration may 
change 5HTT levels in PD (Beucke et al., 2011). Similarly, DLB cases may not have reduction 
in 5HTT in cortical regions based on [123I]-FP-CIT binding (Joling et al., 2018). In one post 
mortem study, 5HTT measured using [3H] cyanoimipramine binding was preserved in DLB 
cases with depression, but reduced in DLB cases without depression (Ballard et al., 2002a). 5-
HT levels are suggested to be reduced in cortical regions in DLB (Ohara et al., 1998, PERRY, 
1993), suggesting that despite a potential lack of change in raphe neurone number, there may 
be altered activity of serotonergic systems in DLB. Loss of other serotonergic neurones in PD 
has been described, including from the pontine and medullary raphe (Halliday et al., 1990) 
along with α-synuclein pathology (Seidel et al., 2015). These neuronal groups however project 
to subcortical, cerebellar and brainstem structures rather than neocortical regions. It is possible 
therefore, that changes in serotonergic function are apparent in DLB, as with PD, but that these 
do not relate the dorsal raphe, but to other midline serotonergic nuclei, and may explain the 
finding of changes in striatal 5HTT activity in PD (Qamhawi et al., 2015). In the current study, 
due to the complexity of the dorsal raphe anatomy and its different projection sites (Ren et al., 
2018) and the lack of evidence of changes in established PD, the dorsal raphe neurone numbers 
were not assessed in this DLB cohort. Future studies should determine, using appropriate 
stereological approaches and anatomical markers, the effects of α-synuclein pathology in DLB 
in the brainstem and midbrain serotonergic system. 
Noradrenergic LC projections innervate multiple brain areas involved in the pathophysiology 
of depressive states, with dysregulation of noradrenaline involved in the pathogenesis of 
anxiety and depression (Goddard et al., 2010). The noradrenaline transporter (NET) is 
responsible for the rapid reuptake of noradrenaline into presynaptic terminals, and is involved 
in mediating behavioural responses to stress (Haenisch and Bonisch, 2011). The present results 
show reduced NET levels in the sgACC in DLB patients with and without depression compared 
to controls, which may indicate reduced noradrenergic innervation in the sgACC due to 
noradrenergic neuronal degeneration of the LC, commonly observed in DLB and PD, and also 
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in AD  (Szot et al., 2006, Paulus and Jellinger, 1991, Ordway and Klimek, 2001, Klimek et al., 
1997, Seidel et al., 2015, Haglund et al., 2016). As no reduction in DBH protein levels were 
observed in DLB, this may limit the findings of reduced NET. One suggestion is that surviving 
LC neurones may increase innervation into various regions as a compensatory mechanism 
leading to preserved levels of certain noradrenergic markers (Leverenz et al., 2001). 
The LC in DLB cases is however, severely affected by α-synuclein pathology (Seidel et al., 
2015, Jellinger, 2003a), which may be a major contributor to the neuronal loss observed in the 
LC. Reduced noradrenergic innervation in the ACC, amygdala and NAcc has been shown in 
PD patients with depression based on PET studies using a DAT/NET ligand (Remy et al., 
2005), suggesting noradrenergic system involvement in both depression and 
neurodegeneration. Similarly, in AD LC neurone loss correlates with depression (Forstl et al., 
1992), although depression does not appear to relate to LC neuronal pathology despite marked 
neuronal loss (Hoogendijk et al., 1999). A limitation of the current study is the lack of 
investigation of detailed pathology of noradrenergic systems in DLB. As the available antibody 
to NET did not provide suitable staining, the NET fibre density in the sgACC in DLB or LC 
neurone numbers could not be determined. Further investigation, using neuronal and fibre 
counting in an analogous manner to those used for dopaminergic and serotonergic systems, 
along with investigation in AD and PD cases for comparison would be beneficial in 
determining any role of noradrenaline in depression in DLB. LC cell counts in DLB show 
similar reductions to those found in AD (Leverenz et al., 2001), however, the LC has a 
widespread projection area to cortical, subcortical, cerebellar and brainstem structures. Using 
markers that identify specific cortically projecting neurones, or those LC neurones that 
innervate structures such as the VTA involved in depression (Isingrini et al., 2016) would 
provide suitable tools to accurately investigate the role of the LC and noradrenaline in 
depression in DLB.  
In summary, a major effect of dopaminergic system degeneration of the VTA was observed in 
relation to depressive symptoms in DLB. Changes in serotonergic and noradrenergic markers 
appear to be less involved in the aetiology of depression in DLB. Careful treatment with 
selective dopaminergic agonists or positive allosteric modulators may therefore be of benefit 






Depression is a common illness, with more than 264 million people affected worldwide 
(Disease et al., 2018), and is a leading cause of disability that impacts all aspects of everyday 
life (Steger and Kashdan, 2009). Almost one in five people will experience depression at some 
point in their lifetime (Malhi and Mann, 2018), with depression arising from a complex 
interaction of social, psychological and biological factors. 
The clinical symptoms associated with major depressive disorder (MDD; as defined by DSM-
IV criteria) implicates many neural systems involved in the regulation of mood, anxiety, reward 
processing, attention, motivation and stress responses (Price and Drevets, 2012). Structural and 
functional studies in MDD have identified several brain regions that are changed and 
potentially involved in the pathophysiology of depression, such as the prefrontal cortex (PFC), 
orbitofrontal cortex, amygdala, hypothalamus, various brainstem nuclei and the anterior 
cingulate cortex (ACC) (Price and Drevets, 2012, Ongur et al., 2003, Price and Drevets, 2010). 
The ACC, especially the subgenual region (sgACC), is integral in mood regulation, as well as 
in the symptomatic expression of depression, displaying structural, functional and metabolic 
abnormalities (Drevets et al., 2008b, Rodriguez-Cano et al., 2014). The sgACC is activated 
during simple emotions, such as sadness, and deep brain stimulation (DBS) of the sgACC has 
been shown to partially alleviate the symptoms associated with depression (Mayberg et al., 
2005). Furthermore, increased metabolism in the sgACC has been shown to be involved in 
MDD (Greicius et al., 2007, Mayberg et al., 2005), with decreased sgACC activity observed in 
response to antidepressant medication or ECT in treatment resistant depression (Baeken et al., 
2015) underscoring the importance of the sgACC as a region intimately involved in the 
pathophysiology of depression. 
Depression is a common psychiatric symptom in DLB, observed in around half of DLB 
patients, often occurring in prodromal stages (Fujishiro et al., 2015). Depression in DLB is also 
associated with faster cognitive decline, higher mortality rates and a poor response to available 
treatment (Ritchie et al., 1998). The basis of depression in DLB is therefore of major 
importance in understanding the underlying cause of this major symptom and identifying 
treatments that would lead to improved quality of life in patients. In DLB, the ACC is a 
predilection site for the formation of LB, showing early and extensive α-synuclein pathology 
(Thal et al., 2004, Toledo et al., 2016). However, it is not known how pathological or 
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biochemical abnormalities in the ACC and in particular the sgACC may relate to depression in 
DLB. 
6.2 Key findings 
 Pathology does not play a direct role in depression in DLB
 Imbalance in excitatory and inhibitory systems more pronounced in DLB with
depression
 Dopaminergic drive of depression in DLB
6.2.1 No relationship between pathology and depression in DLB 
This study showed no direct relationship between pathological burden in the sgACC and 
depression in DLB. Studies assessing neuropathological changes in relation to depression in 
patients without dementia or in AD are scarce. While some studies have suggested the presence 
of LB in amygdala to be associated with increased risk for MDD in AD (Lopez et al., 2006), 
others have indicated that higher levels of NP and NFT burden in the hippocampus in AD 
patients associates with depression (Rapp et al., 2006). These studies investigating pathology 
and depression in AD have analysed regions that are anatomically associated with depression 
such as the amygdala and hippocampus, and therefore these findings may have direct relevance. 
In line with current findings however, one study found no association between depressive 
symptoms in DLB or AD and severity of cortical or subcortical LB pathology (Samuels et al., 
2004), with again a focus on regions associated with the biology of depression. It is possible 
that, while pathology in AD may associate with depression, differences in the underlying neural 
systems affected in DLB will mean that AD neuropathological changes in DLB have less of an 
effect in promoting depression.  
The present findings also showed that α-synuclein pathological burden was most severe in 
ACC compared to other cingulate subregions in DLB cases, including within the sgACC. 
Although considerable pathological burden was observed in the ACC and sgACC, no major 
changes in neuronal density were observed in DLB. This may suggest that pathology may be 
initiating neuronal dysfunction rather than cell death. The substrates of depression in DLB 
appear therefore to be independent of gross pathology. Changes to different aspects of neuronal 
function, such as synaptic abnormalities, may be caused initially by pathological deposition of, 
for example, α-synuclein. Once these changes in function occur however, an essentially 
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autonomous process is activated where pathology can increase over a background of already 
established dysfunction. Furthermore, since depression is caused by changes to specific 
neuronal systems, using gross pathological measures may simply obscure the fine detail needed 
to observe only depression specific pathological changes (cf. monoaminergic studies).     
The biochemical analysis of pathological changes within the sgACC largely reiterated 
immunohistochemical results, showing no association between pathology in sgACC and 
depression in DLB. In sgACC the highest level of s129 α-synuclein, a suggested marker of 
pathological α-synuclein, was detected in insoluble membrane bound fractions of the tissue. 
This may suggest that the majority of α-synuclein is sequestered in insoluble pathological 
aggregates. These pathological aggregates while demonstrating presence of disease, may lack 
sufficient specificity to show changes only associated with depression, which may be in a 
subset of neurones. 
6.2.2 Imbalance in GABAergic/glutamatergic neurotransmission. 
The sgACC shows increased metabolism in patients with MDD (Greicius et al., 2007) and this 
may suggest dysregulation in excitation and inhibition.  In this study, DLB patients with 
depression show more pronounced dysfunction in GABAergic and glutamatergic 
neurotransmission than DLB patients without depression, suggesting a greater imbalance in 
excitation/inhibition (E/I). 
Reduction in postsynaptic proteins involved in GABAergic and glutamatergic 
neurotransmission, as well as selective loss in presynaptic proteins involved in SNARE 
complex facilitated exocytosis in the sgACC may indicate altered inputs to the sgACC. 
Changes to pre- and postsynaptic markers may be due to dysfunction or degeneration of other 
brain regions involved in emotional processing, with afferent projections to the sgACC, 
including brainstem, VTA, amygdala and NAcc (Vogt et al., 1995, Vogt and Pandya, 1987). 
Certainly, reduced VTA neurone numbers may be a feature of DLB based on current 
investigations. Synaptic dysfunction within the sgACC is however supported by  observation 
of unchanged numbers of GABAergic or glutamatergic synapses but with an accompanying 
increase in the average size of glutamatergic synapses in the DLB group. This increase in size 
may be a result of a compensatory response to the accumulation of pathological phosphorylated 
α-synuclein. The present results are in line with other studies, showing significant increase in 
the size of glutamatergic synapses and presynaptic terminals containing phosphorylated α-
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synuclein (Nakata et al., 2012, Colom-Cadena et al., 2017). The increase in synapse size may 
be simply due to the presence of a physically large protein aggregate, however other 
compensatory mechanisms, such as hypertrophy to increase declining synaptic activity may 
occur (Reeve et al., 2018). Further work to determine the effects of α-synuclein at a synaptic 
level would therefore be of interest. 
In this study, no overall changes in GABAergic cell density within the sgACC and no changes 
in GAD65/67 protein levels was observed between the groups. However, DLB cases with 
depression showed reduced GABAergic cell density in layer V, and reduced parvalbumin (PV) 
and calbindin (CB) protein levels in the sgACC, indicating highly selective changes affecting 
only certain populations of interneurones. These findings are consistent with other post mortem 
studies showing reduced CB neurone density in occipital and PFC in MDD (Rajkowska et al., 
2007, Maciag et al., 2010), as well as reduced CB neurone density in layer II of the ACC in 
schizophrenia and bipolar disorder patients (Cotter et al., 2002). A decrease in PV gene 
expression in sgACC post-mortem tissues has also been observed in MDD (Tripp et al., 2012), 
with PV interneurones shown to contribute to regulation of E:I within the PFC, influencing 
emotional responses (Ferguson and Gao, 2018). GABAergic interneurones belong to a very 
heterogeneous group of cells that differ based on their morphological phenotypes (basket cells, 
Martinotti cells, chandelier cells, Cajal-Retzius cells, double-bouquet cells, long-range 
GABAergic projecting cells) (DeFelipe et al., 2013), neurochemical properties (PV, 
somatostatin (STT) and 5-HT3A receptor-expressing interneurones) (Lee et al., 2010, Rudy et 
al., 2011), and varying electrophysiological properties (fast-spiking cells, non-fast-spiking, 
adapting cells, accelerating cells, irregular-spiking cells, intrinsically bursting cells) 
(Riedemann, 2019). STT expressing interneurones constitute around 30% of all GABAergic 
interneurones. Downregulation of STT gene expression has been observed in DLB (Khundakar 
et al., 2016) and MDD (Tripp et al., 2011) and this may correlate with present observation of 
a loss of CB in the sgACC in DLB, since CB identifies SST expressing Martinotti cells within 
the cortex. Reduced SST expression in the sgACC has been observed across all cortical layers 
in sgACC in MDD cases (Tripp et al., 2011, Seney et al., 2015) and how SST neurones are 
affected in DLB would be of major interest. This intrinsic vulnerability of SST positive 
neurones in MDD and also DLB might result in increased excitation of pyramidal cells, and 
further dysregulation in E/I balance. Therefore, a more in depth assessment of specific loss or 
dysfunction of certain types of interneurones such as CB positive Martinotti cells or PV 
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expressing chandelier cells may provide clues to their role in neurodegeneration, as well as 
neuropsychiatric diseases. 
Downregulation of glutamatergic and GABAergic receptors is often observed in MDD (Feyissa 
et al., 2009, Luscher et al., 2011, Sequeira et al., 2007). Selective reduction in NMDA2B and 
GABAAα5 and α3 receptor subunits was seen in DLB cases with depression in the present 
study, therefore, selective targeting of specific receptors might lead to more effective 
psychotherapeutics for treatment of depression in DLB. Recent advances in the development 
of fast-acting antidepressants to overcome current therapeutic limitations of monoaminergic 
drugs has resulted in the development of more selective glutamatergic and GABAergic agents. 
Esketamine, a non-competitive NMDA receptor antagonist has been recently approved for use 
in treatment resistant MDD (Jauhar and Morrison, 2019). Selective targeting of the NMDA2B 
receptor by using the antagonists MK-0657 and CP-101,606, has also been shown to be 
effective in treating depression without serious side effects (Preskorn et al., 2008, Ibrahim et 
al., 2012). The use of NMDA antagonists such as memantine which is effective in the treatment 
of mild to moderate DLB could therefore be explored for specific effects on depression (Emre 
et al 2010). Similarly, positive modulators of GABAAα5 (Piantadosi et al., 2016) and α3 
receptor subunits (Fava et al., 2011) have shown antidepressant efficacy in animal and human 
studies and also cognitive enhancing properties (Jacob, 2019). GABAAα5 negative allosteric 
modulators such as MRK-016 and L-655,708 have also shown promise in alleviating 
depressive symptoms in animal models (Fischell et al., 2015, Zanos et al., 2017), and also 
demonstrate cognitive enhancing properties in preclinical models. Using GABAAα5 
modulation of synaptic or extrasynaptic receptors might be a therapeutic target for use in DLB. 
The GABAergic dysfunction in MDD may be due to downregulation of specific receptors, 
whereas GABAergic deficits in DLB may reflect a loss of intrinsic neurones and synapses that 
express these receptors.  
The present findings provide a platform for much needed future research in depression in DLB. 
While α-synuclein pathology in glutamatergic and GABAergic synapses was observed in the 
sgACC, possibly contributing to synaptic dysfunction and development of depression in DLB, 
given the wide diversity of cortical interneurones, it is not known which specific interneurone 
populations are the most affected by pathological changes. To address this, further 
neuropathological, biochemical and transcriptomic studies are much needed. To determine the 
effects of α-synuclein on specific interneurone populations, future studies should use targeted 
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single cell nuclei RNA sequencing to identify the molecular changes caused by α-synuclein in 
vulnerable cell groups. 
6.2.3 Dopaminergic drive of depression in DLB 
Monoaminergic abnormalities in depression are well established (Moore and Bloom, 1979). 
DLB patients show abnormalities in serotonergic (Vermeiren et al., 2015, Ballard et al., 2013, 
Sharp et al., 2008), noradrenergic (Ohara et al., 1998) and dopaminergic neurotransmission 
(Walker et al., 2004). Little is known however, of how changes within monoaminergic 
neurotransmission within the sgACC relate to development of depression in DLB. These results 
suggest that primarily there is a reduced dopaminergic drive associated with depression in 
DLB, with reduced dopaminergic innervation in the sgACC, along with reduced levels of 
dopaminergic markers and receptors, and changes in dopaminergic synaptic function. Changes 
in serotonergic and noradrenergic markers appear to be less involved in the aetiology of 
depression in DLB. STED based analysis also revealed the presence of phosphorylated α-
synuclein within dopaminergic and serotonergic synapses in the sgACC, directly linking a 
major pathological change in DLB, that of aggregated α-synuclein, with monoaminergic 
dysfunction in DLB. These α-synuclein changes in monoaminergic synapses in DLB also 
showed a positive correlation with SNAP25 in DLB cases with depression. One explanation 
may be that pathological α-synuclein causes sequestration of SNAP25 within synapses leading 
to synaptic dysfunction (Choi et al., 2018). How α-synuclein interacts with synaptic 
components in DLB would be a useful area of future study.  
Recent evidence suggests a close relationship between differential expression profiles of α-
synuclein and selective vulnerability of certain neuronal populations (Taguchi et al., 2019, Li 
et al., 2002), with aggregation of α-synuclein thought to be dependent on its endogenous 
expression (Volpicelli-Daley et al., 2011b, Erskine et al., 2018). While the effect of 
phosphorylated α-synuclein on monoaminergic synapses was explored, future studies should 
focus how different α-synuclein species affect synaptic function in DLB using approaches such 
as cell culture and aggregation based assays (Lau et al., 2020). 
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6.3 Study strengths and limitations 
6.3.1 Study strengths 
All cases included in this study were well characterised based on clinical and neuropathological 
criteria. The case selection criteria was based on the availability of clinical information, 
including MMSE, UPDRS, CSDD and GDS scores. The cases for immunohistochemical 
analysis were selected with shorter time in fixative, and to ensure the optimal biochemical 
analysis the cases were chosen with higher pH (as a surrogate for agonal state). One of the 
strengths of this study was the ability to assess pathological changes within cingulate 
subregions, and more importantly the sgACC, using immunohistochemical and biochemical 
techniques. Furthermore, by using fractionated tissue samples and multiple pathological 
markers, the analysis of pathological changes and its relationship with clinical findings was 
carried out much more in depth. The use of dot blot analysis enabled comparison of a wide 
range of proteins, considerably adding greater breadth to the study. 
Another strength of this study was using super-resolution stimulated emission depletion 
(STED) microscopy. STED achieves spatial resolution in the ~20-80 nanometer range 
(Vicidomini et al., 2018), revealing molecular features of synapses beyond the diffraction limit, 
approaching the gold standard of electron microscopy (Spuhler et al., 2016, Hell, 2007). This 
improved imaging technique was used in the present monoamine study to assess dopaminergic 
and serotonergic synapses. 
6.3.2 Study limitations 
One of the limitations of this study is that we only looked at the overall GABAergic cell density 
within the sgACC. This rather generalised approach may prevent us from identifying subtle 
changes that are important in the aetiology of depression in DLB. The limbic system also 
expresses high levels of GABAB receptors (McDonald et al., 2004) indicating their role in 
regulating emotional behaviour. A limitation of the current study was the lack of assessment 
of GABAB receptors, as the available antibody for GABAB2 receptor did not provide a band 
of the right molecular weight. Recently, there has been greater emphasis on antagonism of 
GABAB receptors as a potential therapeutic strategy for depression (Bowery et al., 2002). 
Chronic treatment with the GABAB receptor antagonist CGP36742 has shown antidepressant-
like responses in rats (Nakagawa et al., 1999), and one GABAB receptor antagonist 
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CGP56433A showed an increase in the BDNF concentration in the hippocampus and cortex 
(Heese et al., 2000), which might contribute to their antidepressant-like effects (Shirayama et 
al., 2002). Further investigations of the role of GABAB receptors in DLB and selective 
targeting of GABAB receptors might therefore lead to more effective psychotherapeutics for 
mood disorders in which there is a high and unmet medical need. 
The methodological approach to imaging of glutamatergic and GABAergic synapses is one 
possible limitation of this study. Although confocal microscopy is useful in imaging individual 
synapses in cortical tissues (Schoonover et al., 2014), the diffraction limit of conventional 
optical microscopy (~200nm) precludes accurate analyses of such information. When imaging 
very small cellular structures, such as synapses, confocal imaging does not achieve the required 
resolution, and multiple synapses that are very close together could be seen as one single 
synaptic unit. This may result in the distortion of quantitative measures, such as size and 
volume.  
6.4 Further Considerations 
The clinical diagnosis of depression in DLB cases was based on symptom rating scales, 
primarily CSDD or GDS. These patients were also diagnosed with depression at different 
stages of the disease and had variable duration of depression and antidepressant treatment. The 
lack of a unifying depression scale in assessment of depression in DLB, variability in timing, 
duration and treatment of depression, thus precluded comparison of the pathological and 
biochemical findings with severity and frequency of depression in DLB. Studies with larger 
donor cohorts, with more uniform assessment of depression would be useful to show the effects 
of pathology, biochemistry and structure on depression in DLB. In a similar way, the role of 
anxiety in DLB, which is typically present in DLB and closely mirrors the presence of 
depression has not been assessed (McKeith et al., 2017). Accurate indicators of anxiety within 
this DLB population would allow us to determine how, for example, GABAergic changes 
might contribute to the development of anxiety in DLB, over and above the occurrence of 
depression. 
The use of DLB cases with and without depression has allowed us to identify disease and 
depression specific changes in DLB. The incidence of depression is also high in PD, PDD and 
is common in AD patients and comparison between other disease groups with depression may 
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help us understand similarities and differences in depression in neurodegenerative diseases. It 
is likely that given the high incidence of depression in PD/PDD and the dopaminergic changes 
that dominate this disorder, abnormal dopaminergic activity may underpin depression in 
PD/DLB in a similar way to depression in DLB. In AD, due to the changes in regions such as 
the dorsal raphe, serotonergic changes may be more likely to contribute to depression, although 
studies so far have not shown this (Hendricksen et al., 2004). Nevertheless, comparing AD and 
DLB cases using similar methods to those used in the current studies would be able to show 
the differences and similarities between the two disorders.   
While the sgACC has been shown to be highly important in depression (Drevets et al., 2008b, 
Rodriguez-Cano et al., 2014), other brain regions, such as PFC, orbitofrontal cortex, amygdala 
and hypothalamus, also have been shown to play a role in regulation of mood, anxiety, reward, 
attention, motivation and stress responses (Price and Drevets, 2012). Considering the 
interconnected nature of the brain, further studies involving other brain regions would likely 
further current understanding in the pathophysiology of depression in DLB. Similarly, the 
individual components of the sgACC were assessed essentially in isolation, and there is likely 
to be a considerable interplay between glutamatergic, GABAergic, and monoaminergic 
systems throughout the brain. For example, noradrenergic input to the dorsal raphe from the 
LC promotes arousal (Szabadi, 2013), and input from the dorsal raphe onto VTA GABAergic 
neurones is anxiolytic (Kimmey et al., 2019). An integrated approach to the anatomy and 
biochemistry of depression in DLB would undoubtedly prove beneficial. 
Due to time restrictions, other neurotransmitter systems were not explored that are also 
important in regulation of mood, including cholinergic neurotransmission (Janowsky et al., 
1972). Cholinergic dysfunction is profound in DLB patients (Perry et al., 1994), often observed 
early in the disease course, and possibly contributing to clinical symptoms such as cognitive 
fluctuations. Therefore assessing cholinergic changes may provide further insight in the 
aetiology of depression in DLB. Using STED microscopy to determine cortical synaptic 
changes in cholinergic neurones would be able to show how specific changes contribute to 
depression in DLB. 
Gender differences in relation to depression have been considered, but not explored in the 
present study due to the relatively small sample size and should be the focus of the future 
studies. The prevalence of MDD is higher in women than in men, with women having higher 
number of symptoms, a more severe depression, and greater risk of recurring episodes (Perugi 
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et al., 1990). Gender differences in volumetric changes in the ACC (Brun et al., 2009, Mann et 
al., 2011), as well as structural and functional connectivity of the sgACC have been observed 
(Wang et al., 2014), and the higher prevalence of MDD in women may be due to greater 
functional connectivity of the sgACC with other affective regions. Sex differences were also 
observed in pharmacological treatment of depression, with females shown to respond better to 
serotonergic antidepressants than males, which may be related to antidepressant metabolism 
(Sramek et al., 2016). Therefore, a better understanding of anatomical, functional, metabolic 
and neurochemical changes associated with gender differences in relation to depression may 
result in identifying novel targets and improved treatment response. 
6.5 Conclusion 
Overall, these results demonstrate that in DLB, depression appears to associate with a reduction 
in dopaminergic markers in the sgACC, most likely derived from mild loss of VTA neurones. 
This would suggest that selective treatment with agents that improve cortical dopaminergic 
function may provide treatment for depression in DLB. Pathological changes at a gross level 
do not appear to associate with depression or imaging changes in DLB, although synaptic 
accumulation of pathological α-synuclein within synapses may play a role. Additional changes 
in glutamatergic and GABAergic markers associated with specific neuronal groups occurs in 
DLB cases with depression. Further investigation of specific glutamatergic and GABAergic 
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Table A-1. Clinical data for control cases. 
Clinical information for pathological (green) and biochemical (blue) cohorts. 
Case ID Diagnosis Depression Anxiety VH Fluctuations REM sleep L-DOPA Other medication Antidepressants
Depression 
scores NPI MMSE UPDRS
19890980 Control no no n/a n/a n/a no n/a n/a n/a n/a n/a n/a
19960194 Control no no n/a n/a n/a no n/a n/a n/a n/a n/a n/a
20100685 Control no no no no no no n/a n/a n/a n/a 30 n/a
20050102 Control no no no no no no Chemo n/a n/a n/a n/a n/a
20110891 Control no no no no no no Trazodone n/a GDS-6 n/a 30 n/a
20120854 Control no no n/a n/a n/a no n/a n/a n/a n/a n/a n/a
19960188 Control no no n/a n/a n/a no n/a n/a n/a n/a n/a n/a
19891035 Control no no n/a n/a n/a no n/a n/a n/a n/a n/a n/a
20100742 Control no no no no no no n/a n/a n/a n/a n/a n/a
20110272 Control no no no no no no Carboplatin n/a n/a n/a n/a n/a
19930051 Control no no n/a n/a n/a no n/a n/a n/a n/a n/a n/a
20152904 Control no no no no no no Warafarin, digoxin, allopurinol, metoprolol, lisinopril, insulin, furosemide, amlodipine n/a GDS-3 0 27 n/a
20152903 Control no no n/a n/a n/a no n/a n/a GDS-7 0 29 n/a
20151077 Control no no n/a n/a n/a no Codeine phos, aspirin, lisinoprol, furosemide, atorvastatin, allopurinol, alendronic acid, paracetamol n/a GDS-3 0 MoCA-23 n/a
20151023 Control no no no no no no Frusemide, diltiazem, simavastatin, omeprazole, warfarin, latanoprost drops n/a GDS-4 n/a 22 n/a
20150535 Control no no n/a n/a n/a no Aspirin, Bispoprolol, ferrous fumarate, ISMN, levothyroxine, perindopril, simvastatin n/a n/a n/a n/a n/a
20150242 Control no no n/a n/a n/a no Lisinipril, simvastatin, atenolol, aspirin n/a GDS-1 0 MoCA-27 7
20140562 Control no no n/a n/a n/a no Codeine, lansaprazole, paracetamol n/a GDS-1 0 30 0
20140523 Control no no n/a n/a n/a no Prednisolone/dexamethasone and oromorph n/a GDS-0 0 28 2
20140155 Control no no n/a n/a n/a no Alodipine, atorvastatin, atenolol, ISMN, lansaprazole, aspirin n/a GDS-5 n/a 28 n/a
20131129 Control no no no no no no Valsartan, bendroflumethiazide, tinzaparin n/a n/a n/a 29 n/a
20130656 Control no no no no no no Alendronic acid, frusemide n/a GDS-4 1 27 n/a
20130020 Control no no no no no no Nitrazepam, atenolol, tramadol, paracetamol, risedronate n/a GDS-3 n/a 22/25 n/a
20100359 Control no no n/a n/a n/a no n/a n/a n/a n/a 29 n/a
20080014 Control no no n/a n/a n/a no n/a n/a GDS-1 n/a 30 n/a
20070049 Control no no n/a n/a n/a no Steroids n/a n/a n/a n/a n/a
20060093 Control no no n/a n/a n/a no Gaviscon, frusemide, ipatropium bromide, lansaprazole, simvastatin, losartan n/a n/a n/a n/a n/a
20060081 Control no no n/a n/a n/a no n/a n/a n/a n/a n/a n/a
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Table A-2. Clinical data for DLB cases without depression. 
Clinical information for pathological (green) and biochemical (blue) cohorts. 
Case ID Diagnosis Depression Anxiety VH Fluctuations REM sleep L-DOPA Other medication Antidepressants
Depression 
scores NPI MMSE UPDRS
19980019 DLB no yes n/a n/a n/a n/a n/a n/a Cornell-5 n/a 24 n/a
19950019 DLB no no yes n/a n/a L-Dopa, Seleginine Madopar, bromocryptine, selegeline n/a n/a n/a 5 n/a
19920202 DLB no no yes yes n/a Haloperidol n/a n/a n/a
26/37 
MTS n/a
19910172 DLB no no yes yes poss L-Dopa Anticonvulsants, neuroleptics  n/a n/a n/a 23/37 n/a
20121032 DLB no no yes yes n/a Donepezil, Clonazepam n/a n/a n/a 25 n/a
20020008 DLB no no no yes n/a n/a - n/a n/a n/a 27 n/a
20152919 DLB no no yes yes yes L-Dopa Rivastigmine, ropinirole, amitryptyline, cetrirzine, quinine, latanaoprost Amitryptyline Cornell - 2 5 29 53
20150907 DLB no yes yes yes no n/a Olanzapine, simvastatin, metaprolol, omeprazole n/a GDS - 6 24 25 26
20150159 DLB no no yes yes yes Sinemet
Rivastigmine, Donepezil, ibuprofen, lansaprazole, 
latanoprost, brinzolamide, paracetamol, tolterodine, 
movicol, tramadol
n/a n/a n/a 8 26
20111090 DLB no no yes yes n/a Sinemet Rivastigmine, atorvastatin, tamulosin, alendronate, calcium carbonate & cholecalciferol, aspirin, lisinopril n/a GDS - 6 29 21 28
20110932 DLB no no yes yes L-Dopa/ Carbidopa Donepezil, stalevo, pravastatin n/a GDS - 1 13 9 55
20110645 DLB no yes yes yes yes n/a Rivastigmine, clonazepam n/a n/a n/a 20 n/a
20070105 DLB no no yes yes yes Sinemet Donepezil, rivastigmine, thyroxine, quetiapine no  Cornell - 3 5 1 21
20070017 DLB no yes yes yes n/a n/a Donepezil, quetiapine no  Cornell - 5 20 24 n/a
20050098 DLB no no yes n/a yes n/a Lorazepam, donepezil, lansaprazole, atenolol, ISMN, trazodone, aspirin, frusemide, clopixol Trazodone n/a n/a n/a n/a
20050040 DLB no no yes no no n/a Donepezil, risperidone no  Cornell - 0 4 15 33
20050010 DLB no no yes yes no n/a
Donepezil, calcichew, chlormethiazole, midodrine, 
fludrocortisone, quetiapine, hydroxycobalamine, senna, 
lorazepam, prednisolone
no  Cornell - 5 5 9 14
20030128 DLB no yes yes yes no Madopar Donepezil, aspirin, calcium D3, sodium risedronate, GTN spray, madopar, atenolol no  6 15 4 45
20030007 DLB no no yes yes no Madopar Clonazepam,  donepezil  n/a Cornell - 0 21 18 50
20010080 DLB no no yes yes n/a Sinemet - n/a n/a n/a n/a n/a
20010074 DLB no no yes no yes Sinemet Rivastigmine n/a n/a 2 22 24
20010026 DLB no no yes yes n/a n/a Rivastigmine, ferrous sulphate, Vit B12, paracetamol n/a Cornell - 6 n/a 9 46
20010025 DLB no no yes yes n/a L-Dopa Rivastigmine n/a n/a 26 10 37
20000064 DLB no no yes yes n/a L-Dopa Rivastigmine n/a GDS - 2 n/a 15 37
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Table A-3. Clinical data for DLB cases with depression. 
Clinical information for pathological (green) and biochemical (blue) cohorts. 
Case ID Diagnosis Depression Anxiety VH Fluctuations REM sleep L-DOPA Other medication Antidepressants
Depression 
scores NPI MMSE UPDRS
20152920 DLB yes no yes yes n/a Simemet Donepezil, memantine, quetiapine Fluoxetine n/a n/a n/a prob 0 n/a
20141164 DLB yes no yes no n/a n/a
Donepezil, galanthamine, memantine, 
antipsychotics, benzodiazepines, 
candesartan, amlodipine, dabigatran
Citalopram Cornell - 17 27 n/a prob 0 4
20110403 DLB yes yes n/a yes n/a Co-Careldopa Donepezil Venlafaxine, mirtazepine GDS - 8 n/a 13 54
20110310 DLB yes no yes yes yes n/a Donezepil, Rivastigmine Sertraline, paroxetine GDS-14 13 21 26
20100745 DLB yes no yes yes yes n/a Donepezil 5mg Citalopram n/a 44 17 n/a
20100575 DLB yes yes yes yes yes n/a Donepezil Fluoxetine Cornell - 5 23 8 21
20070009 DLB yes yes yes yes yes Sinemet Clonazepam, donepezil, allopurinol, hydroxycobalmine Fluoxetine, mirtazepine GDS-10 13 12 31




Cornell-9 n/a 23 27
20060025 DLB yes no yes yes yes Co-Careldopa Donepezil, clonazepam, oxybutynin, paracetamol, aspirin Citalopram Cornell-11 29 2 36
20060019 DLB yes no yes yes n/a Sinomet Citalopram n/a n/a 18 n/a
20050030 DLB yes yes yes yes no n/a Olanzapine,  donepezil, risperidone Paroxetine Cornell-13 103 0 24
20040085 DLB yes no yes yes no Sinomet Donepezil, risperidone, midodrine, fludrocortisone Citalopram Cornell-4 0 4 58
20040034 DLB yes no yes yes no Sinemet Donepezil, gabapentin, clonazepam Citalopram Cornell-16 49 14 20
20030113 DLB yes no yes yes n/a Sinemet  Donepezil No anti deps GDS-8, Cornell-9 20 12 51
20020079 DLB yes no yes n/a n/a n/a Rivastigmine Paroxetine, fluoxetine, venlafaxine, Cornell-14 n/a 4 32
20020052 DLB yes no yes yes n/a n/a Donepezil, chlormethiazole, lansaprazole, gaviscon Citalopram n/a n/a 14 18
19950221 DLB yes no yes yes n/a Sinemet  Clozapine  Sertraline, dothiepin n/a n/a 0 42
19980060 DLB yes yes yes yes Sinemet Rivastigmine Diazapam, trazedone Cornell-8 n/a 19 n/a
19960131 DLB yes no yes yes n/a n/a - Paroxitine Cornell-10 n/a 0 n/a
19980841 DLB yes yes n/a - Lofepremine, lithium, GDS-14 n/a n/a n/a
19870884 DLB yes no n/a n/a n/a Sinemet, L-Dopa, akineton, eldepryl - Diothiepin Hamilton-11 n/a n/a n/a
20040063 DLB yes no yes yes L-Dopa, Co-Carbedopa Rivastigmine Flouxetine n/a n/a 12 23





Figure B-1. Validation of pathology and metabolic markers. 
The specificity of antibodies used for dot blot analysis was verified using western blotting. The proteins of interest were imaged using NIR 










































































































































































Figure B-2. Validation of glutamatergic and GABAergic markers. 
The specificity of antibodies used for dot blot analysis was verified using western blotting. The proteins of interest were imaged using NIR 














































































































































































Figure B-3. Validation of monoaminergic markers. 
The specificity of antibodies used for dot blot analysis was verified using western blotting. The proteins of interest were imaged using NIR 
Odyssey Fc system at 800nm together with SeeBlue pre-stained protein standard (Invitrogen) or Chameleon 800 (LI-COR) ladder.
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